Treatment of calcitonin receptor and / or amyloid receptor-related disorders
By using a pharmaceutical composition of small molecule calcitonin and amylin receptor modulators, receptors are activated to improve blood glucose regulation and weight management, solving the problem of poor receptor modulation effects in existing technologies and achieving therapeutic effects for a variety of diseases.
Patent Information
- Application Number
- CN202580025698.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-12-24
- Filing Date
- 2025-02-07
- Publication Date
- 2026-11-10
AI Technical Summary
Existing technologies have difficulty effectively modulating calcitonin receptors and amylin receptors, resulting in poor efficacy of therapies for metabolic disorders such as obesity and diabetes.
We provide small molecule calcitonin receptor and amylin receptor modulators, such as amylin receptor agonists, for the preparation of pharmaceutical compositions that can be combined with other therapies, such as antidiabetic agents and anti-obesity agents, to treat related diseases.
By activating calcitonin and amylin receptors, it improves blood sugar regulation, promotes weight loss and reduced food intake, and provides therapeutic effects for a variety of diseases.
Smart Images

Figure QLYQS_1 
Figure QLYQS_2 
Figure QLYQS_3
Abstract
Description
Cross-references to related applications
[0001] This application claims the benefits of International Patent Application No. PCT / CN2024 / 076922, filed February 8, 2024; International Patent Application No. PCT / CN2024 / 097824, filed June 6, 2024; International Patent Application No. PCT / CN2024 / 133596, filed November 21, 2024; and International Patent Application No. PCT / CN2024 / 141875, filed December 24, 2024, each of which is incorporated herein by reference in its entirety. Technical Field
[0002] This disclosure provides compounds for modulating the activity of calcitonin receptors and / or amylin receptors, as well as pharmaceutical compositions comprising the compounds disclosed herein. Methods for treating diseases, disorders, and conditions related to calcitonin receptors and / or amylin receptors are also provided. Background Technology
[0003] Calcitonin and amylin are hormones that interact with receptors in the same family to exert their effects on human organisms. Calcitonin, derived from thyroid C cells, is known for its inhibitory effect on osteoclasts. Mammal-derived calcitonin promotes insulin sensitivity, while the more potent calcitonin derived from salmon also inhibits gastric emptying, promotes gallbladder relaxation, increases energy expenditure, induces satiety, and reduces weight. Studies have also shown that oral administration of salmon calcitonin (sCT) exerts insulin sensitization to improve glucose metabolism in obesity and type 2 diabetes. European Journal of Pharmacology, 2024, 737(7): 91-96.
[0004] The amylin receptor (AMYR) is a G protein-coupled receptor (GPCR) that responds to the peptide hormones amylin and calcitonin. The amylin receptor is a heterodimer containing the calcitonin receptor (a G protein-coupled receptor) and one of three receptor-modifying proteins. Amylin, primarily formed in pancreatic β-cells, is co-secreted with insulin in response to calorie intake. Patients with type 1 diabetes have lower baseline serum amylin concentrations and lack an amylin response to calorie intake. Patients with type 2 diabetes who require insulin also show a reduced amylin response to calorie intake, which may be related to the degree of β-cell damage. Key physiological functions of amylin in maintaining glucose homeostasis include inhibiting glucagon release in response to calorie intake, delaying gastric emptying rate, and stimulating the satiety center in the brain to restrict calorie intake.
[0005] The synthetic amylin analog pralintide is approved as an adjunct to prandial insulin therapy for the treatment of diabetes, promoting better glycemic control and small but significant weight loss. AM833 (canagliflozin) is an investigational novel long-acting acylated amylin analog that acts as a non-selective amylin receptor agonist. This amylin receptor agonist could serve as an attractive new treatment for obesity, leading to reduced food intake and significant weight loss in a dose-dependent manner. J Obes Metab Syndr. 2021; 30(4): 320-325.
[0006] Therefore, modulators of amylin receptors and / or calcitonin receptors may be useful in treating various metabolic disorders and inducing weight loss. Summary of the Invention
[0007] This disclosure provides small molecule calcitonin receptor and / or amylin receptor modulators (e.g., amylin receptor agonists) and pharmaceutical compositions comprising the compounds disclosed herein. Methods for treating diseases or disorders related to calcitonin receptors and / or amylin receptors are also provided. Calcitonin receptor activation has been shown to be important for glycemic regulation in diabetes; this complements the known metabolically beneficial effects of amylin receptor activation. Journal of Pharmacology and Experimental Therapeutics, 2020, 374(1) 74-83.
[0008] This disclosure also provides pharmaceutical compositions comprising one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients thereof.
[0009] This document also provides pharmaceutical compositions comprising one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients thereof.
[0010] This document also provides methods for treating or preventing calcitonin receptor and / or amylin receptor-related diseases or disorders in subjects of need, the methods comprising administering to the subject of need a therapeutically effective amount of a compound disclosed herein (e.g., a compound of formula I or a derivative thereof, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) or a pharmaceutical composition thereof. In some embodiments, the methods further comprise administering to the subject a therapeutically effective amount of one or more other therapies or therapeutic agents, such as, but not limited to, antidiabetic agents, antiobesity agents, weight-loss agents, GLP-1 receptor agonists, antiemetics, agents for treating nonalcoholic steatohepatitis (NASH), gastric electrical stimulation, dietary monitoring, physical activity, or combinations thereof.
[0011] In some embodiments, the calcitonin receptor and / or amylin receptor-related diseases or disorders are bone disorders, metabolic disorders, pain, neurodegenerative diseases or disorders, cardiovascular diseases, or other diseases or disorders.
[0012] In some implementations, the calcitonin receptor and / or amylin receptor-related diseases or disorders are bone disorders, including but not limited to osteoporosis, Paget's disease, hypercalcemia, Zudeck atrophy, multiple fibrous dysplasia of bone, costoclavicular ossification, osteogenesis imperfecta, osteopenia, periodontal disease or periodontal defects, osteolytic bone disease, metastatic bone disorders, or bone loss caused by malignancy, autoimmune arthritis, bone fissures or fractures, or inactivity or disuse.
[0013] In some embodiments, the calcitonin receptor and / or amylin receptor-related disease or disorder is pain, including but not limited to osteopathic pain, phantom limb pain, generalized pain, hyperalgesia, or pain associated with diabetic neuropathy.
[0014] In some embodiments, the calcitonin receptor and / or amylin receptor-related diseases or disorders are neurodegenerative diseases or disorders, including but not limited to Alzheimer's disease.
[0015] In some embodiments, the calcitonin receptor and / or amylin receptor-related diseases or disorders are metabolic disorders, including but not limited to non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, impaired glucose tolerance, obesity, syndrome X, or other diabetic complications.
[0016] In some implementations, the calcitonin receptor and / or amylin receptor-related diseases or disorders include primary or secondary hyperthyroidism, endocrine disorders, conditions associated with inhibition of gastric juice secretion, gastrointestinal disorders, renal osteodystrophy, or male infertility. Detailed Implementation definition
[0017] The following description illustrates exemplary embodiments of the present invention. However, it should be understood that this description is not intended to limit the scope of this disclosure, but is provided as a description of exemplary embodiments.
[0018] As used in this specification, the following words, phrases and symbols are generally intended to have the meanings set forth below, unless the context in which they are used indicates otherwise.
[0019] A dash ("-") not located between two letters or symbols is used to indicate the attachment point of a substituent. For example, -C(O)NH2 is attached via a carbon atom. A dash at the beginning or end of a chemical group is for convenience; a chemical group may be depicted with or without one or more dashes without losing its ordinary meaning. A wavy or dashed line drawn through a line in the structure indicates the designated attachment point of the group. Unless chemically or structurally required, the order in which chemical groups are written or named does not indicate or imply directionality or stereochemistry.
[0020] prefix "C" u-v This indicates that the subsequent group has u to v carbon atoms. For example, "C 1-6 "alkyl" indicates that the alkyl group has 1 to 6 carbon atoms.
[0021] When this document refers to a value or parameter “about,” it includes (and describes) embodiments relating to that value or parameter itself. In some embodiments, the term “about” includes an indicated amount ± 10%. In other embodiments, the term “about” includes an indicated amount ± 5%. In some other embodiments, the term “about” includes an indicated amount ± 1%. Furthermore, the term “about x” includes a description of “x.” Additionally, the singular forms “a” and “the” include plural indicators unless the context clearly specifies otherwise. Thus, for example, reference to “compound” includes multiple such compounds, and reference to “the determination” includes reference to one or more determinations known to those skilled in the art and their equivalents.
[0022] "Alkyl" refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl groups have 1 to 20 carbon atoms (i.e., C64-C ... 1-20 Alkyl groups, 1 to 12 carbon atoms (i.e., C464) 1-12 Alkyl groups, 1 to 8 carbon atoms (i.e., C464-C ... 1-8 Alkyl groups, 1 to 6 carbon atoms (i.e., C646) 1-6 Alkyl groups or 1 to 4 carbon atoms (i.e., C46) 1-4Alkyl groups. Examples of alkyl groups include, for example, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When naming an alkyl residue with a specific number of carbons by its chemical name or identifying the alkyl residue by its molecular formula, all positional isomers having that number of carbons may be covered; thus, for example, "butyl" includes n-butyl (i.e., -(CH2)3CH3), sec-butyl (i.e., -CH(CH3)CH2CH3), isobutyl (i.e., -CH2CH(CH3)2), and tert-butyl (i.e., -C(CH3)3), and "propyl" includes n-propyl (i.e., -(CH2)2CH3) and isopropyl (i.e., -CH(CH3)2).
[0023] "Alkenyl" refers to an alkyl group containing at least one (e.g., 1-3 or 1) carbon-carbon double bond and having 2 to 20 carbon atoms (i.e., C36, C46, C56, C6 ... 2-20 alkenyl), 2 to 12 carbon atoms (i.e., C 2-12 alkenyl), 2 to 8 carbon atoms (i.e., C 2-8 alkenyl), 2 to 6 carbon atoms (i.e., C 2-6 Alkenyl) or 2 to 4 carbon atoms (i.e., C) 2-4 Alkenyl groups. Examples of alkenyl groups include, for example, vinyl, propenyl, and butadienyl (including 1,2-butadienyl and 1,3-butadienyl).
[0024] "Alkynyl" refers to an alkyl group that contains at least one (e.g., 1-3 or 1) carbon-carbon triple bond and has 2 to 20 carbon atoms (i.e., C360-C4 ... 2-20 alkynyl group), 2 to 12 carbon atoms (i.e., C 2-12 acetylsyl), 2 to 8 carbon atoms (i.e., C 2-8 acetylsyl), 2 to 6 carbon atoms (i.e., C10, C20, C30, C40, C50, C60, C7 ... 2-6 (alkynyl group) or 2 to 4 carbon atoms (i.e., C46) 2-4 (Alkyne group). The term "alkynyl group" also includes those groups that have one triple bond and one double bond.
[0025] Some commonly used alternative chemical names can be used. For example, divalent groups (such as divalent "alkyl", divalent "aryl", etc.) can also be called "alkylene" or "alkylenyl" groups, "arylene" or "arylenyl" groups, respectively.
[0026] "Alkoxy" refers to the "alkyl-O-" group. Examples of alkoxy groups include, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.
[0027] "Alkoxyalkyl" refers to an alkyl group as defined above, wherein the hydrogen atom is replaced by an alkoxy group as defined herein.
[0028] "Haloalkyl" refers to an unbranched or branched alkyl group as defined above, wherein one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by independently selected halogroups. For example, in the case where the residues are substituted by more than one halogen, it can be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl groups substituted by two ("di") or three ("tri") halogroups, which may be, but are not necessarily, the same halogen. Examples of haloalkyl groups include, for example, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, etc.
[0029] "Haloalkoxy" refers to an alkoxy group as defined above, in which one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by independently selected halogen groups.
[0030] "Haloalkoxyalkyl" refers to an alkyl group as defined above, wherein the hydrogen atom is replaced by a haloalkoxy group as defined herein.
[0031] "Hydroxyalkyl" refers to an alkyl group as defined above, in which one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by hydroxyl groups.
[0032] "Cyanoalkyl" means an alkyl group as defined above, in which one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by cyano groups.
[0033] "Alkylthio" refers to the "alkyl-S-" group.
[0034] "Acyl" refers to the group -C(O)R, where R is hydrogen, alkyl, cycloalkyl, heterocyclic, aryl, heteroalkyl, or heteroaryl; each of these may be optionally substituted, as defined herein. Examples of acyl groups include formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.
[0035] "Amide group" refers to both "C-amide group" and "N-amide group", wherein the "C-amide group" refers to the group -C(O)NR. y R z The "N-amide group" refers to the -NR group. y C(O)R z , where R y and R zIndependently, they are hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroalkyl, or heteroaryl; each may optionally be substituted, as defined herein, or R y and R z Together they form cycloalkyl or heterocyclic groups; each of them may optionally be substituted, as defined herein.
[0036] "Amino" refers to the -NR group. y R z , where R y and R z Independently, they are hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroalkyl, or heteroaryl; each may be optionally substituted as defined herein.
[0037] "Amino group" refers to -C(NR) y (NR) z 2), where R y and R z Independently, they are hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroalkyl, or heteroaryl; each may be optionally substituted as defined herein.
[0038] "Aryl" refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic), including fused systems. As used herein, aryl groups have 6 to 20 ring carbon atoms (i.e., C646 ... 6-20 aryl), 6 to 12 carbon ring atoms (i.e., C 6-12 aryl), or 6 to 10 carbon ring atoms (i.e., C 6-10 Aryl groups. Examples of aryl groups include, for example, phenyl, naphthyl, fluorenyl, and anthracene. However, aryl groups do not encompass heteroaryl groups as defined below or overlap with them in any way. If one or more aryl groups are fused with a heteroaryl group, the resulting ring system is a heteroaryl group, regardless of the attachment point. If one or more aryl groups are fused with a heterocyclic group, the resulting ring system is a heterocyclic group, regardless of the attachment point. If one or more aryl groups are fused with a cycloalkyl group, the resulting ring system is a cycloalkyl group, regardless of the attachment point.
[0039] "Carbamoyl" refers to both "O-carbamoyl" and "N-carbamoyl", with "O-carbamoyl" specifically referring to the group -OC(O)NR. y R z The "N-carbamoyl" group refers to the -NR group. y C(O)OR z , where R y and R z Independently, they are hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroalkyl, or heteroaryl; each may be optionally substituted as defined herein.
[0040] "Carboxylic ester" or "ester" refers to -OC(O)R x and -C(O)OR x Of the two, R x They are alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroalkyl, or heteroaryl; each may optionally be substituted as defined herein.
[0041] "Cycloalkyl" refers to a saturated or partially unsaturated cyclic alkyl group having a single ring or multiple rings, including fused, bridged, and spirocyclic systems. The term "cycloalkyl" includes cycloalkenyl (i.e., a cyclic group having at least one double bond) and cycloalkenyl (a cyclic group having at least one sp). 3 A carbocyclic fused-ring system with at least one carbon atom (i.e., at least one non-aromatic ring). As used herein, cycloalkyl groups have 3 to 20 ring carbon atoms (i.e., C164667 ... 3-20 cycloalkyl groups), 3 to 14 cyclic carbon atoms (i.e., C1456 ... 3-12 cycloalkyl groups), 3 to 12 cyclic carbon atoms (i.e., C12+ ... 3-12 cycloalkyl groups), 3 to 10 cyclic carbon atoms (i.e., C146 ... 3-10 cycloalkyl groups), 3 to 8 cyclic carbon atoms (i.e., C1646-C ... 3-8 cycloalkyl groups or 3 to 6 cyclic carbon atoms (i.e., C16, C26, C36, C46, C56, C6 ... 3-6 Cycloalkyl. Monocyclic groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic groups include, for example, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl, adamantyl, norbornyl, decahydronaphthyl, 7,7-dimethyl-bicyclo[2.2.1]heptyl, etc. Furthermore, the term cycloalkyl is intended to cover any non-aromatic ring that can fused with an aryl ring, regardless of its attachment to the rest of the molecule (e.g., 2,3-dihydro-1H-indenyl). Still, cycloalkyl also includes "spirocycloalkyl", where there are two substitution positions on the same carbon atom, such as spiro[2.5]octyl, spiro[4.5]decyl, or spiro[5.5]undecyl.
[0042] "Cycloalkylalkyl" refers to an alkyl group as defined above, wherein hydrogen atoms are replaced by cycloalkyl groups as defined herein.
[0043] "Imine" refers to the group -C(NR) y )R z , where R y and R z Independently, they are hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroalkyl, or heteroaryl; each may be optionally substituted as defined herein.
[0044] "Imidin group" refers to the group -C(O)NR y C(O)Rz or -N(C(O)R y )C(O)R z , where R y and R z Each is independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroalkyl, or heteroaryl; each may optionally be substituted, as defined herein, or R y and R z Together they form a heterocyclic group, which may optionally be substituted as defined herein.
[0045] "Halogen" or "halogenated group" refers to an atom that occupies Group VIIA of the periodic table, such as fluorine, chlorine, bromine, or iodine.
[0046] "Heteroalkyl" refers to an alkyl group in which one or more carbon atoms (and any associated hydrogen atoms) are each independently replaced by the same or different heteroatom groups. The term "heteroalkyl" includes unbranched or branched saturated chains having carbon atoms and heteroatoms. For example, one, two, or three carbon atoms may be independently replaced by the same or different heteroatom groups. Heteroatom groups include, but are not limited to, -NR-, -O-, -S-, -S(O)-, -S(O)2-, etc., where R is H, alkyl, aryl, cycloalkyl, heteroalkyl, heteroaryl, or heterocyclic, each of which may be optionally substituted. Examples of heteroalkyl groups include -OCH3, -CH2OCH3, -SCH3, -CH2SCH3, -NRCH3, and -CH2NRCH3, where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which may be optionally substituted. As used herein, heteroalkyl groups include 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.
[0047] "Hybrid alkylene" refers to a divalent heteroalkyl group. A "heteroalkylene" must have at least one carbon atom and at least one heteroatom group within the chain. The term "heteroalkylene" includes unbranched or branched saturated chains having carbon atoms and heteroatoms. For example, one, two, or three carbon atoms can be independently replaced by the same or different heteroatom groups. Heteroatom groups include, but are not limited to, -NR. y -, -O-, -S-, -S(O)-, -S(O)2-, etc., among which R yIt is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroalkyl, or heteroaryl; each of them may be optionally substituted as defined herein. Examples of heteroalkylene groups include, for example, -CH2OCH2-, -CH(CH3)OCH2-, -CH2CH2OCH2-, -OCH2-, -CH(CH3)O-, -CH2CH2O-, -CH2CH2OCH2CH2OCH2-, -CH2CH2OCH2CH2O-, -CH2SCH2-, -CH(CH3)SCH2-, -CH2CH2SCH2-, -CH2CH2SCH2CH2SCH2-, -SCH2-, -CH(CH3)S-, -CH2CH2S-, -CH2CH2SCH2CH2S-, -CH2S(O)2CH2-, -CH(CH3)S(O)2CH2-, -CH2CH2S(O)2CH2-, -CH2CH2S(O)2CH2CH2OCH2-, -CH2NR y CH2-、-CH(CH3)NR y CH2-、-CH2CH2NR y CH2-、-CH2CH2NR y CH2CH2NR y CH2- etc., where R y It is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroalkyl, or heteroaryl; each of which may optionally be substituted as defined herein. As used herein, a heteroalkylene comprises 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom. As used herein, the term "heteroalkylene" does not include groups such as amides, or other functional groups having an oxo group present on one or more carbon atoms.
[0048] "Heteroaryl" refers to an aromatic group having a single ring or multiple fused rings, wherein one or more ring heteroatoms are independently selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryl groups comprise 1 to 20 ring carbon atoms (i.e., C16, C26, C36, C46, C56, C6 ... 1-20 (heteroaryl), 3 to 12 cyclic carbon atoms (i.e., C 3-12 (heteroaryl) or 3 to 8 carbon ring atoms (i.e., C 3-8The heteroaryl group comprises 1 to 5 cyclic heteroatoms, 1 to 4 cyclic heteroatoms, 1 to 3 cyclic heteroatoms, 1 to 2 cyclic heteroatoms, or 1 cyclic heteroatomium, wherein the cyclic heteroatoms are independently selected from nitrogen, oxygen, and sulfur. In some cases, the heteroaryl group comprises a 5-10 membered ring system, a 5-7 membered ring system, or a 5-6 membered ring system, each ring system independently having 1 to 4 cyclic heteroatoms, 1 to 3 cyclic heteroatoms, 1 to 2 cyclic heteroatoms, or 1 cyclic heteroatomium, wherein the cyclic heteroatoms are independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include, for example, acridinel, benzimidazolyl, benzothiazolyl, benzoindolyl, benzofuranyl, benzothiazolyl, benzothiadiazolyl, benzonaphthofuranyl, benzooxazolyl, benzothiophenyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridyl, carbazolel, cenolinyl, dibenzofuranyl, dibenzothiaphenyl, furanyl, isothiazolyl, imidazolyl, indazolel, indolyl, indazolel, isoindazole, and isoindolyl. Dolyl, isoquinolinyl, isoxazolyl, naphridinyl, oxadiazolyl, oxazolyl, 1-pyridinyl oxide, 1-pyrimidinyl oxide, 1-pyrazinyl oxide, 1-pyridazinyl oxide, phenazinyl, phthalazinyl, pteridinyl, purine, pyrroleyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxolinyl, quinolinyl, quininecycloyl, isoquinolinyl, thiazolyl, thiadiazolyl, thiophene, triazolyl, tetrazolyl, and triazinyl. Examples of fused heteroaryl rings include, but are not limited to, benzo[d]thiazolyl, quinolinyl, isoquinolinyl, benzo[b]thiophene, indazole, benzo[d]imidazolyl, pyrazolo[1,5-a]pyridinyl, and imidazo[1,5-a]pyridinyl, wherein the heteroaryl group can be linked via any ring of the fused system. Any aromatic ring containing at least one heteroatom and having one or more fused rings is considered a heteroaryl, regardless of its attachment to the rest of the molecule (i.e., via any one of the fused rings). A heteroaryl does not encompass or overlap with an aryl as defined above.
[0049] "Heterocyclic group" refers to a saturated or partially unsaturated cyclic alkyl group, wherein one or more cyclic heteroatoms are independently selected from nitrogen, oxygen, and sulfur. The term "heterocyclic group" includes heterocyclic alkenyl groups (i.e., heterocyclic groups having at least one double bond), bridged heterocyclic groups, fused heterocyclic groups, and spirocyclic groups. A heterocyclic group can be a single ring or multiple rings, wherein the multiple rings can be fused, bridged, or spirocyclic, and can contain one or more (e.g., 1 to 3) oxo groups (=O) (e.g., -C(O)-, -S(O)-, -S(O)2-, or -P(O)-) or N-oxides (-O... -The term heterocyclic group refers to any non-aromatic ring or fused ring system containing at least one heteroatom and a non-aromatic ring, regardless of its attachment to the rest of the molecule. For example, fused ring systems (such as 6,7-dihydro-5H-cyclopentadieno[b]pyridyl, decahydroquinazolinyl, 1,2,3,4-tetrahydroquinazolinyl, and 5,6,7,8-tetrahydroquinazolinyl) are heterocyclic groups regardless of their attachment (i.e., they can be bonded via carbon atoms or heteroatoms). Furthermore, the term heterocyclic group is intended to cover any non-aromatic ring containing at least one heteroatom, which can be fused with a cycloalkyl, aryl, or heteroaryl ring, regardless of its attachment to the rest of the molecule. As used herein, heterocyclic groups have 2 to 20 ring carbon atoms (i.e., C2, C3, C4, C5, C6, C6, C7 ... 2-20 Heterocyclic group), 2 to 12 ring carbon atoms (i.e., C 2-12 Heterocyclic group), 2 to 10 ring carbon atoms (i.e., C 2-10 Heterocyclic group), 2 to 8 ring carbon atoms (i.e., C 2-8 Heterocyclic group), 3 to 12 ring carbon atoms (i.e., C 3-12 Heterocyclic group), 3 to 8 ring carbon atoms (i.e., C 3-8 Heterocyclic group) or 3 to 6 ring carbon atoms (i.e., C 3-6Heterocyclic groups); having 1 to 5 cyclic heteroatoms, 1 to 4 cyclic heteroatoms, 1 to 3 cyclic heteroatoms, 1 to 2 cyclic heteroatoms, or 1 cyclic heteroatomide, wherein the cyclic heteroatoms are independently selected from nitrogen, sulfur, or oxygen. Examples of heterocyclic groups include, for example, azirrobutyl, azirroyl, benzodioxanyl, benzo[b][1,4]dioxanyl, 1,4-benzodioxane, benzopyranyl, benzodioxinyl, benzopyranoneyl, benzofuranoneyl, dioxanyl, dihydropyranyl, hydropyranyl, thiophene[1,3]dithiaalkyl, decahydroisoquinolinyl, furanoneyl, imidazolinyl, imidazoalkyl, indololinyl, indolazinyl, isoindololinyl, isothiazolyl, isoxazolyl, morphoyl, etc. The following groups are included: linyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopiperylalkyl, oxazolylalkyl, ethylene oxide, oxacyclobutyl, phenthiazinyl, phenoxazinyl, piperidinyl, piperazinyl, 4-piperidinoneyl, pyrrolylalkyl, pyrazolylalkyl, quininecycloyl, thiazolyl, tetrahydrofuranyl, tetrahydropyranyl, trithiazylalkyl, tetrahydroquinolinyl, thiomorpholinyl, thio-morpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. The term "heterocyclic group" also includes "spiroheterocyclic group," where there are two substitution positions on the same carbon atom. Examples of spirocyclic base rings include, for example, bicyclic and tricyclic ring systems, such as oxabicyclo[2.2.2]octyl, 2-oxa-7-azaspiro[3.5]nonyl, 2-oxa-6-azaspiro[3.4]octyl, and 6-oxa-1-azaspiro[3.3]heptyl. Examples of fused heterocyclic base rings include, but are not limited to, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridyl, indololinyl, and isoindololinyl, wherein the heterocyclic group can be linked via any ring of the fused system.
[0050] "Sulfonyl" refers to the group -S(O)2R. y , where R y It is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroalkyl, or heteroaryl; each of them may be optionally substituted as defined herein. Examples of sulfonyl groups are methanesulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.
[0051] "Sulinate group" refers to the group -S(O)R y , where R y It is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclic, aryl, heteroalkyl, or heteroaryl; each of them may be optionally substituted as defined herein.
[0052] The terms “optional” or “optionally” mean that the event or situation described below may or may not occur, and the description includes both scenarios in which the event or situation occurs and scenarios in which the event or situation does not occur. Furthermore, the term “optionally substituted” means that any one or more (e.g., 1 to 5 or 1 to 3) hydrogen atoms on a specified atom or group may be partially substituted, or may not be substituted at all.
[0053] As used herein, the term "compound" is intended to include any or all stereoisomers, geometric isomers, tautomers, and isotopically enriched analogs (e.g., deuterated analogs) of the described structure. Compounds identified herein by name or structure as a particular tautomer are intended to include other tautomers unless otherwise specified.
[0054] Some compounds exist as tautomers. These tautomers exist in equilibrium with each other. For example, compounds containing amides can exist in equilibrium with imine tautomers. Regardless of which tautomer is exhibited, and regardless of the nature of the equilibrium between the tautomers, those skilled in the art will understand that the compound comprises both amide and imine tautomers. Therefore, compounds containing amides should be understood to include their imine tautomers. Similarly, compounds containing imines should be understood to include their amide tautomers.
[0055] Any compound or structure described herein is intended to represent both the unlabeled and isotopically labeled forms of the compound. These forms of the compound may also be referred to as “isotopically enriched analogs.” Isotopically labeled compounds have the structures described herein, but one or more atoms are replaced by atoms having selected atomic masses or mass numbers. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, chlorine, and iodine, such as… 2 H, 3 H, 11 C 13 C 14 C 13 N、 15 N、 15 O、 17 O、 18 O、 31 P, 32 P, 35 S, 18 F, 36 Cl、 123 I and 125 I. Various isotopically labeled compounds, such as those doped with radioactive isotopes (e.g., ...) disclosed herein. 3 H and 14Those compounds in (C). Such isotopically labeled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques (such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT), including determination of drug or substrate tissue distribution), or in the treatment of patients with radiotherapy.
[0056] The term “isotope-enriched analogues” includes “deuterated analogues” of the compounds described herein, wherein one or more hydrogen atoms (such as hydrogen on carbon atoms) are replaced by deuterium. Such compounds exhibit enhanced metabolic resistance and can therefore be used to extend the half-life of any compound administered to mammals, particularly humans. See, for example, Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by using starting materials in which one or more hydrogen atoms have been replaced by deuterium.
[0057] The deuterium-labeled or substituted therapeutic compounds of this disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, involving distribution, metabolism, and excretion (ADME). Substitution with a heavier isotope such as deuterium can provide certain therapeutic advantages stemming from greater metabolic stability, such as prolonged in vivo half-life, reduced dose requirements, and / or improved therapeutic index. 18 F, 3 H, 11 C-labeled compounds can be used in PET or SPECT or other imaging studies. The isotopically labeled compounds and their prodrugs of this disclosure can generally be prepared by replacing non-isotopically labeled reagents with readily available isotopically labeled reagents by performing the procedures disclosed in the schemes or examples and preparations described below. It should be understood that, in this case, deuterium is considered a substituent in the compounds described herein.
[0058] The concentration of such heavier isotopes (particularly deuterium) can be defined by the isotope enrichment factor. In the compounds of this disclosure, any atom not explicitly designated as a particular isotope is intended to represent any stable isotope of that atom. Unless otherwise stated, when a position is explicitly designated as “H” or “hydrogen”, that position should be understood to have hydrogen in its naturally occurring isotopic composition. Therefore, in the compounds of this disclosure, any atom explicitly designated as deuterium (D) is intended to represent deuterium.
[0059] In many cases, the compounds of this disclosure are capable of forming acidic and / or basic salts due to the presence of amino and / or carboxyl groups or similar groups.
[0060] Pharmaceutically acceptable salts, hydrates, solvates, tautomers, polymorphs, and prodrugs of the compounds described herein are also provided. "Pharmaceutically acceptable" or "physiologically acceptable" means compounds, salts, compositions, dosage forms, and other materials that can be used to prepare pharmaceutical compositions suitable for veterinary or human use.
[0061] The term "pharmaceutically acceptable salt" for a given compound refers to a salt that retains the biological efficacy and properties of the given compound and is not undesirable in biological or other respects. "Pharmaceutically acceptable salt" or "physiologically acceptable salt" includes, for example, salts formed with inorganic acids and salts formed with organic acids. Furthermore, if the compound described herein is obtained as an acid addition salt, the free base can be obtained by alkalizing a solution of the acid salt. Conversely, if the product is a free base, the addition salt (particularly pharmaceutically acceptable addition salts) can be produced by dissolving the free base in a suitable organic solvent and treating said solution with an acid, following conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize the various synthetic methods that can be used to prepare non-toxic, pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts can be prepared from inorganic and organic acids. Salts derived from inorganic acids include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc. Salts derived from organic acids include, for example, acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicylic acid. Similarly, pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. For example, salts derived from inorganic bases include sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of NH3 or primary, secondary, and tertiary amines, such as those derived from N-containing heterocycles, N-containing heteroaryl groups, or those derived from the formula N(R) N )3 amine salts (e.g., HN) + (R N )3 or (alkyl)N + (R N )3), where each R NIndependently, it is hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocyclic, aryl, or heteroaryl, wherein each group is optionally substituted, such as by one or more (e.g., 1-5 or 1-3) substituents (e.g., haloyl, cyano, hydroxyl, amino, alkyl, alkenyl, alkynyl, alkoxy, or haloalkoxy). Specific examples of suitable amines, by way of example only, include isopropylamine, trimethylamine, diethylamine, tri(isopropyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, etc.
[0062] The term "substituted" means that any one or more hydrogen atoms on a specified atom or group are replaced by one or more substituents that are not hydrogen, provided that the substitution does not exceed the normal valence of the specified atom. One or more substituents include, but are not limited to, acyl, alkenyl, alkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, amidyl, amide, amino, aryl, azide, carbamoyl, carboxyl, carboxyl ester, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, guanidinyl, haloyl, haloalkoxy, haloalkoxyalkyl, haloalkyl, heteroalkyl, heteroaryl, heterocyclic, hydrazyl, hydroxy, hydroxyalkyl, imide, imino, nitro, oxo, sulfinyl, sulfonic acid, sulfonyl, thiocyanate, thiol, thion, or combinations thereof.
[0063] Polymers or similar indeterminate structures obtained by defining substituents with an unlimited number of additional substituents (e.g., substituted aryl groups with substituted alkyl groups, where the substituted alkyl group itself is substituted by a substituted aryl group, the substituted aryl group is further substituted by a substituted heteroalkyl group, etc.) are not intended to be included herein. Unless otherwise stated, the maximum number of successive substitutions in the compounds described herein is three. For example, the successive substitution of a substituted aryl group by two other substituted aryl groups is limited to ((substituted aryl) substituted aryl) substituted aryl. Similarly, the above definitions are not intended to include disallowed substitution patterns (e.g., methyl groups substituted by five fluorine atoms or heteroaryl groups having two adjacent oxygen ring atoms). Such disallowed substitution patterns are well known to those skilled in the art. When used to modify chemical groups, the term "substituted" may describe other chemical groups as defined herein. Unless otherwise specified, when a group is described as optionally substituted, any substituents in that group are themselves not substituted. For example, in some embodiments, the term "substituted alkyl" refers to an alkyl group having one or more substituents, including hydroxyl, haloyl, alkoxy, cycloalkyl, heterocyclic, aryl, and heteroaryl groups. In other embodiments, one or more substituents may be further substituted with a haloyl, alkyl, haloalkyl, hydroxyl, alkoxy, cycloalkyl, heterocyclic, aryl, or heteroaryl group, each of which is substituted. In other embodiments, the substituents may be further substituted with a haloyl, alkyl, haloalkyl, alkoxy, hydroxyl, cycloalkyl, heterocyclic, aryl, or heteroaryl group, each of which is unsubstituted.
[0064] As used herein, "pharmaceutically acceptable carrier" or "pharmaceutical acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, and absorption delay agents. The use of such media and reagents for pharmaceutically active substances is well known in the art. Unless any conventional media or reagent is incompatible with the active ingredient, its use in therapeutic compositions is considered. Complementary active ingredients may also be incorporated into the composition.
[0065] A "solvent" is formed through the interaction of a solvent with a compound. Solvents of salts of the compounds described herein are also provided. Hydrates of the compounds described herein are also provided.
[0066] As used herein, the term "pharmaceutically acceptable" means that the compound or its salt or composition is chemically and / or toxicologically compatible with other components constituting the formulation and / or with the subject being treated therein.
[0067] The term "administration" or "administering" refers to the method of administering a given dose of a compound or pharmaceutical composition to a vertebrate or invertebrate (including mammals, birds, fish, or amphibians). The method of administration can vary depending on a variety of factors, such as the composition of the pharmaceutical composition, the site of the disease, and the severity of the disease.
[0068] As used herein, the terms "effective amount" or "effective dose" or "pharmaceutically effective amount" or "therapeutic effective amount" refer to an amount of chemical entity (e.g., a compound of Formula I or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) that will alleviate one or more symptoms of the treated disease or condition to a certain extent and may include a cure for said disease. "Cure" means the elimination of symptoms of an active disease. Results include a reduction and / or alleviation of the signs, symptoms, or cause of the disease, or any other desired alteration of the biological system. For example, an "effective amount" for therapeutic use is the amount required for a composition comprising a compound as disclosed herein to provide a clinically significant reduction in the symptoms of a disease. In any individual case, an appropriate "effective" amount is determined using any suitable technique, such as dose escalation studies. In some embodiments, a "therapeutic effective amount" of a compound as provided herein refers to an amount in which said compound is effective as a monotherapy or combination therapy.
[0069] The term "excipient" or "pharmaceuticalally acceptable excipient" means a pharmaceutically acceptable material, composition, or medium, such as a liquid or solid filler, diluent, carrier, solvent, or encapsulating material. In some embodiments, each component is "pharmaceuticalally acceptable" in the sense that it is compatible with other components of the pharmaceutical formulation and is suitable for contact with human or animal tissues or organs without excessive toxicity, irritation, allergic reactions, immunogenicity, or other problems or complications, in proportion to a reasonable benefit / risk ratio. See, for example, Remington: The Science and Practice of Pharmacy, 21st edition; Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 6th edition; edited by Rowe et al.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd edition; edited by Ash and Ash; Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd edition; edited by Gibson; CRC Press LLC: Boca Raton, FL, 2009.
[0070] The term "pharmaceutical composition" refers to a compound of Formula I as provided herein, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvation thereof, mixed with other chemical components (collectively referred to herein as "excipients," such as carriers, stabilizers, diluents, dispersants, suspending agents, and / or thickeners). Pharmaceutical compositions facilitate the administration of compounds to a living organism. Various techniques for administering compounds exist in the art, including but not limited to rectal, oral, intravenous, aerosol, parenteral, ocular, pulmonary, and topical administration.
[0071] As used herein, the term "calcitonin receptor and / or amylin receptor-related disease or disorder" is intended to include, but is not limited to, diseases, disorders, or conditions in which activation of at least one calcitonin receptor (CTR) and / or amylin receptor (AMY) via calcitonin and / or amylin contributes to the symptoms or progression of the disease or disorder. These diseases or disorders may be caused by one or more of the following etiologies: genetic, iatrogenic, immunological, infectious, metabolic, neoplastic, toxic, surgical, and / or traumatic.
[0072] In the context of treating a disease, disorder, or symptom, the terms “treat,” “treating,” and “treatment” are intended to include relieving or eradicating a disorder, disease, or symptom, or one or more symptoms associated with said disorder, disease, or symptom; or to slow the progression, spread, or worsening of a disease, disorder, or symptom, or one or more symptoms thereof.
[0073] As used in this article, the term "prevention" means the complete or partial prevention of the onset, recurrence, or spread of a disease or condition or its symptoms as described herein.
[0074] As used herein, the terms “subject,” “patient,” or “individual” are used interchangeably and refer to any animal, including mammals such as mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, sheep, horses, primates, and humans. In some embodiments, the term refers to a subject who expects or needs a diagnosis, prognosis, or therapy, particularly a mammalian subject. In some embodiments, the subject is a human. In some embodiments, the subject has experienced and / or exhibits at least one symptom of a disease, disorder, or condition to be treated and / or prevented.
[0075] The terms “treatment regimen” and “dosage regimen” are used interchangeably to refer to the dosage and timing of each therapeutic agent in the combination.
[0076] As used herein, the term "drug combination" refers to a drug treatment obtained by mixing or combining more than one active ingredient, and includes both fixed and non-fixed combinations of active ingredients.
[0077] As used herein, the term “combination therapy” refers to a dosing regimen of two different therapeutic agents (i.e., combined components or combination couples) in which the therapeutic agents are administered together or separately in a manner prescribed by a healthcare professional or in accordance with a regulatory body as defined herein.
[0078] As used herein, the terms “modulate,” “modulating,” or “modulation” refer to regulation or adjustment (e.g., increasing or decreasing) and may include, for example, agonistic, partial agonistic, or antagonistic effects. compound
[0079] This document provides compounds as regulators of amyloidin. In some embodiments, compounds of formula I are provided: I Or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or solvate thereof, wherein X 1 X 2 X3 X 4 A, Y 1 Y 2 Y 3 L 1 L 2 R 4 and R 5 Each is defined independently as described in this article.
[0080] In some implementations, compounds of formula I are provided: I Or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein: A is C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 Cycloalkylene, heterocyclic, arylene, or heteroarylene; wherein the C of A 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 Cycloalkylene, heterocycloalkylene, arylene or heteroaryl are independently and optionally separated by one to five Z A replace; X 1 It is O, S, NH, NR A CH or CR B ; X 2 and X 3 One of them is C(O); and X 2 and X 3 The other one is O, S, NH, NR A CH or CR B ; X 4 Is it N, CH or CR? B ; The condition is X 1 X 2 X 3 and X 4 At least one of them is a heteroatom; Each R A Independently selected from cyano, C 1-3 Alkyl and C 1-3 Halogenated alkyl groups; wherein R A Each C 1-3 Alkyl groups are independently and optionally prefixed with -NH2 or -NHC. 1-3 Alkyl, -N(C) 1-3 alkyl)2, hydroxyl or C 1-3Alkyl substitution; Each R B Independently selected from halogenated groups, hydroxyl groups, -NH2 groups, cyano groups, and C groups. 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; wherein R B Each C 1-3 Alkyl groups are independently and optionally prefixed with -NH2 or -NHC. 1-3 Alkyl, -N(C) 1-3 alkyl)2, hydroxyl or C 1-3 Alkyl substitution; •Y 1 Is -C(O)-, -C(S)-, -S(O)2-, -S(O)(NR 6 - or - P(O)(R 7 )-; Y 2 It is -O-, -S-, -NR 2 -or-C(R) 2 )2-; where Y 1 With Y 2 The key between them is a single key; and Y 3 Yes -NR 8 -、-O-、-S-、-C(R 3 )2-、-NR 8 -C(R 3 )2-、-OC(R 3 )2-、-SC(R 3 )2-、-C(R 3a )2-C(R 3a )2-、-C(R 3a )2-C(R 3a )2-C(R 3a )2- or -CR 3 =CR 3 -;or •Y 1 Is -C(O)-, -C(S)-, -S(O)2-, -S(O)(NR 6 - or - P(O)(R 7 )-; Y 2 Is it -N- or -CR? 2 -,and Y 3 Is it -N- or -CR? 3 -;where Y 2 With Y 3 The key between them is a double bond; or •Y 1 Is it -N- or -CR? 1 -; Y 2 Is it -N- or -CR? 2 -;where Y 1 With Y 2 The bond between them is a double bond; and Y 3 Yes -NR 8 -、-O- or -S-; The condition is that it contains Y. 1 Y 2 and Y 3 The ring contains at least one heteroatom; L 1 It is C 1-3 Alkylene, C 2-3 imidene group, C 2-3 Ethyne group, C 1-3 Heteroalkylene, C 3-6 Cycloalkylene or 4-6-membered heterocyclic alkylene groups; wherein L 1 C 1-3 Alkylene, C 2-3 imidene group, C 2-3 Ethyne group, C 1-3 Heteroalkylene, C 3-6 The cycloalkylene group or the 4- to 6-membered heterocyclic group is independently and optionally substituted by one to five substituents independently selected from the following: halogen, oxo, hydroxyl, cyano, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; L 2 It is a key, -O-, -S-, -NR 2a -, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -C(O)NR 2a -、-NR 2a C(O)-、-OC(O)NR 2a -、-NR 2a C(O)O-、-NR 2a C(O)NR 2b -, -S(O)-, -S(O)2-, -S(O)NR 2a -、-S(O)2NR 2a -、-NR 2a S(O)-、-NR 2a S(O)2-、-NR 2a S(O)NR 2b -、-NR 2a S(O)2NR2b -、C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 1-6 Heteroalkylene, C 3-6 Cycloalkylene, 4-6-membered heterocyclic cycloidene or 5-membered heteroarylene; wherein L 2 C 1-3 Alkylene, C 2-3 imidene group, C 2-3 Ethyne group, C 1-3 Heteroalkylene, C 3-6 The cycloalkylene, 4-6-membered heterocyclic or 5-membered heteroarylene is independently and optionally substituted by one to five substituents independently selected from the following: halogen, oxo, hydroxy, cyano, -NH2, -NHC. 1-3 Alkyl, -N(C) 1-3 Alkyl)2, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; R 1 It is hydrogen, halogenated group, hydroxyl group, cyano group, C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy or C 1-3 Halogenated alkoxy groups; Each R 2 Independently, it is hydrogen and C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 3-6 Cycloalkyl, phenyl, 4- to 6-membered heterocyclic or 5- to 6-membered heteroaryl; wherein R 2 Each C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 3-6 The cycloalkyl, phenyl, 4- to 6-membered heterocyclic or 5- to 6-membered heteroaryl groups are independently and optionally substituted by one to five substituents independently selected from the following: halogroup, hydroxyl group, cyano group, C4 group, C6 group, C5 group, C6 ... 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy or C 1-3 Halogenated alkoxy groups; Or R 2 and R1 R 3 R 3a R 6 R 7 and R 8 Any one or two of them together with the atoms to which they are attached form C 3-10 cycloalkyl, heterocyclic, or heteroaryl; wherein the C 3-10 Cycloalkyl, heterocyclic, or heteroaryl groups are optionally separated by one to five Z groups. 2 replace; Each R 2a and R 2b Independently, it is hydrogen and C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 2a and R 2b Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 2a replace; Or R 2a and R 2b Together with the atoms to which they are attached, they form independently, optionally, one to five Z. 2a Substituted heterocyclic groups; Each R 3 Independently, it is hydrogen, hydroxyl, -NR 3b R 3c C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 3 Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups.3 replace; Or two Rs 3 Together with one or more atoms to which they are attached, they form C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein the C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally separated by one to five Z groups. 3 replace; Or two Rs 3 Together with the carbon atoms attached to both, they form oxo groups; Each R 3a Independently, it is hydrogen and C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 3a Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 3a replace; Or two Rs 3a Together with one or more atoms to which they are attached, they form C 3-10 cycloalkyl, heterocyclic, or heteroaryl; wherein the C 3-10 Cycloalkyl, heterocyclic, or heteroaryl groups are optionally separated by one to five Z groups. 3a replace; Or two Rs 3a Together with the carbon atoms attached to both, they form oxo groups; R 3b and R 3c Each is independently hydrogen, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 3b and R 3c Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10The cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally and independently substituted by one to five substituents independently selected from the following: halogenated, hydroxyl, cyano, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; Or R 3b and R 3c Together with the nitrogen atoms to which they are attached, they form optional groups of one to five Zn atoms. 3b Substituted heterocyclic groups; R 4 It is C 1-6 Alkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 4 C 1-6 Alkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 4 replace; R 5 It is hydrogen, halogenated group, hydroxyl group, amino group, cyano group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 5 C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 5 replace; R 6 It is hydrogen, C 1-3 Alkyl, C 1-3 Haloalkyl, C 3-6 cycloalkyl or 4- to 6-membered heterocyclic groups; wherein the C 1-3 Alkyl, C 1-3 Haloalkyl, C 3-6 The cycloalkyl or 4- to 6-membered heterocyclic group is optionally substituted by one to five independent substituents selected from the following: halogen, oxo, hydroxyl, cyano, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; R 7 It is hydroxyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Alkyl or C 1-3 Halogenated alkyl groups; R 8 It is hydrogen, -S(O)2-C 1-3 Alkyl, -S(O)2-C 1-3 Haloalkyl, C 1-3 Alkyl, C 1-3 Halogenated alkyl C 3-6 cycloalkyl or 4- to 6-membered heterocyclic groups; wherein R 8 -S(O)2-C 1-3 Alkyl, -S(O)2-C 1-3 Haloalkyl, C 1-3 Alkyl, C 1-3 Halogenated alkyl C 3-6 The cycloalkyl or 4- to 6-membered heterocyclic group is optionally substituted by one to five independent substituents selected from the following: halogen, oxo, hydroxyl, cyano, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; Each Z A Z 2 Z 2a Z 3 Z 3a Z 3b Z 4 and Z 5 Independently, it is a halogenated group, a cyano group, a nitro group, an oxo group, or a C group. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, heteroaryl, -LH, -LC 1-6 Alkyl, -LC 2-6 alkenyl, -LC 2-6 alkynyl, -LC 1-6 Halogenated alkyl, -LC 3-10 Cycloalkyl, -L-heterocyclic, -L-aryl, or -L-heteroaryl; wherein Z A Z 2 Z 2a Z 3 Z 3a Z 3b Z 4 and Z 5 Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are each independently and optionally divided by one to five Z groups.1a replace; Each L is independently -O-, -S-, -NR 20 -, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -C(O)NR 20 -、-NR 20 C(O)-、-OC(O)NR 20 -、-NR 20 C(O)O-、-NR 20 C(O)NR 21 -, -S(O)-, -S(O)2-, -S(O)NR 20 -、-S(O)2NR 20 -、-NR 20 S(O)-、-NR 20 S(O)2-、-NR 20 S(O)NR 21 -or-NR 20 S(O)2NR 21 -; Each R 20 and R 21 Independently, it is hydrogen and C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 20 and R 21 Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 1a Replace; or R 20 and R 21 Together with the atoms to which they are attached, they form independently, optionally, one to five Z. 1a Substituted heterocyclic groups; and Each Z 1a Independently, it can be a halogenated group, hydroxyl group, cyano group, nitro group, oxo group, -SH, -NH2, or -NH-C group. 1-6 Alkyl, -N(C) 1-6 Alkyl)2, -SC 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein Z 1a Each -NH-C 1-6 Alkyl, -N(C) 1-6 Alkyl)2, -SC 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 The cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally and independently substituted by one to five substituents independently selected from the following: C 1-6 Alkyl, oxo, halogen, hydroxyl, and cyano groups.
[0081] In some implementations, compounds of formula I are provided: I Or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein: A is C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 Cycloalkylene, heterocyclic, arylene, or heteroarylene; wherein the C of A 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 Cycloalkylene, heterocycloalkylene, arylene or heteroaryl are independently and optionally separated by one to five Z A replace; X 1 It is O, S, NH, NR A CH or CR B ; X 2 and X 3 One of them is C(O); and X 2 and X 3 The other one is O, S, NH, NR A CH or CR B ; X 4 Is it N, CH or CR? B ; The condition is X 1 X 2 X 3 and X 4 At least one of them is a heteroatom; Each R A Independently selected from cyano, C 1-3Alkyl and C 1-3 Halogenated alkyl groups; wherein R A Each C 1-3 Alkyl groups are independently and optionally prefixed with -NH2 or -NHC. 1-3 Alkyl, -N(C) 1-3 alkyl)2, hydroxyl or C 1-3 Alkyl substitution; Each R B Independently selected from halogenated group, hydroxyl group, cyano group, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; wherein R B Each C 1-3 Alkyl groups are independently and optionally prefixed with -NH2 or -NHC. 1-3 Alkyl, -N(C) 1-3 alkyl)2, hydroxyl or C 1-3 Alkyl substitution; •Y 1 Is -C(O)-, -C(S)-, -S(O)2-, -S(O)(NR 6 - or - P(O)(R 7 )-; Y 2 It is -O-, -S-, -NR 2 -or-C(R) 2 )2-; where Y 1 With Y 2 The key between them is a single key; and Y 3 Yes -NR 8 -、-O-、-S-、-C(R 3 )2-、-NR 8 -C(R 3 )2-、-OC(R 3 )2-、-SC(R 3 )2-、-C(R 3a )2-C(R 3a )2-、-C(R 3a )2-C(R 3a )2-C(R 3a )2- or -CR 3 =CR 3 -;or •Y 1 Is -C(O)-, -C(S)-, -S(O)2-, -S(O)(NR 6 - or - P(O)(R 7 )-; Y 2Is it -N- or -CR? 2 -,and Y 3 Is it -N- or -CR? 3 -;where Y 2 With Y 3 The key between them is a double bond; or •Y 1 Is it -N- or -CR? 1 -; Y 2 Is it -N- or -CR? 2 -;where Y 1 With Y 2 The bond between them is a double bond; and Y 3 Yes -NR 8 -、-O- or -S-; The condition is that it contains Y. 1 Y 2 and Y 3 The ring contains at least one heteroatom; L 1 It is C 1-3 Alkylene, C 2-3 imidene group, C 2-3 Ethyne group, C 1-3 Heteroalkylene, C 3-6 Cycloalkylene or 4-6-membered heterocyclic alkylene groups; wherein L 1 C 1-3 Alkylene, C 2-3 imidene group, C 2-3 Ethyne group, C 1-3 Heteroalkylene, C 3-6 The cycloalkylene group or the 4- to 6-membered heterocyclic group is independently and optionally substituted by one to five substituents independently selected from the following: halogen, oxo, hydroxyl, cyano, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; L 2 It is a key, -O-, -S-, -NR 2a -, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -C(O)NR 2a -、-NR 2a C(O)-、-OC(O)NR 2a -、-NR 2a C(O)O-、-NR 2a C(O)NR 2b -, -S(O)-, -S(O)2-, -S(O)NR 2a-、-S(O)2NR 2a -、-NR 2a S(O)-、-NR 2a S(O)2-、-NR 2a S(O)NR 2b -、-NR 2a S(O)2NR 2b -、C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 1-6 Heteroalkylene, C 3-6 Cycloalkylene, 4-6-membered heterocyclic cycloidene or 5-membered heteroarylene; wherein L 2 C 1-3 Alkylene, C 2-3 imidene group, C 2-3 Ethyne group, C 1-3 Heteroalkylene, C 3-6 The cycloalkylene, 4-6-membered heterocyclic or 5-membered heteroarylene is independently and optionally substituted by one to five substituents independently selected from the following: halogen, oxo, hydroxy, cyano, -NH2, -NHC. 1-3 Alkyl, -N(C) 1-3 Alkyl)2, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; R 1 It is hydrogen, halogenated group, hydroxyl group, cyano group, C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy or C 1-3 Halogenated alkoxy groups; Each R 2 Independently, it is hydrogen and C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 3-6 Cycloalkyl, phenyl, 4- to 6-membered heterocyclic or 5- to 6-membered heteroaryl; wherein R 2 Each C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 3-6 The cycloalkyl, phenyl, 4- to 6-membered heterocyclic or 5- to 6-membered heteroaryl groups are independently and optionally substituted by one to five substituents independently selected from the following: halogroup, hydroxyl group, cyano group, C4 group, C6 group, C5 group, C6 ...1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy or C 1-3 Halogenated alkoxy groups; Or R 2 and R 1 R 3 R 3a R 6 R 7 and R 8 Each of them, together with the atoms to which they are attached, forms C. 3-10 cycloalkyl, heterocyclic, or heteroaryl; wherein the C 3-10 Cycloalkyl, heterocyclic, or heteroaryl groups are optionally separated by one to five Z groups. 2 replace; Each R 2a and R 2b Independently, it is hydrogen and C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 2a and R 2b Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 2a replace; Or R 2a and R 2b Together with the atoms to which they are attached, they form independently, optionally, one to five Z. 2a Substituted heterocyclic groups; Each R 3 Each is independently a hydroxyl group, -NR 3b R 3c C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 3 Each C 1-6 Alkyl, C 2-6 alkenyl, C2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 3 replace; Or two Rs 3 Together with one or more atoms to which they are attached, they form C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein the C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally separated by one to five Z groups. 3 replace; Or two Rs 3 Together with the carbon atoms attached to both, they form oxo groups; Each R 3a Independently, it is hydrogen and C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 3a Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 3a replace; Or two Rs 3a Together with one or more atoms to which they are attached, they form C 3-10 cycloalkyl, heterocyclic, or heteroaryl; wherein the C 3-10 Cycloalkyl, heterocyclic, or heteroaryl groups are optionally separated by one to five Z groups. 3a replace; Or two Rs 3a Together with the carbon atoms attached to both, they form oxo groups; R 3b and R 3c Each is independently hydrogen, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 3b and R 3c Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 The cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally and independently substituted by one to five substituents independently selected from the following: halogenated, hydroxyl, cyano, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; Or R 3b and R 3c Together with the nitrogen atoms to which they are attached, they form optional groups of one to five Zn atoms. 3b Substituted heterocyclic groups; R 4 It is C 1-6 Alkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein the C of R4 is... 1-6 Alkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 4 replace; R 5 It is hydrogen, halogenated group, hydroxyl group, amino group, cyano group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein the C of R5 is... 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 5 replace; R 6 It is hydrogen, C 1-3 Alkyl, C 1-3 Haloalkyl, C 3-6 cycloalkyl or 4- to 6-membered heterocyclic groups; wherein the C 1-3 Alkyl, C 1-3 Haloalkyl, C 3-6 The cycloalkyl or 4- to 6-membered heterocyclic group is optionally substituted by one to five independent substituents selected from the following: halogen, oxo, hydroxyl, cyano, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3Halogenated alkoxy groups; R 7 It is hydroxyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Alkyl or C 1-3 Halogenated alkyl groups; R 8 It is hydrogen, -S(O)2-C 1-3 Alkyl, -S(O)2-C 1-3 Haloalkyl, C 1-3 Alkyl, C 1-3 Halogenated alkyl C 3-6 cycloalkyl or 4- to 6-membered heterocyclic groups; wherein R 8 -S(O)2-C 1-3 Alkyl, -S(O)2-C 1-3 Haloalkyl, C 1-3 Alkyl, C 1-3 Halogenated alkyl C 3-6 The cycloalkyl or 4- to 6-membered heterocyclic group is optionally substituted by one to five independent substituents selected from the following: halogen, oxo, hydroxyl, cyano, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; Each Z A Z 2 Z 2a Z 3 Z 3a Z 3b Z 4 and Z 5 Independently, it is a halogenated group, a cyano group, a nitro group, an oxo group, or a C group. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, heteroaryl, -LH, -LC 1-6 Alkyl, -LC 2-6 alkenyl, -LC 2-6 alkynyl, -LC 1-6 Halogenated alkyl, -LC 3-10 Cycloalkyl, -L-heterocyclic, -L-aryl, or -L-heteroaryl; wherein Z A Z 2 Z 2a Z 3 Z 3a Z 3b Z 4 and Z 5 Each C1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are each independently and optionally divided by one to five Z groups. 1a replace; Each L is independently -O-, -S-, -NR 20 -, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -C(O)NR 20 -、-NR 20 C(O)-、-OC(O)NR 20 -、-NR 20 C(O)O-、-NR 20 C(O)NR 21 -, -S(O)-, -S(O)2-, -S(O)NR 20 -、-S(O)2NR 20 -、-NR 20 S(O)-、-NR 20 S(O)2-、-NR 20 S(O)NR 21 -or-NR 20 S(O)2NR 21 -; Each R 20 and R 21 Independently, it is hydrogen and C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 20 and R 21 Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 1a Replace; or R 20 and R 21 Together with the atoms to which they are attached, they form independently, optionally, one to five Z. 1a Substituted heterocyclic groups; and Each Z 1a Independently, it can be a halogenated group, hydroxyl group, cyano group, nitro group, oxo group, -SH, -NH2, or -NH-C group. 1-6 Alkyl, -N(C) 1-6Alkyl)2, -SC 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein Z 1a Each -NH-C 1-6 Alkyl, -N(C) 1-6 Alkyl)2, -SC 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 The cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally and independently substituted by one to five substituents independently selected from the following: C 1-6 Alkyl, oxo, halogen, hydroxyl, and cyano groups.
[0082] In some implementations, when A is C 1-6 When alkylene, then R 5 It is C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein the C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups may be substituted independently or optionally.
[0083] In some implementation schemes, Y 1 is -C(O)-, -S(O)2-, -S(O)(NR 6 - or - P(O)(R 7 )-;Y 2 It is -O-, -S-, -NR 2 -or-C(R) 2 )2-; and Y 1 With Y 2 The bond between them is a single bond; and Y 3 Yes -NR 8 -、-C(R 3 )2-、-C(R 3a )2-C(R 3a )2- or -C(R 3a )2-C(R 3a )2-C(R 3a )2-.
[0084] In some implementation schemes, Y 1 is -C(O)-, -S(O)2-, -S(O)(NR 6- or - P(O)(R 7 )-;Y 2 It is -O-, -S-, -NR 2 -or-C(R) 2 )2-; and Y 1 With Y 2 The bond between them is a single bond; and Y 3 Yes -NR 8 -
[0085] In some implementation schemes, R 6 It is C 1-3 alkyl.
[0086] In some implementation schemes, R 7 It is C 1-3 alkyl.
[0087] In some implementation schemes, Y 1 It is -C(O)- or -S(O)2-.
[0088] In some implementation schemes, Y 1 It is -C(O)- or -S(O)2-; and Y 1 With Y 2 The key between them is a single key.
[0089] In some implementation schemes, Y 1 It is -C(O)-.
[0090] In some implementation schemes, Y 1 It is -C(O)-; and Y 1 With Y 2 The key between them is a single key.
[0091] In some implementation schemes, Y 1 It is -S(O)2-; and Y 1 With Y 2 The key between them is a single key.
[0092] In some implementation schemes, Y 2 Yes -NR 2 -or-C(R) 2 )2-; and Y 1 With Y 2 The key between them is a single key.
[0093] In some implementation schemes, Y 2 Yes -NR 2 -or-C(R) 2 )2-; and Y 1 With Y 2 The key between them is a single key.
[0094] In some implementation schemes, Y 2 It is -NR2-.
[0095] In some implementation schemes, Y 2 Yes -NR 2 -;and Y 1 With Y 2 The key between them is a single key.
[0096] In some implementation schemes, Y 1 It is -C(O)-; and Y 2 Yes -NR 2 -;and Y 1 With Y 2 The key between them is a single key.
[0097] In some implementation schemes, Y 3 Is it -N- or -C(R)? 3 )2-.
[0098] In some implementation schemes, Y 3 It is -C(R) 3 )2-.
[0099] In some implementation schemes, Y 1 It is -C(O)- or -S(O)2-; Y 2 Yes -NR 2 -or-C(R) 2 )2-; and Y 1 With Y 2 The bond between them is a single bond; and Y 3 Is it -N- or -C(R)? 3 )2-.
[0100] In some embodiments, a compound of formula IA is provided: IA Or its pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates, wherein each X 1 X 2 X 3 X 4 A, L 1 L 2 R 2 R 3 R 4 and R 5 Independently as defined in this article.
[0101] In some implementation schemes, R 2 and R 3 Together with the atoms to which they are attached, they form a group optionally bounded by one to five Z. 2Substituted heterocyclic groups.
[0102] In some implementation schemes, R 2 and R 3 Together with the atoms to which they are attached, they form unsubstituted heterocyclic groups.
[0103] In some implementation schemes, R 2 It is hydrogen.
[0104] In some implementations, each R 3 Independently hydrogen or C 1-3 alkyl.
[0105] In some implementations, a compound of formula IB is provided: IB Or its pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates, wherein each X 1 X 2 X 3 X 4 A, L 1 L 2 R 3 R 4 and R 5 Independently as defined in this article.
[0106] In some implementations, a compound of formula IC is provided: IC Or its pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates, wherein each X 1 X 2 X 3 X 4 A, L 1 L 2 R 3 R 4 and R 5 Independently as defined in this article.
[0107] In some implementations, a compound of formula ID is provided: ID Or its pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates, wherein each X 1 X 2 X 3 X 4 A, L 1 L 2 R 4 and R 5Independently as defined in this article.
[0108] In some implementations, a compound of formula IE is provided: IE Or its pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates, wherein each X 1 X 2 X 3 X 4 A, L 1 L 2 R 4 and R 5 Independently as defined in this article.
[0109] In some implementations, a compound of formula IF is provided: IF Or its pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates, wherein each X 1 X 2 X 3 X 4 A, L 1 L 2 R 4 and R 5 Independently as defined in this article.
[0110] In some embodiments, a compound of formula IG is provided: IG Or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or solvate thereof, wherein each A, L 1 L 2 R 2 R 3 R 4 and R 5 Independently as defined in this article.
[0111] In some implementation schemes, R 2 and R 3 Together with the atoms to which they are attached, they form a group optionally bounded by one to five Z. 2 Substituted heterocyclic groups.
[0112] In some implementation schemes, R 2 and R 3 Together with the atoms to which they are attached, they form unsubstituted heterocyclic groups.
[0113] In some implementation schemes, R 2 It is hydrogen.
[0114] In some implementations, each R 3 Independently hydrogen or C 1-3 alkyl.
[0115] In some embodiments, a compound of formula IH is provided: IH Or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or solvate thereof, wherein each A, L 1 L 2 R 3 R 4 and R 5 Independently as defined in this article.
[0116] In some embodiments, a compound of formula IJ is provided: IJ Or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or solvate thereof, wherein each A, L 1 L 2 R 3 R 4 and R 5 Independently as defined in this article.
[0117] In some embodiments, a compound of formula IK is provided: IK Or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or solvate thereof, wherein each A, L 1 L 2 R 4 and R 5 Independently as defined in this article.
[0118] In some embodiments, a compound of the formula IL is provided: IL Or its pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates, wherein each X 1 X 2 X 3 X 4 A, L 1 L 2 R 4 and R 5 Independently as defined in this article.
[0119] In some implementations, a compound of formula IM is provided: IM Or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or solvate thereof, wherein each A, L 1 L 2 R 4 and R 5 Independently as defined in this article.
[0120] In some implementations, A is C 1-6 Alkylene, C 3-10 Cycloalkylene, heterocyclic, arylene, or heteroarylene; wherein the C of A 1-6 Alkylene, C 3-10 Cycloalkylene, heterocycloalkylene, arylene, or heteroarylene is independently and optionally surrounded by one to five Z. A replace.
[0121] In some implementations, A is C 1-6 Alkylene, C 3-10 Cycloalkylene, 3- to 10-membered heterocyclic cycloidenes, C 6-10 arylene or 5- to 10-membered heteroarylene; wherein each group is independently and optionally surrounded by one to five Z. A replace.
[0122] In some implementations, A is C 3-10 Cycloalkylene, 3- to 10-membered heterocyclic cycloidenes, C 6-10 arylene or 5- to 10-membered heteroarylene; wherein each group is independently and optionally surrounded by one to five Z. A replace.
[0123] In some implementations, A is C 3-10 Cycloalkylene or 3 to 10-membered heterocyclic alkylene; wherein the cycloalkylene or heterocyclic alkylene is optionally surrounded by one to five Z-membered groups. A replace.
[0124] In some embodiments, A is an arylene or heteroarylene; wherein the arylene or heteroarylene is optionally surrounded by one to five Z. A replace.
[0125] In some implementations, A is optionally defined by one to five Z. A Substituted aryl groups.
[0126] In some implementations, A is optionally defined by one to five Z. A Substituted heteroaryl groups.
[0127] In some implementations, A is optionally defined by one to five Z. A Replacement C 3-10 Cycloalkylene.
[0128] In some implementations, A is optionally defined by one to five Z. A Replaced 3 to 10 heterocyclic subgroups.
[0129] In some implementations, A is unsubstituted C. 3-10 Cycloalkylene, unsubstituted 3- to 10-membered heterocyclic alkylene, unsubstituted C 6-10 Aryl or unsubstituted 5 to 10 heteroarylene compounds.
[0130] In some implementations, A is an unsubstituted aryl group.
[0131] In some implementations, A is an unsubstituted heteroaryl group.
[0132] In some implementations, A is unsubstituted C. 3-10 Cycloalkylene.
[0133] In some implementations, A is an unsubstituted 3- to 10-membered heterocyclic subgroup.
[0134] In some implementations, A is methylene, ethylene, n-propylene, , , , , , , , , , , , , , , , , , , , , , , or ;where bond a and L 2 Bonding.
[0135] In some implementation schemes, A is , , , , , , , , , , , , , , , , , or Each group is independently and optionally divided by one to five Z groups. A Replacement; and where bond a and L 2 Bonding.
[0136] In some implementation schemes, A is , , , , , , , , , , , , , , , , , or Each group is independently and optionally substituted by one to three substituents independently selected from the following: halogenated groups, C... 1-6 Alkyl and C 1-6 Haloalkyl; and wherein bond a and L 2 Bonding.
[0137] In some implementation schemes, A is , , , , , , , , , , , , , , , , , or Each group is independently and optionally substituted by one to three substituents independently selected from the following: C 1-6 Alkyl and C 1-6 Haloalkyl; and wherein bond a and L 2 Bonding.
[0138] In some implementation schemes, A is , , , , , , , , , , , , , , , , , , or Each group is independently and optionally substituted by one to three substituents independently selected from the following: methyl, CHF2, and CF3; and wherein bond a is opposite to L. 2 Bonding.
[0139] In some embodiments, A is , , , , , , , , , or ; and where the bond a and L 2 Bonding.
[0140] In some implementation schemes, A is , , , , , or ;where bond a and L 2 Bonding.
[0141] In some implementation schemes, A is or ;where bond a and L 2 Bonding.
[0142] In some implementation schemes, X 1 X 2 X 3 and X 4 At least one of them is not CH or CR B .
[0143] In some implementation schemes, X 1 X 2 X 3 and X 4 At least one of them is O, S, N, NH or NRA .
[0144] In some implementation schemes, X 1 Is it O, NH or NR? A In some implementations, X 1 It is O. In some implementations, X 1 Is it NH or NR? A In some implementations, X 1 It is NH. In some implementations, X 1 It is NR A In some implementations, R A It is methyl. In some embodiments, X 1 It is O, NH or NCH3.
[0145] In some implementation schemes, X 2 It is C(O). In some implementations, part of yes .
[0146] In some implementation schemes, X 3 Is it O, NH or NR? A In some implementations, X 3 It is O. In some implementations, X 3 Is it NH or NR? A In some implementations, X 3 It is NH. In some implementations, X 3 It is NR A In some implementations, R A It is a methyl group.
[0147] In some implementation schemes, X 3 It is C(O). In some implementations, part of yes .
[0148] In some implementation schemes, X 2 Is it O, NH or NR? A In some implementations, X 2 It is O. In some implementations, X 2 Is it NH or NR? A In some implementations, X 2 It is NH. In some implementations, X 2 It is NR A In some implementations, R A It is a methyl group.
[0149] In some implementation schemes, X 4 Is it N, CH or CR?B In some implementations, X 4 It is N or CH. In some implementations, X 4 It is N. In some implementations, X 4 It is CH.
[0150] In some implementation schemes, part yes or .
[0151] In some implementation schemes, part for , , or Each group is optionally R B replace.
[0152] In some implementation schemes, part yes , or Each group is optionally R B replace.
[0153] In some implementations, each R B C is independent 1-3 alkyl.
[0154] In some implementation schemes, part yes , , or ;
[0155] In some implementations, L 1 It is C 1-3 Alkylene or C 1-3 Heteroalkylene groups; wherein each group is optionally substituted with one to five independently selected halogroups. In some embodiments, L 1 It is C 1-3 Alkylene or C 1-3 Heteroalkylene compounds. In some embodiments, L 1 It is C 1-3 Alkylene.
[0156] In some implementation schemes, R 4 It is arbitrarily selected by one to five Z. 4 Replacement C 1-6 alkyl.
[0157] In some implementation schemes, R 4 It is an aryl or heteroaryl group; wherein the aryl or heteroaryl group is optionally composed of one to five Z groups. 4replace.
[0158] In some implementation schemes, R 4 It is C 3-10 cycloalkyl or aryl; wherein, the C 3-10 cycloalkyl or heteroaryl groups are optionally separated by one to five Z groups. 4 replace.
[0159] In some implementation schemes, R 4 It is C 3-10 cycloalkyl or aryl; wherein the C 3-10 cycloalkyl or heteroaryl groups are optionally replaced by halogenated groups, C 1-6 Alkyl, C 1-6 Halogenated alkyl or C 3-10 Cycloalkyl substitution.
[0160] In some implementation schemes, R 4 It is cyclohexyl or phenyl; wherein the cyclohexyl or phenyl is optionally surrounded by one to five Z-terminal radicals. 4 replace.
[0161] In some embodiments, R 4 It is cyclohexyl or phenyl; wherein the cyclohexyl or phenyl is independently and optionally converted by a halogenated group, C 1-6 Alkyl, C 1-6 Halogenated alkyl or C 3-10 Cycloalkyl substitution.
[0162] In some implementation schemes, R 4 It is C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 4 C 1-6 Alkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 4 replace.
[0163] In some implementation schemes, R 4 It is C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 4 C 1-6 Alkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally replaced by halogenated groups, C... 1-6 Alkyl, C 1-6 Halogenated alkyl or C 3-10 Cycloalkyl substitution.
[0164] In some implementation schemes, R 4 It is C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 4 C 1-6 Alkyl, C3-10 The cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally substituted by one to three substituents independently selected from the following: halogenated, C... 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, heteroaryl and C 3-10 Cycloalkyl.
[0165] In some implementation schemes, R 4 It is phenyl, , , , , , or Each group is independently and optionally divided by one to three Z groups. 4 replace.
[0166] In some implementation schemes, R 4 It is phenyl, , , , , , or Each group is independently and optionally substituted by one to three substituents independently selected from the following: halogenated groups, C... 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, pyrazolyl and C 3-6 Cycloalkyl.
[0167] In some implementations, L 1 -R 4 yes , , , , , , , , , , , , , , , , , , or .
[0168] In some implementations, L 2 It is a key, -NR 2a-、-C(O)-、-C(O)NR 2a -、-NR 2a C(O)-, C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 1-6 Heteroalkylene, 4-6-membered heterocyclic alkylene, or 5-membered heteroaryl; wherein the C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 1-6 The heteroalkylene, 4-6-membered heterocyclic or 5-membered heteroarylene is independently and optionally substituted by one to five substituents independently selected from the following: halogroup, oxogroup, hydroxyl group, cyano group, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups.
[0169] In some implementations, L 2 It is a bond, -C(O)-, -NR 2a -、-C(O)NR 2a -、-NR 2a C(O)-, C 1-6 Alkylene, C 1-6 Heteroalkylene, 4-6-membered heterocyclic alkylene, or 5-membered heteroaryl; wherein the C 1-6 Alkylene, C 1-6 The heteroalkylene, 4-6-membered heterocyclic or 5-membered heteroarylene is independently and optionally substituted by one to five substituents independently selected from the following: halogroup, oxogroup, hydroxyl group, cyano group, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups.
[0170] In some embodiments, L 2 It is a key, -NR 2a -、-C(O)-、-C(O)NR 2a -、C 1-6 Alkylene, C 1-6 Heteroalkylene or 4-6-membered heterocyclic alkylene; wherein the C 1-6 Alkylene or C 1-6 The heteroalkylene group is optionally substituted by one to three independent substituents selected from methyl and oxo groups.
[0171] In some embodiments, L 2 It is a key, -NR 2a -、-C(O)-、-C(O)NR 2a -、C1-6 Alkylene, C 1-6 Heteroalkylene or 4-6-membered heterocyclic alkylene; wherein the C 1-6 Alkylene or C 1-6 The heteroalkylene group may optionally be substituted with a methyl group.
[0172] In some implementation schemes, R 2a It is hydrogen or methyl. In some embodiments, R 2a It is hydrogen.
[0173] In some implementations, L 2 It is a key, -NR 2a -、-C(O)-、-C(O)NR 2a -、C 1-6 Alkylene, C 1-6 Heteroalkylene or 4-6-membered heterocyclic alkylene; wherein R 2a It is hydrogen or methyl; and wherein the C is... 1-6 Alkylene or C 1-6 The heteroalkylene group may optionally be substituted with a methyl group.
[0174] In some implementations, L 2 It is a key, -NR 2a -、-C(O)-、-C(O)NR 2a -、C 1-6 Alkylene, C 1-6 Heteroalkylene or 4-6-membered heterocyclic alkylene; wherein R 2a It is hydrogen or methyl; and wherein the C is... 1-6 Alkylene or C 1-6 The heteroalkylene group is optionally substituted by one to three independent substituents selected from methyl and oxo groups.
[0175] In some implementations, L 2 The following are bonds: -NH-, -NHCH2-, -NH-CH(CH3)-, -N(CH3)-CH2-, -OCH2-, -CH2-, -CH2CH2-, -C(O)-, -C(O)NH-CH2-, -C(O)N(CH3)-CH2-.
[0176] In some embodiments, L 2 The following are bonds: -NH-, -NHCH2-, -NH-CH(CH3)-, -N(CH3)-CH2-, -OCH2-, -CH2-, -CH(CH3)-, -CH2CH2-, -C(O)-, -C(O)NH-CH2-, -C(O)N(CH3)-CH2-.
[0177] In some implementation schemes, R 5 It is hydrogen, halogenated group, amino group, cyano group, C1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 5 replace.
[0178] In some implementation schemes, R 5 It is C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 5 The cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally surrounded by one to five Z groups. 5 replace.
[0179] In some implementation schemes, R 5 It is C 3-10 cycloalkyl, heterocyclic or aryl; wherein R 5 The cycloalkyl, heterocyclic, or aryl groups are independently and optionally surrounded by one to five Z groups. 5 replace.
[0180] In some implementation schemes, R 5 It is arbitrarily C 3-10 C-substituted with cycloalkyl, heterocyclic, aryl or heteroaryl groups 1-6 Alkyl; wherein the C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally separated by one to five Z groups. 1a replace.
[0181] In some implementation schemes, R 5 It is C 1-6 Alkyl, aryl, or heteroaryl; wherein the aryl or heteroaryl group is optionally composed of one to five Z-terminal groups. 5 replace.
[0182] In some implementation schemes, R 5 It is an aryl or heteroaryl group; wherein the aryl or heteroaryl group is optionally composed of one to five Z groups. 5 replace.
[0183] In some implementation schemes, R 5 It is hydrogen, halogenated group, amino group, cyano group, C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 cycloalkyl, heterocyclic, or aryl; wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 3-10 Cycloalkyl, heterocyclic, or aryl groups are independently and optionally bound by one to five Z groups. 5 replace.
[0184] In some implementation schemes, R 5 It is C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 5 The cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally surrounded by one to five Z groups. 5 Replace, and at least one of them Z 5 The radical is fluorine.
[0185] In some implementation schemes, R 5 yes , , , , , , , , , , , , or Each group is independently and optionally divided by one to five Z groups. 5 replace.
[0186] In some implementation schemes, R 5 yes , , , , , , , , , , , , or Each group is independently and optionally substituted by one to five substituents independently selected from the following: halogenated groups, C... 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Halogenated alkyl, cyano and halogenated phenyl groups.
[0187] In some implementations, L 2 -R 5 yes , , , , , , , , , , , , , , , , , , , , , , , , , or Each group's ring moiety is independently and optionally substituted by one to five substituents independently selected from the following: halogenated groups, C... 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 1-6 Halogenated alkyl, cyano and halogenated phenyl groups.
[0188] In some implementation schemes, R 6 It is C 1-3 Alkyl or cyclopropyl. In some embodiments, R 6 It is C 1-3 alkyl.
[0189] In some implementation schemes, R 7 It is C 1-3 Alkyl or cyclopropyl. In some embodiments, R 7 It is C 1-3 alkyl.
[0190] In some embodiments, compounds selected from Table 1, or pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates thereof are provided: Table 1
[0191] The compounds of Formula I provided herein cover stereochemical forms of the compounds, such as optical isomers, enantiomers, diastereomers, and mixtures thereof, such as mixtures of enantiomers and / or diastereomers, including racemic mixtures, and homogeneous or heterogeneous mixtures of individual enantiomers and / or diastereomers. All stereochemical forms are considered in this disclosure. Unless otherwise indicated, when a disclosed compound is named or described by its structure without specifying a stereochemistry and has one or more chiral centers, it should be understood to represent all possible stereoisomers of the compound. Representative stereochemical forms are provided throughout the specification, including but not limited to those described in Table 2. In some embodiments, compounds selected from Table 2, or pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates thereof are provided: Table 2
[0192] Compounds of Formula I and its derivatives include pharmaceutically acceptable salts. Furthermore, compounds of Formula I and its derivatives also include other salts of such compounds, which are not necessarily pharmaceutically acceptable salts and can serve as intermediates for the preparation and / or purification of compounds of Formula I and its derivatives and / or for the isolation of enantiomers of compounds of Formula I and its derivatives.
[0193] It should also be understood that compounds of Formula I and its sub-forms, or their salts, can be isolated as solvates, and therefore any such solvates are included within the scope of this disclosure. For example, compounds of Formula I and its sub-forms and their respective salts can exist in non-solventized forms as well as in forms solvated with pharmaceutically acceptable solvents (such as water, ethanol, etc.). Pharmaceutical composition and administration
[0194] When used as a medicine, compounds as described herein (e.g., one or more compounds disclosed herein, or stereoisomers or mixtures thereof) may be administered in the form of pharmaceutical compositions. These compositions may be prepared in a manner well known in the pharmaceutical field and may be administered via a variety of routes, depending on whether local or systemic treatment is desired and the area to be treated. Administration may be external (including transdermal, epidermal, ocular, and mucous membrane delivery, including intranasal, vaginal, and rectal delivery), pulmonary (e.g., by inhalation or blowing of powders or aerosols, including via nebulizers; intratracheal or intranasal), oral, or parenteral. Oral administration may include formulations for once-daily or twice-daily (BID) administration. Parenteral administration includes intravenous, intra-arterial, subcutaneous, intraperitoneal, intramuscular, injection, or infusion; or intracranial, such as intrathecal or intraventricular administration. Parenteral administration may be in the form of a single bolus dose or may be administered, for example, via a continuous infusion pump. Pharmaceutical compositions and formulations for external application may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders. Conventional drug carriers, aqueous, powdered, or oily bases, thickeners, etc., may be necessary or desirable.
[0195] This document also provides pharmaceutical compositions comprising one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, as active ingredients, in combination with one or more pharmaceutically acceptable excipients (carriers). For example, pharmaceutical compositions prepared using one or more compounds as disclosed herein, or stereoisomers or mixtures thereof.
[0196] In one embodiment, a pharmaceutical composition is provided comprising a compound as disclosed herein, a stereoisomer or mixture thereof, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. In another embodiment, a pharmaceutical composition is provided comprising a compound as disclosed herein, a stereoisomer or mixture thereof, a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein the compound, a stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof is present in the pharmaceutical composition in amounts greater than about 0.1%, greater than about 1%, greater than about 5%, greater than about 10%, greater than about 15%, greater than about 20%, and greater than about 25% by weight. %, greater than about 35%, or greater than about 40%, or greater than about 45%, or greater than about 50%, or greater than about 55%, or greater than about 60%, or greater than about 65%, or greater than about 70%, or greater than about 75%, or greater than about 80%, or greater than about 85%, or greater than about 90%, or greater than about 95% purity, or about 40%, or about 45%, or about 50%, or about 55%, or about 60%, or about 65%, or about 70%, or about 75%, or about 80%, or about 85%, or about 90%, or about 95%.
[0197] In some embodiments, the composition is suitable for external application. In manufacturing the compositions provided herein, the active ingredient is typically mixed with an excipient, diluted with the excipient, or encapsulated in a carrier, such as a capsule, sachet, paper, or other container. When the excipient is used as a diluent, it can be a solid, semi-solid, or liquid material that acts as a medium, carrier, or medium for the active ingredient. Therefore, the composition can be in the following forms: tablets, pills, powders, lozenges, sachets, capsules, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments (containing, for example, up to 10% by weight of the active compound), soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders. In some embodiments, the composition is formulated for oral administration. In some embodiments, the composition is a solid oral formulation. In some embodiments, the composition is formulated as a tablet or capsule.
[0198] This document further provides pharmaceutical compositions comprising one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, and pharmaceutically acceptable excipients. Pharmaceutical compositions comprising one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, as active ingredients can be prepared according to conventional pharmaceutical compounding techniques by thoroughly mixing one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, with a pharmaceutical carrier. The carrier can take many forms, depending on the desired route of administration (e.g., oral, parenteral). In some embodiments, the composition is a solid oral composition.
[0199] Suitable pharmaceutically acceptable carriers are well known in the art. Descriptions of some of these pharmaceutically acceptable carriers can be found in The Handbook of Pharmaceutical Excipients, published by the American Pharmaceutical Association and the Pharmaceutical Society of Great Britain.
[0200] Methods for preparing pharmaceutical compositions have been described in several publications, such as Pharmaceutical Dosage Forms: Tablets, Second Edition, Revised and Supplemented, Volumes 1–3, edited by Lieberman et al.; Pharmaceutical Dosage Forms: Parenteral Medications, Volumes 1–2, edited by Avis et al.; and Pharmaceutical Dosage Forms: Disperse Systems, Volumes 1–2, edited by Lieberman et al.; published by Marcel Dekker, Inc.
[0201] In some embodiments, the compound or pharmaceutical composition may be administered in combination with one or more conventional pharmaceutical excipients. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers; alumina; aluminum stearate; lecithin; self-emulsifying drug delivery systems (SEDDS), such as d-α-tocopherol polyethylene glycol 1000 succinate; surfactants used in pharmaceutical dosage forms, such as Tween, poloxamer, or other similar polymeric delivery matrices; serum proteins, such as human serum albumin; buffering substances, such as phosphates, tris, glycine, sorbic acid, potassium sorbate; mixtures of saturated vegetable fatty acids in the form of glycerides; water, salts, or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts; colloidal silica; magnesium trisilicate; polyvinylpyrrolidone; cellulose-based substances; polyethylene glycol; sodium carboxymethyl cellulose; polyacrylates; waxes; polyethylene-polyoxypropylene block copolymers; and lanolin. Cyclodextrins (such as α-cyclodextrin, β-cyclodextrin, and γ-cyclodextrin) or chemically modified derivatives (such as hydroxyalkyl cyclodextrins, including 2- and 3-hydroxypropyl-β-cyclodextrin) or other solubilizing derivatives can also be used to facilitate the delivery of the compounds described herein. Dosage forms or compositions containing 0.005% to 100% of the chemical entities described herein, with the balance consisting of non-toxic excipients, can be prepared. The compositions under consideration may contain 0.001%–100%, 0.1%–95% in one embodiment, 75%–85% in another embodiment, and 20%–80% in yet another embodiment of the chemical entities provided herein. Practical methods for preparing such dosage forms are known to or will be apparent to those skilled in the art; see, for example, Remington: The Science and Practice of Pharmacy, 22nd edition (Pharmaceutical Press, London, UK. 2012).
[0202] In some implementations, the compounds and pharmaceutical compositions described herein, or pharmaceutical compositions thereof, may be administered to patients in need via any acceptable route of administration. Acceptable routes of administration include, but are not limited to, buccal, skin, intracervical, intrasinus, trachea, intestine, epidural, interstitial, intraperitoneal, intraarterial, intrabronchial, intracystic, intracerebral, intracisary, intracoronary, intradermal, intracatheter, duodenal, intradural, intraepithelial, intraepithelial, esophageal, intragastric, intragingival, intraileum, intraileum, intralymphatic, intramedullary, intrameningeal, intramuscular, intraovarian, intraperitoneal, intraprostatic, intrapulmonary, intrasinus, spinal cord, intrasynovial, intratesticular, intrasheath, intraduct, intrauterine, intravascular, intravenous, nasal (e.g., intranasal), nasogastric, oral, parenteral, percutaneous, transdural, rectal, respiratory (inhalation), subcutaneous, sublingual, submucosal, topical, transdermal, transmucosal, tracheal, ureteral, urethral, and vaginal. In some implementations, the route of administration is parenteral (e.g., intratumoral).
[0203] In some embodiments, one or more compounds as disclosed herein, or stereoisomers or mixtures thereof as described herein, or pharmaceutical compositions thereof, may be formulated for parenteral administration, for example, for injection via intra-arterial, intrasternal, intracranial, intravenous, intramuscular, subcutaneous, or intraperitoneal routes. Such compositions may be prepared as injectable formulations, as liquid solutions or suspensions; or as solid forms suitable for preparation as solutions or suspensions after the addition of liquid prior to injection; and may also be emulsified formulations. The preparation of such formulations will be known to those skilled in the art based on this disclosure. In some embodiments, a device is used for parenteral administration. Such devices may include, for example, needle injectors, microneedle injectors, needle-free injectors, and infusion techniques.
[0204] In some embodiments, suitable pharmaceutical forms for injection include sterile aqueous solutions or dispersions; formulations containing sesame oil, peanut oil, or aqueous propylene glycol; and sterile powders for the ad hoc preparation of sterile injectable solutions or dispersions. In some embodiments, the form must be sterile and its flowability must be sufficient for easy injection. In some embodiments, the form should be stable under manufacturing and storage conditions and must be preserved against contamination by microorganisms such as bacteria and fungi.
[0205] In some embodiments, the carrier may also be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.), suitable mixtures thereof, and vegetable oils. In some embodiments, suitable flowability can be maintained, for example, by using coatings (such as lecithin), by maintaining the desired particle size in the case of dispersions, and by using surfactants. In some embodiments, antimicrobial activity can be achieved by a variety of antibacterial and antifungal agents (e.g., parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc.). In some embodiments, isotonic agents, such as sugars or sodium chloride, are included. In some embodiments, prolonged absorption of the injectable composition can be achieved by using a delayed-absorption agent (e.g., aluminum monostearate and gelatin) in the composition.
[0206] In some embodiments, a sterile injectable solution is prepared by incorporating one or more compounds, or stereoisomers or mixtures thereof, as disclosed herein, into a suitable solvent containing, as needed, the various other components listed above, followed by filtration sterilization. In some embodiments, a dispersion is prepared by incorporating a variety of sterilized active ingredients into a sterile medium containing a base dispersion medium and other desired components from those listed above. In some embodiments, sterile powders are used to prepare the sterile injectable solution. In some embodiments, preparation methods include vacuum drying and freeze-drying techniques, which produce powders of the active ingredient plus any other desired components from solutions that have been previously sterile filtered.
[0207] In some embodiments, pharmacologically acceptable excipients that may be used in rectal compositions as gels, creams, enemas, or rectal suppositories include, but are not limited to, any one or more of the following: glyceryl cocoa butter, synthetic polymers (such as polyvinylpyrrolidone), PEG (such as PEG ointment), glycerin, glycerin gelatin, hydrogenated vegetable oils, poloxamer, mixtures of polyethylene glycols of different molecular weights and fatty acid esters of polyethylene glycol, petrolatum, anhydrous lanolin, shark liver oil, sodium saccharin, menthol, sweet almond oil, sorbitol, sodium benzoate, anoxid SBN, vanilla essential oil, aerosols, parabens in phenoxyethanol, sodium methylparaben, sodium propylparaben, diethylamine, carbomer, carbopol, methylparaben, polyethylene glycol cetearyl ether, cocoyl caprylate (cocoyl ethyl ethyl decanoate). Caprylocaprate), isopropanol, propylene glycol, liquid paraffin, xanthan gum, carboxymethyl metabisulfite, sodium edetate, sodium benzoate, potassium metabisulfite, grapefruit seed extract, methanesulfonylmethane (MSM), lactic acid, glycine, vitamins (such as vitamins A and E), and potassium acetate.
[0208] In some embodiments, the suppository can be prepared by mixing one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, or pharmaceutical compositions as described herein, with a suitable non-irritating excipient or carrier (such as cocoa butter, polyethylene glycol, or suppository wax), which is solid at ambient temperature but liquid at body temperature, thus melting in the rectum and releasing the active compound. In some embodiments, the composition for rectal administration is in the form of an enema.
[0209] In some embodiments, one or more compounds as disclosed herein, or stereoisomers or mixtures thereof as described herein, or pharmaceutical compositions thereof, are formulated for local delivery to the digestive tract or GI tract by means of oral administration (e.g., solid or liquid dosage forms).
[0210] In some implementations, solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In some embodiments, one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, are mixed with one or more pharmaceutically acceptable excipients, such as sodium citrate or dicalcium phosphate, and / or: a) fillers or extenders, such as starch, lactose, sucrose, glucose, mannitol, and silica; b) binders, such as, for example, carboxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; c) humectants, such as glycerin; d) disintegrants, such as agar, calcium carbonate, potato or cassava starch, alginate, certain silicates, and sodium carbonate; e) solution blockers, such as paraffin; f) absorption enhancers, such as quaternary ammonium compounds; g) wetting agents, such as, for example, cetyl alcohol and glyceryl monostearate; h) adsorbents, such as kaolin and bentonite; and i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, and mixtures thereof. For example, in the case of capsules, tablets, and pills, the dosage form may also contain a buffer. In some embodiments, similar types of solid compositions may also be used as fillers in soft-filled and hard-filled gelatin capsules, which use excipients such as lactose or toffee and high molecular weight polyethylene glycol.
[0211] In some embodiments, the pharmaceutical composition will be in the form of a unit dosage form (such as a pill or tablet), and therefore, in addition to one or more compounds as disclosed herein, or stereoisomers or mixtures thereof as provided herein, the composition may contain diluents such as lactose, sucrose, dicalcium phosphate, etc.; lubricants such as magnesium stearate, etc.; and binders such as starch, gum arabic, polyvinylpyrrolidone, gelatin, cellulose, cellulose derivatives, etc. In some embodiments, another solid dosage form (i.e., powder, granules (marume)), solution, or suspension (e.g., in propylene carbonate, vegetable oil, PEG, poloxamer 124, or triglycerides) is encapsulated in a capsule (gelatin or cellulose-based capsule). In some embodiments, unit dosage forms in which one or more compounds and pharmaceutical compositions or additional active agents as provided herein are physically separated are also considered; for example, capsules having granules (or tablets in capsule form) of each drug; two-layer tablets; two-compartment gel capsules, etc. In some implementations, enteric-coated or delayed-release oral dosage forms are also considered.
[0212] In some embodiments, other physiologically acceptable compounds may include wetting agents, emulsifiers, dispersants, or preservatives that are particularly effective in preventing the growth or action of microorganisms. For example, a variety of preservatives are well known and include, for example, phenol and ascorbic acid.
[0213] In some embodiments, the excipients are sterile and generally free of undesirable substances. For example, these compositions can be sterilized using conventional, well-known sterilization techniques. In some embodiments, sterility is not required for excipients used in various oral dosage forms, such as tablets and capsules. For example, United States Pharmacopeia / National Formulary (USP / NF) standards may be sufficient.
[0214] In some embodiments, one or more compounds as disclosed herein, or stereoisomers or mixtures thereof as described herein, or pharmaceutical compositions thereof, are formulated for ocular application. In some embodiments, the ocular composition may include, but is not limited to, any one or more of the following: a viscogen (e.g., carboxymethyl cellulose, glycerin, polyvinylpyrrolidone, polyethylene glycol); a stabilizer (e.g., Pluronic (triblock copolymer), cyclodextrin); a preservative (e.g., benzalkonium chloride, EDTA, SofZia (boric acid, propylene glycol, sorbitol, and zinc chloride; Alcon Laboratories, Inc.), Purite (stabilized oxychloride complex; Allergan, Inc.)).
[0215] In some embodiments, one or more compounds as disclosed herein, or stereoisomers or mixtures thereof as described herein, or pharmaceutical compositions thereof, are formulated for topical application to the skin or mucous membranes (e.g., transdermal or percutaneous). In some embodiments, the topical composition may include ointments and creams. In some embodiments, ointments are typically semi-solid formulations based on petrolatum or other petroleum derivatives. In some embodiments, creams containing selected active agents are typically viscous liquids or semi-solid emulsions, generally oil-in-water or water-in-oil. For example, the cream matrix is typically washable and contains an oil phase, an emulsifier, and an aqueous phase. For example, the oil phase (sometimes referred to as the "internal" phase) typically consists of petrolatum and fatty alcohols (such as cetyl alcohol or stearyl alcohol); the aqueous phase is typically (but not necessarily) larger in volume than the oil phase and typically contains a humectant. In some embodiments, the emulsifier in the cream formulation is typically a nonionic, anionic, cationic, or amphoteric surfactant. In some implementations, the ointment base, like other carriers or media, should be inert, stable, non-irritating, and non-sensitizing.
[0216] In any of the foregoing embodiments, the pharmaceutical composition described herein may comprise one or more of the following: lipids, interlayer cross-linked multilayer vesicles, biodegradable poly(D,L-lactic acid-co-glycolic acid) (PLGA)-based or polyanhydride-based nanoparticles or microparticles, and lipid bilayers supported by nanoporous particles.
[0217] The amount of compounds in a pharmaceutical composition or formulation can vary within a full range applicable to those skilled in the art. Typically, based on the total formulation, the formulation will contain about 0.01 wt% to 99.99 wt% of the compounds described herein by weight percentage (wt%), with the balance being one or more suitable pharmaceutical excipients. In one embodiment, the compounds are present at a level of about 1 wt% to 80 wt%. Representative pharmaceutical formulations are described below. Example 1 of formulation - Tablet formulation
[0218] Mix the following ingredients thoroughly and compress them into a single-score tablet. Example 2 of formulation - Capsule formulation
[0219] Mix the following ingredients thoroughly and fill them into hard-shell gelatin capsules. Formulation Example 3 - Suspension Formulation
[0220] The following ingredients are mixed to form a suspension for oral administration. Example 4 of formulations - Injectable formulations
[0221] The following ingredients are mixed to form an injectable formulation. Example 5 of formulation - Suppository formulation
[0222] A suppository with a total weight of 2.5 g was prepared by mixing the compounds of this disclosure with Wiptsol® H-15 (a triglyceride of saturated vegetable fatty acids; Riches-Nelson, Inc., New York), and the suppository has the following composition:
[0223] In some embodiments, the dosage of one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, is determined based on a number of factors, including but not limited to patient type, age, weight, sex, condition, severity of the patient's condition, route of administration, and the activity of the compound or its pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates. In some embodiments, the appropriate dosage for a particular situation may be determined by a person skilled in the medical field. In some embodiments, the total daily dose may be divided and administered in portions throughout the day, or administered by means of continuous delivery.
[0224] In some embodiments, one or more compounds, or stereoisomers or mixtures thereof, as disclosed herein, are administered in doses of about 0.01 to about 1000 mg. Examples include about 0.1 to about 30 mg, about 10 to about 80 mg, about 0.5 to about 15 mg, about 50 mg to about 200 mg, about 100 mg to about 300 mg, about 200 to about 400 mg, about 300 mg to about 500 mg, about 400 mg to about 600 mg, about 500 mg to about 800 mg, about 600 mg to about 900 mg, or about 700 mg to about 1000 mg. In some embodiments, the dose is a therapeutically effective amount.
[0225] In some embodiments, one or more of the compounds disclosed herein, or their stereoisomers or mixtures as described herein, are administered at the following doses: about 0.0002 mg / kg to about 100 mg / kg (e.g., about 0.0002 mg / kg to about 50 mg / kg; about 0.0002 mg / kg to about 25 mg / kg; about 0.0002 mg / kg to about 10 mg / kg; about 0.0002 mg / kg to about 5 mg / kg; about 0.0002 mg / kg to about 1 mg / kg; about 0.0002 mg / kg to about 0.5 mg / kg; about 0.0002 mg / kg to about 0.1 mg / kg; about 0.001 mg / kg to about 50 mg / kg; about 0.001 mg / kg to about 25 mg / kg; about 0.001 mg / kg to about 10 mg / kg). mg / Kg; about 0.001 mg / Kg to about 5 mg / Kg; about 0.001 mg / Kg to about 1 mg / Kg; about 0.001 mg / Kg to about 0.5 mg / Kg; about 0.001 mg / Kg to about 0.1 mg / Kg; about 0.01 mg / Kg to about 50 mg / Kg; about 0.01 mg / Kg to about 25 mg / Kg; about 0.01 mg / Kg to about 10 mg / Kg; about 0.01 mg / Kg to about 5 mg / Kg; about 0.01 mg / Kg to about 1 mg / Kg; about 0.01 mg / Kg to about 0.5 mg / Kg; about 0.01 mg / Kg to about 0.1 mg / Kg; about 0.1 mg / Kg to about 50 mg / Kg; about 0.1 mg / Kg to about 25 mg / Kg; about 0.1 mg / Kg to about 10 mg / Kg mg / Kg; about 0.1 mg / Kg to about 5 mg / Kg; about 0.1 mg / Kg to about 1 mg / Kg; about 0.1 mg / Kg to about 0.5 mg / Kg). In some embodiments, one or more of the compounds disclosed herein, or stereoisomers or mixtures thereof as described herein, are administered at a dose of about 100 mg / Kg.
[0226] In some embodiments, the aforementioned dose of one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, may be administered daily (e.g., as a single dose or as two or more fractional doses) or non-daily (e.g., every other day, every two days, every three days, once a week, twice a week, once every two weeks, once a month).
[0227] In some embodiments, the administration of one or more compounds as disclosed herein, or their stereoisomers or mixtures as described herein, may last for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or longer. In some embodiments, the period of discontinuation of administration may last for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or longer. In some embodiments, one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, are administered to a patient for a sustained period of time, followed by a separate period of discontinuation of administration of one or more compounds as disclosed herein, or stereoisomers or mixtures thereof. In some embodiments, one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, are applied for a first time period, followed by a second time period, during which application is stopped, followed by a third time period initiating application of one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, and then a fourth time period following the third time period initiating application. For example, the time periods for applying one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, and the subsequent time periods for stopping application are repeated for defined or indeterminate time periods. In some embodiments, the application period lasts for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or longer. In some implementation schemes, the period of discontinuation of application may last for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or longer.
[0228] In some embodiments, one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, are administered orally to a patient once or more times daily (e.g., once daily, twice daily, three times daily, four times daily, or a single daily dose).
[0229] In some embodiments, one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, are administered to a patient once or more daily (e.g., 1 to 4 times, once daily, twice daily, three times daily, four times daily, or a single daily dose) via parenteral administration.
[0230] In some embodiments, one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, are administered to a patient weekly via parenteral administration. Treatment
[0231] In some embodiments, this disclosure provides methods for treating a subject (e.g., a person) suffering from a disease, disorder, or condition in which inhibition of one or more calcitonin receptors and / or amylin receptors is beneficial for treating the underlying condition and / or symptoms and / or progression of the disease, disorder, or condition. In some embodiments, the methods provided herein may include treating one or more conditions, comorbidities, or sequelae associated with any one or more of the conditions provided herein.
[0232] This document provides a method for treating calcitonin receptor and / or amylin receptor-related diseases or disorders, the method comprising administering to a subject in need an effective amount of a compound disclosed herein (e.g., a compound of Formula I or any of its subforms, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) or a pharmaceutical composition as disclosed herein. This document also provides a method for treating or preventing calcitonin receptor and / or amylin receptor-related diseases or disorders in a subject in need, the method comprising administering to a subject in need a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I or any of its subforms, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) or a pharmaceutical composition thereof.
[0233] In some implementations, calcitonin receptor and / or amylin receptor-related diseases or disorders are bone disorders, metabolic disorders, pain, neurodegenerative diseases or disorders, cardiovascular diseases, or other diseases or disorders as described herein.
[0234] In some implementation schemes, the disease or disorder includes, but is not limited to, type 1 diabetes, type 2 diabetes, early-onset type 2 diabetes, idiopathic type 1 diabetes (type 1b), juvenile atypical diabetes (YOAD), young adult-onset diabetes (MODY), latent autoimmune diabetes in adults (LADA), obesity, weight gain due to the use of other medications, gout, excessive sugar consumption, hypertriglyceridemia, dyslipidemia, malnutrition-related diabetes, gestational diabetes, kidney disease, adipocyte dysfunction, sleep apnea, visceral fat deposition, eating disorders, cardiovascular disease, congestive heart failure, myocardial infarction, left ventricular hypertrophy, peripheral artery disease, stroke, hemorrhagic stroke, ischemic stroke, transient ischemic attack, atherosclerotic cardiovascular disease, traumatic brain injury, peripheral vascular disease, endothelial dysfunction, impaired vascular compliance, restenosis, thrombosis, hypertension, and pulmonary hypertension. Compression, restenosis after angioplasty, intermittent claudication, hyperglycemia, postprandial lipemia, metabolic acidosis, ketosis, hyperinsulinemia, impaired glucose metabolism, insulin resistance, hepatic insulin resistance, alcohol use disorder, chronic renal failure, metabolic syndrome, syndrome X, smoking cessation, premenstrual syndrome, angina pectoris, diabetic nephropathy, impaired glucose tolerance, diabetic neuropathy, diabetic retinopathy, macular degeneration, cataracts, glomerulosclerosis, arthritis, osteoporosis, addiction treatment, cocaine dependence, bipolar disorder / major depressive disorder, skin and connective tissue disorders, foot ulcers, psoriasis, essential polydipsia, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), ulcerative colitis, inflammatory bowel disease, colitis, irritable bowel syndrome, Crohn's disease, short bowel syndrome, Parkinson's disease, Alzheimer's disease, cognitive impairment, schizophrenia, and polycystic ovary syndrome (PCOS).
[0235] In some implementation schemes, the disease or disorder includes, but is not limited to, type 2 diabetes, early-onset type 2 diabetes, obesity, weight gain due to the use of other medications, gout, excessive sugar consumption, hypertriglyceridemia, dyslipidemia, gestational diabetes, kidney disease, adipocyte dysfunction, sleep apnea, visceral fat deposition, eating disorders, cardiovascular disease, congestive heart failure, myocardial infarction, left ventricular hypertrophy, peripheral artery disease, stroke, hemorrhagic stroke, ischemic stroke, transient ischemic attack, atherosclerotic cardiovascular disease, hyperglycemia, postprandial hyperlipidemia, and metabolic acidosis. Ketoacidosis, hyperinsulinemia, impaired glucose metabolism, insulin resistance, hepatic insulin resistance, alcohol use disorder, chronic renal failure, metabolic syndrome, syndrome X, smoking cessation, premenstrual syndrome, angina pectoris, diabetic nephropathy, impaired glucose tolerance, diabetic neuropathy, diabetic retinopathy, bipolar disorder / major depressive disorder, skin and connective tissue disorders, foot ulcers, psoriasis, essential polydipsia, nonalcoholic steatohepatitis (NASH), nonalcoholic fatty liver disease (NAFLD), short bowel syndrome, Parkinson's disease, polycystic ovary syndrome (PCOS), or any combination thereof.
[0236] In some implementations, the disease or disorder includes, but is not limited to, type 2 diabetes, early-onset type 2 diabetes, obesity, weight gain due to the use of other medications, gout, excessive sugar consumption, hypertriglyceridemia, dyslipidemia, gestational diabetes, adipocyte dysfunction, visceral fat deposition, myocardial infarction, peripheral artery disease, stroke, transient ischemic attack, hyperglycemia, postprandial lipemia, metabolic acidosis, ketosis, hyperinsulinemia, impaired glucose metabolism, insulin resistance, hepatic insulin resistance, chronic renal failure, syndrome X, angina pectoris, diabetic nephropathy, impaired glucose tolerance, diabetic neuropathy, diabetic retinopathy, skin and connective tissue disorders, foot ulcers, or any combination thereof.
[0237] In some embodiments, the compounds and pharmaceutical compositions and methods described herein for treating a patient induce one or more of the following: a decrease in blood glucose (e.g., a reduction in blood glucose levels), a decrease in blood hemoglobin A1c (HbA1c) levels, a promotion of insulin synthesis, a stimulation of insulin secretion, an increase in β-cell mass, a regulation of gastric acid secretion, a regulation of gastric emptying, a decrease in body mass index (BMI), and / or a decrease in glucagon production (e.g., levels). In some embodiments, the compounds and pharmaceutical compositions and methods described herein for treating a patient stabilize serum glucose and serum insulin levels (e.g., serum glucose and serum insulin concentrations). This document also provides methods for regulating glucose or insulin levels in a patient requiring such regulation, the methods comprising administering to the patient an effective amount of one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, or pharmaceutical compositions as disclosed herein.
[0238] In some embodiments, this document provides a method for reducing the risk of major adverse cardiovascular events (MACE) in a patient in need (e.g., a reduction of about 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80%), said method comprising administering to said patient an effective amount of one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, or pharmaceutical compositions as disclosed herein. In some embodiments of these embodiments, the patient is an adult diagnosed with type 2 diabetes (T2D). In some embodiments, the patient is an adult diagnosed with heart disease. In some embodiments, the patient is an adult diagnosed with both type 2 diabetes (T2D) and heart disease. In some embodiments, the patient is an adult with type 2 diabetes (T2D). In some embodiments, the patient is an adult with heart disease. In some embodiments, the patient has both type 2 diabetes (T2D) and heart disease.
[0239] In some implementations, calcitonin receptor and / or amylin receptor-related diseases or disorders are bone disorders, including but not limited to osteoporosis, Paget's disease, hypercalcemia, Zudeck atrophy, multiple fibrous dysplasia of bone, costoclavicular ossification, osteogenesis imperfecta, osteopenia, periodontal disease or periodontal defects, osteolytic bone disease, metastatic bone disorders, or bone loss caused by malignancy, autoimmune arthritis, bone fissures or fractures, or inactivity or disuse.
[0240] In some implementations, calcitonin receptor and / or amylin receptor-related diseases or disorders are pain, including but not limited to osteopathic pain, phantom limb pain, general pain, hyperalgesia, or pain associated with diabetic neuropathy.
[0241] In some implementations, calcitonin receptor and / or amylin receptor-related diseases or disorders are neurodegenerative diseases or disorders, including but not limited to Alzheimer's disease.
[0242] In some implementations, calcitonin receptor and / or amylin receptor-related diseases or disorders are metabolic disorders, including but not limited to non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, impaired glucose tolerance, obesity, syndrome X, or other diabetic complications.
[0243] In some implementations, calcitonin receptor and / or amylin receptor-related diseases or disorders include primary or secondary hyperthyroidism, endocrine disorders, conditions associated with inhibition of gastric juice secretion, gastrointestinal disorders, renal osteodystrophy, or male infertility.
[0244] In some embodiments, the compounds disclosed herein (e.g., compounds of Formula I, or pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates thereof) or pharmaceutical compositions as provided herein can be used to alleviate insulin inhibition in pancreatic tissue.
[0245] In some embodiments, the compounds disclosed herein (e.g., compounds of Formula I, or pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates thereof) or pharmaceutical compositions as provided herein may be used to treat and reduce insulin resistance.
[0246] In some embodiments, the compounds disclosed herein (e.g., compounds of Formula I, or pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates thereof) or pharmaceutical compositions as provided herein may be used to treat impaired glucose tolerance.
[0247] In some embodiments, the compounds disclosed herein (e.g., compounds of Formula I, or pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates thereof) or pharmaceutical compositions as provided herein may be used to treat obesity and its symptoms.
[0248] In some embodiments, a method for reducing body fat or increasing body fat is provided, the method comprising administering to a subject in need a therapeutically effective amount of a compound disclosed herein (e.g., a compound of formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) or a pharmaceutical composition as provided herein.
[0249] In some embodiments, a method is provided to alter the body composition of a subject requiring treatment, wherein body fat is reduced and lean body mass is maintained or increased, the method comprising administering to the subject a therapeutically effective amount of a compound disclosed herein (e.g., a compound of formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) or a pharmaceutical composition as provided herein.
[0250] In some embodiments, a method for reducing the weight of a subject in need is provided, the method comprising administering to the subject a therapeutically effective amount of a compound disclosed herein (e.g., a compound of formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) or a pharmaceutical composition as provided herein.
[0251] In some embodiments, a method is provided for reducing calorie intake in a subject who requires reduced calorie intake, the method comprising administering to the subject a therapeutically effective amount of a compound disclosed herein (e.g., a compound of formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) or a pharmaceutical composition as provided herein.
[0252] In some embodiments, a method is provided for reducing body fat or increased body fat in a subject requiring treatment while maintaining or increasing lean body mass, the method comprising administering to the subject a therapeutically effective amount of a compound disclosed herein (e.g., a compound of formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) or a pharmaceutical composition as provided herein.
[0253] In some embodiments, the compounds disclosed herein (e.g., compounds of Formula I, or pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates thereof) or pharmaceutical compositions as provided herein may be used to treat hypertension.
[0254] In some embodiments, the compounds disclosed herein (e.g., compounds of Formula I, or pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates thereof) or pharmaceutical compositions as provided herein may be used to treat essential hypertension.
[0255] In some embodiments, the compounds disclosed herein (e.g., compounds of Formula I, or pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates thereof) or pharmaceutical compositions as provided herein may be used to treat subjects suffering from hypertension and hyperamylinemia.
[0256] In some embodiments, a method for treating hyperinsulinemia is provided, the method comprising administering to a subject in need a therapeutically effective amount of a compound disclosed herein (e.g., a compound of formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) or a pharmaceutical composition as provided herein.
[0257] In some embodiments, a method is provided for treating a hypertensive, insulin-resistant subject with coronary artery disease and hyperamylinemia or hyperinsulinemia, the method comprising administering to the subject in need a therapeutically effective amount of a compound disclosed herein (e.g., a compound of formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) or a pharmaceutical composition as provided herein.
[0258] In some embodiments, a method is provided for reducing the basal and submaximal stimulation rates of glycogen synthesis in a subject, the method comprising administering to a subject in need a therapeutically effective amount of a compound disclosed herein (e.g., a compound of formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) or a pharmaceutical composition as provided herein.
[0259] In some embodiments, a method is provided for reducing the rate at which glucose is incorporated into glycogen in the muscle tissue of a subject, the method comprising administering to a subject in need a therapeutically effective amount of a compound disclosed herein (e.g., a compound of formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) or a pharmaceutical composition as provided herein.
[0260] In some embodiments, a method is provided for treating a subject with obesity and hypertension, as well as associated lipid disorders and atherosclerosis, the method comprising administering to a subject in need a therapeutically effective amount of a compound disclosed herein (e.g., a compound of formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) or a pharmaceutical composition as provided herein.
[0261] In some embodiments, the compounds disclosed herein (e.g., compounds of Formula I, or pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates thereof) or pharmaceutical compositions as provided herein may be used to modulate renin activity in a subject in need.
[0262] In some embodiments, a method for treating or preventing the development of heart failure in a subject is provided, the method comprising administering to a subject in need a therapeutically effective amount of a compound disclosed herein (e.g., a compound of formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) or a pharmaceutical composition as provided herein.
[0263] In some embodiments, the compounds disclosed herein (e.g., compounds of Formula I, or pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates thereof) or pharmaceutical compositions as provided herein may be used to beneficially modulate gastrointestinal motility in a subject of need. In some embodiments, beneficial modulation of gastrointestinal motility includes delaying gastric emptying.
[0264] In some embodiments, the compounds disclosed herein (e.g., compounds of Formula I, or pharmaceutically acceptable salts, stereoisomers, mixtures of stereoisomers, or solvates thereof) or pharmaceutical compositions as provided herein may be used to treat postprandial hyperglycemia in subjects of need. obesity
[0265] In some implementations, the condition, disease, or disorder is obesity and conditions, diseases, or disorders related to or associated with obesity. Non-limiting examples of obesity and obesity-related conditions include symptomatic obesity, simple obesity, childhood obesity, morbid obesity, and abdominal obesity (central obesity characterized by abdominal wall fat deposits). Non-limiting examples of symptomatic obesity include endocrine obesity (e.g., Cushing syndrome, hypothyroidism, insulinoma, obese type 2 diabetes, pseudohypoparathyroidism, hypogonadism), hypothalamic obesity, hereditary obesity (e.g., Prader-Willi syndrome, Laurence-Moon-Biedl syndrome), and drug-induced obesity (e.g., obesity induced by steroids, phenothiazines, insulin, sulfonylureas, or beta-blockers).
[0266] In some implementations, the condition, disease, or disorder is associated with obesity. Examples of such conditions, diseases, or disorders include, but are not limited to, glucose intolerance, diabetes (e.g., type 2 diabetes, obese diabetes), lipid metabolism disorders, hyperlipidemia, hypertension, heart failure, hyperuricemia, gout, fatty liver (including non-alcoholic steatohepatitis (NASH)), coronary artery disease (e.g., myocardial infarction, angina pectoris), cerebral infarction (e.g., cerebral thrombosis, transient ischemic attack), bone or joint disorders (e.g., knee osteoarthritis, hip osteoarthritis, degenerative spondylitis, low back pain), sleep apnea syndrome, obesity-related hypoventilation syndrome (Pickwickian syndrome), menstrual disorders (e.g., abnormal menstrual cycles, abnormal menstrual flow and cycle, amenorrhea, abnormal menstrual symptoms), visceral obesity syndrome, and metabolic syndrome. In some implementations, the chemical compounds and pharmaceutical compositions described herein can be used to treat patients exhibiting symptoms of both obesity and insulin deficiency. diabetes
[0267] In some implementations, the condition, disease, or disorder is diabetes. Non-limiting examples of diabetes include type 1 diabetes, type 2 diabetes (e.g., type 2 diabetes treated with diet, type 2 diabetes treated with sulfonylureas, very advanced type 2 diabetes, type 2 diabetes treated with long-term insulin therapy), diabetes (e.g., non-insulin-dependent diabetes, insulin-dependent diabetes), gestational diabetes, obese diabetes, autoimmune diabetes, and borderline diabetes. In some implementations, the condition, disease, or disorder is type 2 diabetes (e.g., type 2 diabetes treated with diet, type 2 diabetes treated with sulfonylureas, very advanced type 2 diabetes, type 2 diabetes treated with long-term insulin therapy).
[0268] This document provides a method for treating a patient with diabetes, the method comprising (a) determining that the patient has type 2 diabetes, and (b) administering to the patient a therapeutically effective amount of one or more compounds, stereoisomers or mixtures thereof, or pharmaceutical compositions disclosed herein.
[0269] This document provides a method for treating a patient with type 2 diabetes, the method comprising administering to a patient identified or diagnosed with type 2 diabetes a therapeutically effective amount of one or more compounds, stereoisomers thereof, or mixtures thereof, or pharmaceutical compositions disclosed herein.
[0270] This document also provides a method for treating type 2 diabetes in a patient in need, the method comprising administering to the patient a therapeutically effective amount of one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, or pharmaceutical compositions as disclosed herein.
[0271] In some embodiments, compounds and pharmaceutical compositions and methods for treating patients with the conditions, diseases, or disorders described herein (e.g., type 2 diabetes) reduce fasting plasma glucose levels. In some embodiments, compounds and pharmaceutical compositions and methods for treating patients with the conditions, diseases, or disorders described herein (e.g., type 2 diabetes) reduce non-fasting plasma glucose levels. In some embodiments, compounds and pharmaceutical compositions and methods for treating patients with the conditions, diseases, or disorders described herein (e.g., type 2 diabetes) reduce HbA1c levels. In some embodiments, compounds and pharmaceutical compositions and methods for treating patients with the conditions, diseases, or disorders described herein (e.g., type 2 diabetes) reduce glucagon levels. In some embodiments, compounds and pharmaceutical compositions and methods for treating patients with the conditions, diseases, or disorders described herein (e.g., type 2 diabetes) increase insulin levels. In some embodiments, compounds and pharmaceutical compositions and methods for treating patients with the conditions, diseases, or disorders described herein (e.g., type 2 diabetes) reduce BMI.
[0272] In some embodiments, a reduction in fasting plasma glucose levels of about 5% to about 95% indicates treatment for type 2 diabetes. In some embodiments, a reduction in fasting plasma glucose levels of about 15% to about 80% indicates treatment for type 2 diabetes. In some embodiments, a reduction in fasting plasma glucose levels of about 25% to about 60% indicates treatment for type 2 diabetes. In some embodiments, a reduction in fasting plasma glucose levels of about or below 126 mg / dL, about or below 110 mg / dL, or about or below 90 mg / dL indicates treatment for type 2 diabetes.
[0273] In some embodiments, a reduction in non-fasting plasma glucose levels of about 5% to about 95% indicates treatment for type 2 diabetes. In some embodiments, a reduction in non-fasting plasma glucose levels of about 15% to about 80% indicates treatment for type 2 diabetes. In some embodiments, a reduction in non-fasting plasma glucose levels of about 25% to about 60% indicates treatment for type 2 diabetes. In some embodiments, a reduction in non-fasting plasma glucose levels of about or below 200 mg / dL, about or below 150 mg / dL, or about or below 130 mg / dL indicates treatment for type 2 diabetes.
[0274] In some embodiments, a reduction in HbA1c levels of about 5% to about 95% indicates treatment for type 2 diabetes. In some embodiments, a reduction in HbA1c levels of about 15% to about 80% indicates treatment for type 2 diabetes. In some embodiments, a reduction in HbA1c levels of about 25% to about 60% indicates treatment for type 2 diabetes. In some embodiments, a reduction in HbA1c levels of about or less than 6.5%, about or less than 6.0%, or about or less than 5.0% indicates treatment for type 2 diabetes.
[0275] In some embodiments, a decrease in glucagon levels of about 5% to about 95% indicates treatment for type 2 diabetes. In some embodiments, a decrease in glucagon levels of about 15% to about 80% indicates treatment for type 2 diabetes. In some embodiments, a decrease in glucagon levels of about 25% to about 60% indicates treatment for type 2 diabetes. In some embodiments, an increase in insulin levels of about 5% to about 95% indicates treatment for type 2 diabetes. In some embodiments, an increase in insulin levels of about 15% to about 80% indicates treatment for type 2 diabetes. In some embodiments, an increase in insulin levels of about 25% to about 60% indicates treatment for type 2 diabetes.
[0276] In some embodiments, a BMI reduction of about 5% to about 95% indicates treatment for type 2 diabetes. In some embodiments, a BMI reduction of about 15% to about 80% indicates treatment for type 2 diabetes. In some embodiments, a BMI reduction of about 25% to about 60% indicates treatment for type 2 diabetes. In some embodiments, a BMI reduction of about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% indicates treatment for type 2 diabetes. In some embodiments, a BMI reduction to or below 40, about or below 30, or about or below 20 indicates treatment for type 2 diabetes.
[0277] In some implementations, the condition, disease, or disorder is associated with diabetes (e.g., complications of diabetes). Non-limiting examples of diabetes-related disorders include obesity, obesity-related disorders, metabolic syndrome, neuropathy, nephropathy (e.g., diabetic nephropathy), retinopathy, diabetic cardiomyopathy, cataracts, macrovascular disease, osteoporosis, hyperosmolar diabetic coma, infectious diseases (e.g., respiratory infections, urinary tract infections, gastrointestinal infections, skin and soft tissue infections, lower extremity infections), diabetic gangrene, xerostomia, hearing loss, cerebrovascular disorders, diabetic cachexia, delayed wound healing, diabetic dyslipidemia, peripheral circulatory disorders, cardiovascular risk factors (e.g., coronary artery disease, peripheral artery disease, cerebrovascular disease, hypertension, and risk factors and / or inflammation associated with uncontrolled cholesterol and / or lipid levels), NASH, fractures, and cognitive impairment.
[0278] Other non-limiting examples of diabetes-related disorders include prediabetes, hyperlipidemia (e.g., hypertriglyceridemia, hypercholesterolemia, hyperLDL-cholesterolemia, lowHDL-cholesterolemia, postprandial hyperlipidemia), metabolic syndrome (e.g., metabolic disorder of beneficial GLP-1R activation, metabolic X syndrome), hypertension, impaired glucose tolerance (IGT), insulin resistance, and sarcopenia.
[0279] In some implementations, the condition, disease, or disorder is diabetes and obesity (glycosuria). In some implementations, the compounds described herein may also be used to improve the therapeutic efficacy of metformin. Obstacles to metabolism in vital tissues
[0280] In some implementations, the condition, disease, or disorder is an obstruction to metabolically important tissues. Non-limiting examples of metabolically important tissues include the liver, fat, pancreas, kidneys, and intestines.
[0281] In some implementations, the condition, disease, or disorder is fatty liver disease. Fatty liver disease includes, but is not limited to, non-alcoholic fatty liver disease (NAFLD), steatohepatitis, non-alcoholic steatohepatitis (NASH), fatty liver disease caused by hepatitis, fatty liver disease caused by obesity, fatty liver disease caused by diabetes, fatty liver disease caused by insulin resistance, fatty liver disease caused by hypertriglyceridemia, abeta-lipoproteinemia, glycogen storage disease, Weber-Christian disease, Wolman disease, acute fatty liver of pregnancy, and lipodystrophy.
[0282] Nonalcoholic fatty liver disease (NAFLD) refers to a range of conditions that occur in the absence of alcohol abuse and are typically characterized by the presence of fatty liver (fat in the liver). NAFLD is believed to be associated with a variety of conditions, such as metabolic syndrome (including obesity, diabetes, and hypertriglyceridemia) and insulin resistance. It can cause liver disease in adults and children and may eventually lead to cirrhosis (Skelly et al., J Hepatol 2001; 35: 195-9; Chitturi et al., Hepatology 2002; 35(2):373-9). The severity of NAFLD ranges from relatively benign, isolated, macrovesicular predominant steatosis (i.e., nonalcoholic fatty liver or NAFL) to nonalcoholic steatohepatitis (NASH) (Angulo et al., J Gastroenterol Hepatol 2002; 17 Supplement: S186-90). In some implementations, the patient is a pediatric patient. As used herein, the term “pediatric patient” refers to a patient under the age of 21 at the time of diagnosis or treatment. The term “pediatric” can be further subdivided into different subgroups, including: neonates (from birth to the first month of life); infants (1 month to 2 years); children (2 to 12 years); and adolescents (12 to 21 years (until, but not including, their 22nd birthday)). (References: Berhman RE, Kliegman R, Arvin AM, Nelson WE. Nelson Textbook of Pediatrics, 15th edition Philadelphia: WB Saunders Company, 1996; Rudolph AM et al. Rudolph's Pediatrics, 21st edition New York: McGraw-Hill, 2002; and Avery MD, First LR. Pediatric Medicine, 2nd edition Baltimore: Williams & Wilkins; 1994.) In some implementations, pediatric patients are defined as those aged from birth to the first 28 days of life, from 29 days to less than two years of age, from two years to less than 12 years of age, or from 12 years to 21 years of age (up to but not including the twenty-second birthday). In some implementations, pediatric patients are defined as those aged from birth to the first 28 days of life, from 29 days to less than one year of age, from one month to less than four months of age, from three months to less than seven months of age, from six months to less than one year of age, from one year to less than two years of age, from two years to less than three years of age, from two years to less than seven years of age, from three years to less than five years of age, from five years to less than ten years of age, from six years to less than 13 years of age, from 10 years to less than 15 years of age, or from 15 years to less than 22 years of age. In some implementations, patients are adult patients.
[0283] Other non-limiting examples of disorders affecting metabolically important tissues include joint disorders (e.g., osteoarthritis, secondary osteoarthritis), fatty liver (e.g., in the liver); gallstones; gallbladder disorders; gastroesophageal reflux; sleep apnea; hepatitis; fatty liver; skeletal disorders characterized by changes in bone metabolism, such as osteoporosis, including postmenopausal osteoporosis, poor bone strength, osteopenia, Paget's disease, osteolytic metastases in cancer patients, osteodystrophy in liver disease, and changes in bone metabolism caused by renal failure or hemodialysis, fractures, bone surgery, aging, pregnancy, protection against fractures, and malnutrition due to polycystic ovary syndrome; kidney diseases (e.g., chronic renal failure, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end-stage renal disease); muscular dystrophy, angina pectoris, acute or chronic diarrhea, testicular dysfunction, respiratory dysfunction, frailty, sexual dysfunction (e.g., erectile dysfunction), and geriatric syndromes. In some embodiments, the compounds and pharmaceutical compositions described herein can be used to treat surgical trauma by improving postoperative recovery and / or by preventing catabolism caused by surgical trauma. Cardiovascular and vascular diseases
[0284] In some implementations, the disease or disorder is a cardiovascular disease. Non-limiting examples of cardiovascular diseases include congestive heart failure, atherosclerosis, arteriosclerosis, coronary artery disease, coronary artery disease, hypertension, heart failure, cerebrovascular disorders (e.g., cerebral infarction), vascular dysfunction, myocardial infarction, elevated blood pressure (e.g., 130 / 85 mm Hg or higher), and prethrombotic states (exemplified by high levels of fibrinogen or plasminogen activator inhibitors in the blood).
[0285] In some implementations, the disease or disorder is associated with vascular disease. Non-limiting examples of vascular disease include peripheral vascular disease, large vessel complications (e.g., stroke), vascular dysfunction, peripheral artery disease, abdominal aortic aneurysm, carotid artery disease, cerebrovascular disorders (e.g., cerebral infarction), pulmonary embolism, chronic venous insufficiency, severe limb ischemia, retinopathy, nephropathy, and neuropathy. Nervous system diseases
[0286] In some implementations, the disease or disorder is a neurological disorder (e.g., a neurodegenerative disorder) or a mental disorder. Non-limiting examples of neurological disorders include cerebral insulin resistance, mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease (PD), anxiety disorders, dementia (e.g., Alzheimer's disease), traumatic brain injury, Huntington's disease, tardive dyskinesia, hyperkinesia, mania, Morbus Parkinson's disease, Steele-Richard syndrome, Down syndrome, myasthenia gravis, neurological trauma, brain trauma, angioamylindrica, intracerebral hemorrhage with amyloidosis, encephalitis, Friedrich's ataxia, acute confusion disorder, amyotrophic lateral sclerosis (ALS), glaucoma, and apoptosis-mediated central nervous system degenerative diseases (e.g., Creutzfeld-Jakob disease, bovine spongiform encephalopathy (BSE), and chronic wasting syndrome). See, for example, US 2006 / 0275288 A1.
[0287] Non-limiting examples of mental disorders include substance dependence / addiction (narcotics and amphetamines) and attention deficit / hyperactivity disorder (ADHD). The compounds and pharmaceutical compositions described herein can be used to improve behavioral responses to addictive substances, reduce substance dependence, prevent relapse into substance abuse, and alleviate anxiety caused by the absence of a given addictive substance. See, for example, US 2012 / 0021979 A1.
[0288] In some embodiments, the compounds and pharmaceutical compositions described herein can be used to improve learning and memory by enhancing neuronal plasticity and promoting cell differentiation, and can also be used to preserve dopamine neurons and motor function in Parkinson's disease. Insulin-related conditions and disorders
[0289] In some implementations, the disease or disorder is impaired fasting glucose (IFG), impaired fasting glucose regulation (IFG), hyperglycemia, insulin resistance (impaired glucose homeostasis), hyperinsulinemia, elevated blood fatty acid or glycerol levels, hypoglycemia, insulin resistance syndrome, paresthesia caused by hyperinsulinemia, hyperlipidemia, hypercholesterolemia, impaired wound healing, leptin resistance, glucose intolerance, increased fasting glucose, dyslipidemia (e.g., hyperlipidemia, atherogenic dyslipidemia characterized by high triglycerides and low HDL cholesterol), glucagonoma, hyperprolactinemia, hypoglycemia (e.g., nocturnal hypoglycemia), and insulin-related coma endpoints.
[0290] In some embodiments, the compounds and pharmaceutical compositions described herein can reduce or slow the progression of borderline, impaired fasting glucose, or impaired fasting glucose regulation to diabetes. Autoimmune disorders
[0291] In some implementations, the disease or disorder is an autoimmune disorder. Non-limiting examples of autoimmune disorders include multiple sclerosis, experimental autoimmune encephalomyelitis, autoimmune disorders associated with immune rejection, graft-versus-host disease, uveitis, optic neuropathy, optic neuritis, transverse myelitis, inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, myasthenia gravis, and Graves' disease. See, for example, US20120148586 A1. Gastrointestinal disorders
[0292] In some implementations, the disease or disorder is a gastrointestinal-related disorder. Non-limiting examples of these disorders include ulcers of any etiology (e.g., gastric ulcers, Zollinger-Ellison syndrome, drug-induced ulcers, ulcers associated with infection or other pathogens), digestive disorders, malabsorption disorders, short bowel syndrome, cul-de-sac syndrome, inflammatory bowel disease (Crohn's disease and ulcerative colitis), celiac sprue, hypogammaglobulinemic sprue, mucositis and diarrhea induced by chemotherapy and / or radiation therapy, gastrointestinal inflammation, short bowel syndrome, ulcerative colitis, gastric mucosal damage (e.g., gastric mucosal damage caused by aspirin), small intestinal mucosal damage, and cachexia (e.g., cancer cachexia, tuberculous cachexia, cachexia associated with blood disorders, cachexia associated with endocrine disorders, cachexia associated with infectious diseases, and cachexia caused by acquired immunodeficiency syndrome). weight
[0293] In some embodiments, the compounds and pharmaceutical compositions described herein can be used to reduce weight (e.g., overweight), prevent weight gain, induce weight loss, reduce body fat, or reduce food intake in patients (e.g., patients in need). In some embodiments, a patient's weight gain may be attributed to excessive food intake or an unbalanced diet, or may be due to weight gain from accompanying medications (e.g., insulin sensitizers with PPARγ agonist-like effects, such as troglitazone, rosiglitazone, empaglitazone, cycloglitazone, pioglitazone, etc.). In some embodiments, the weight gain may be pre-obesity weight gain or may be weight gain in obese patients. In some embodiments, the weight gain may also be drug-induced weight gain or weight gain after smoking cessation.
[0294] In some implementations, the illness or disorder is an eating disorder, such as hyperphagia, bulimia, binge eating, or compulsive eating. Inflammatory diseases
[0295] In some implementations, the disease or disorder is an inflammatory disorder. Non-limiting examples of inflammatory disorders include chronic rheumatoid arthritis, degenerative spondylitis, osteoarthritis, low back pain, gout, postoperative or post-traumatic inflammation, abdominal distension, neuralgia, pharyngitis, cystitis, pneumonia, pancreatitis, enteritis, inflammatory bowel disease (including inflammatory colitis), inflammation of metabolically important tissues (including the liver, fat, pancreas, kidneys, and intestines), and pro-inflammatory states (e.g., elevated levels of pro-inflammatory cytokines or markers such as inflammatory-like C-reactive protein in the blood). cancer
[0296] In some implementations, the disease or disorder is cancer. Suitable examples of cancer include breast cancer (e.g., invasive ductal breast cancer, non-invasive ductal breast cancer, inflammatory breast cancer), prostate cancer (e.g., hormone-dependent prostate cancer, non-hormone-dependent prostate cancer), pancreatic cancer (e.g., ductal pancreatic cancer), gastric cancer (e.g., papillary adenocarcinoma, mucinous adenocarcinoma, adenosquamous carcinoma), lung cancer (e.g., non-small cell lung cancer, small cell lung cancer, malignant mesothelioma), colon cancer (e.g., gastrointestinal stromal tumor), and colorectal cancer (e.g., gastric...). Gastrointestinal stromal tumors (GISTs), colorectal cancers (e.g., familial colorectal cancer, hereditary nonpolyposis colorectal cancer, GISTs), small bowel cancers (e.g., non-Hodgkin's lymphoma, GISTs), esophageal cancer, duodenal cancer, tongue cancer, pharyngeal cancer (e.g., nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer), salivary gland cancer, brain tumors (e.g., pineal astrocytoma, pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma), schwannomas, liver cancers (e.g., Primary liver cancer, extrahepatic bile duct cancer, kidney cancer (e.g., renal cell carcinoma, transitional cell carcinoma of the renal pelvis and ureter), bile duct cancer, endometrial cancer, cervical cancer, ovarian cancer (e.g., epithelial ovarian cancer, extragonadal germ cell tumors, ovarian germ cell tumors, low-potency ovarian tumors), bladder cancer, urethral cancer, skin cancer (e.g., intraocular (ocular) melanoma, Merkel cell carcinoma), hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer (e.g., medullary thyroid carcinoma). Cancers include: parathyroid carcinoma, nasal cavity carcinoma, sinus carcinoma, bone tumors (e.g., osteosarcoma, Ewing's tumor, uterine sarcoma, soft tissue sarcoma), angiofibroma, retinal sarcoma, penile cancer, testicular tumors, pediatric solid tumors (e.g., nephroblastoma, pediatric kidney tumors), Kaposi's sarcoma, Kaposi's sarcoma caused by AIDS, maxillary sinus tumors, fibrous histiocytoma, leiomyosarcoma, rhabdomyosarcoma, and leukemias (e.g., acute myeloid leukemia, acute lymphoblastic leukemia). Hypothalamic-pituitary disorders
[0297] In some implementations, the condition or disorder is associated with the hypothalamic-pituitary-gonadal axis. For example, the condition, disease, or disorder is associated with the hypothalamic-pituitary-ovarian axis. In another embodiment, the condition, disease, or disorder is associated with the hypothalamic-pituitary-testicular axis. Hypothalamic-pituitary-gonadal axis disorders include, but are not limited to, hypogonadism, polycystic ovary syndrome, hypothyroidism, hypopituitarism, sexual dysfunction, and Cushing's disease.
[0298] In some implementations, diabetes-related diseases or disorders are associated with the hypothalamic-pituitary-gonadal axis. pulmonary disease
[0299] In some implementations, the disease or disorder is associated with lung disease. Lung diseases include, but are not limited to, asthma, idiopathic pulmonary fibrosis, pulmonary hypertension, obstructive sleep apnea-hypopnea syndrome, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis, and refractory (irreversible) asthma).
[0300] In some implementations, the disease or disorder associated with diabetes is lung disease. Combination therapy
[0301] In some implementations, this disclosure considers both monotherapy regimens and combination therapy regimens.
[0302] In some embodiments, the methods described herein may also include administration of one or more additional therapies (e.g., one or more additional therapeutic agents and / or one or more treatment regimens) in combination with the administration of the compounds described herein.
[0303] In some implementations, the methods described herein include administering the compounds described herein in combination with one or more of the following: diet therapy (e.g., diet monitoring, diet therapy for diabetes), exercise therapy (e.g., physical activity), blood glucose monitoring, gastric electrical stimulation (e.g., TANTALUS®), and dietary modifications.
[0304] In some embodiments, one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, may be administered in combination with one or more other therapeutic agents.
[0305] Other representative therapeutic agents include, but are not limited to, anti-obesity agents, diabetes treatment agents, diabetes complication treatment agents, hyperlipidemia treatment agents, antihypertensive agents, diuretics, chemotherapy drugs, immunotherapy drugs, anti-inflammatory drugs, antithrombotic agents, antioxidants, osteoporosis treatment agents, vitamins, anti-dementia drugs, erectile dysfunction drugs, urinary frequency or incontinence treatment agents, NAFLD treatment agents, NASH treatment agents, dysuria treatment agents, and antiemetics.
[0306] In some embodiments, one or more additional therapeutic agents include, for example, those that can be used as anti-obesity agents. Non-limiting examples include monoamine uptake inhibitors (e.g., tramadol, phenbutylide, sibutramine, mazindol, fluoxetine, tesofensine), serotonin 2C receptor agonists (e.g., lorcaserin), serotonin 6 receptor antagonists, histamine H3 receptor modulators, GABA modulators (e.g., topiramate) (including GABA receptor agonists (e.g., gabapentin, pregabalin)), and neuropeptide Y antagonists (e.g., virifibrate). Cannabinoid receptor antagonists (e.g., rimonabant, taranabant), orexin antagonists, orexin receptor antagonists, orexin acylase inhibitors, opioid receptor antagonists (e.g., GSK-1521498), orexin receptor antagonists, melanocortin 4 receptor agonists, 11β-hydroxysteroid dehydrogenase inhibitors (e.g., AZD-4017, BVT-3498, INCB-13739), and pancreatic lipase inhibitors (e.g., orlistat). istat), cetilistat, β3 agonists (e.g., N-5984), diacylglycerol acyltransferase 1 (DGAT1) inhibitors, acetyl-CoA carboxylase (ACC) inhibitors, stearoyl-CoA desaturase inhibitors, microsomal triglyceride transfer protein inhibitors (e.g., R-256918), sodium-glucose cotransporter 2 (SGLT-2) inhibitors (e.g., JNJ-28431754, dapagliflozin, AVE2268, TS-033, YM543, TA- 7284, ASP1941, remogliflozin, NFK inhibitors (e.g., HE-3286), PPAR agonists (e.g., GFT-505, DRF-11605, gemfibrozil, and fenofibrate), phosphotyrosine phosphatase inhibitors (e.g., sodium vanadate, trodusquemin), GPR119 agonists (e.g., PSN-821, MBX-2982, APD597), glucoskinase activators (e.g.,Piraglitin, AZD-1656, AZD6370, TTP-355, compounds described in W0006 / 112549, W0007 / 028135, W0008 / 047821, W0008 / 050821, W0008 / 136428 and W0008 / 156757, leptin, leptin derivatives (e.g., metriptin), leptin resistance modifiers, CNTF (ciliary neurotrophic factor), BDNF ( Brain-derived neurotrophic factor), cholecystokinin agonists, amylin preparations (e.g., pramlinide, AC-2307), neuropeptide Y agonists (e.g., PYY3-36, derivatives of PYY3-36, obineptide, TM-30339, TM-30335), oximin (OXM) preparations, appetite suppressants (e.g., ephedrine), FGF21 preparations (e.g., animal FGF21 preparations extracted from bovine or porcine pancreas; using Escherichia coli (Escherichia coli) preparations). Human FGF21 preparations synthesized from genes of *C. coli* or yeast; fragments or derivatives of FGF21; appetite suppressants (e.g., P-57); human propancreatic peptide (HIP); farnesoid X receptor (FXR) agonists; phenbutylamine; zonisamide; norepinephrine / dopamine reuptake inhibitors; GDF-15 analogs; methionine aminopeptidase 2 (MetAP2) inhibitors; diethylamine phenylacetone; benzotriazine; benzylphenamine; fibroblast growth factor receptor (FGFR) modulators; and AMP-activated protein kinase (AMPK) activators.
[0307] In some embodiments, one or more compounds as disclosed herein, or stereoisomers or mixtures thereof, may be administered in combination with one or more additional therapeutic agents, wherein the additional therapeutic agent is a GLP-1 agonist or exhibits GLP-1 agonist activity.
[0308] In some implementations, additional therapeutic agents include TTP273, LY2944876 (pegapamotide), HDM1002, K-757, K-833, retatrutide, IBI362 (mastautide), cotadutide, AMG133, CT-868, HRS9531, HS-20094, dapiglutide, efinopegdutide, efocipegtrutide, pemvidutide, survodutide, AP026, AZD9550, BGM0504, CT-388, DD01, DR10624, G3215, GMA106, and HEC88473. HZ010, LY3493269, MWN101, NN9487, NN9541, RAY1225, SCO-094, SHR-1816, TB001, VK2735, ZP2929, ecnoglutide, GX-G6, GZR18, HRS-7535, YH14617, avexitide, froniglutide, pegsebrenatide, vurolenatide, JY09, NB1001, Byetalog, GW002, HL08, KN056, SAL0112, SHR2042, VCT220, ZT002, ZYOG1, or utreglutide.
[0309] In some implementations, additional therapeutic agents include endogenous GLP-1, endogenous glucagon, gastrin, kinin-4, exenatide, lixisenatide, abirate, benaglutide, duraglutide, efpeglenatide, langlenatide, liraglutide, semaglutide, taspoglutide, tesipatide, pegapamodutide, lithium chloride, and PF-068829. 61 (danuglipron), LY3502970 (orforglipron), ECC-5004, GSBR-1290, AZD0186, PF-07081532 (lotiglipron), VCT220, TERN-601, RGT-075, CT-996, MDR-001, SAL0112, XW014, AVE-0010, S4P or Boc5.
[0310] In some embodiments, one or more compounds, or stereoisomers or mixtures thereof, disclosed herein may be administered in combination with one or more additional therapeutic agents, wherein the additional therapeutic agents are selected from compounds disclosed in WO2021 / 155841, WO / 2018 / 109607, WO / 2018 / 056453, WO / 2019 / 239319 or WO / 2019 / 239371.
[0311] In some embodiments, one or more additional therapeutic agents include, for example, those that can be used as antidiabetic agents. Non-limiting examples include insulin and insulin preparations (e.g., animal insulin preparations extracted from bovine or porcine pancreas; human insulin preparations synthesized using E. coli or yeast genes; zinc insulin; protamine zinc insulin; insulin fragments or derivatives (e.g., INS-1), oral insulin preparations, synthetic human insulin), insulin sensitizers (e.g., pioglitazone or its salts), biguanides (e.g., metformin, buformin, or their salts (e.g., hydrochloride, fumarate, succinate)), and glucagon analogs (e.g., WO4). Any glucagon analogues described in 2010 / 011439), agents that antagonize the action of glucagon or reduce glucagon secretion, sulfonylurea agents (e.g., chlorpropamide, tolazamide, gliclazide, glimepiride, tolbutamide, glibenclamide, acetohexamide, glipizide, glybuzole, glibenclamide), thiazolidinedione agents (e.g., roxarsone), and thiazolidinediones (e.g., roxarsone). Glitter or pioglitazone), alpha-glucosidase inhibitors (e.g., voglibose, acarbose, miglitol, emiglitate), insulin secretagogues such as dietary glucose regulators (sometimes called "short-acting secretagogues"), such as megglitinide (e.g., repaglinide and nateglinide), cholinesterase inhibitors (e.g., donepezil, galantamine, rivastigmine, tacrine), NMDA receptor antagonists, dual GLP-1 / GIP receptor agonists (e.g., LBT-2000, ZPD1-70), GLP-1R agonists (e.g., exenatide, liraglutide, abiglutide, duraglutide, abiglutide, tasglutide, lixilatide, smegglutide, AVE-0010, S4P, and Boc5), and dipeptidyl peptidase IV (DPP-4) inhibitors (e.g., vildagliptin, dutogliptin, gemigliptin, alogliptin). (ptin), saxagliptin, sitagliptin, linagliptin, berberine, adogliptin, BI1356, GRC8200, MP-513, PF-00734200, PHX1149, SK-0403, ALS2-0426, TA-6666, TS-021, KRP-104, trelagliptin.
[0312] In some embodiments, one or more additional therapeutic agents include, for example, those used to treat NAFL and NASH. Non-limiting examples include FXR agonists, PF-05221304, synthetic fatty acid bile conjugates, anti-lysyl oxidase homolog 2 (LOXL2) monoclonal antibodies, caspase inhibitors, MAPK5 inhibitors, galactoglobulin 3 inhibitors, fibroblast growth factor 21 (FGF21), niacin analogs, leukotriene D4 (LTD4) receptor antagonists, acetyl-CoA carboxylase (ACC) inhibitors, hexokinase (KHK) inhibitors, and apoptosis signal-regulated kinase 1 (ASK). 1) Inhibitors, ileal bile acid transporter (IBAT) inhibitors, glycyrrhizin, Schisandra chinensis extract, ascorbic acid, glutathione, silymarin, lipoic acid and d-α-tocopherol, ascorbic acid, glutathione, vitamin B complex, glitazone / thiazolidinediones (e.g., troglitazone, rosiglitazone, pioglitazone), metformin, cysteine, sulfonylureas, α-glucosidase inhibitors, megglitinide, vitamin E, tetrahydroliprostine, milk thistle protein, antiviral drugs and antioxidants.
[0313] In some embodiments, one or more additional therapeutic agents include, for example, those used to treat complications of diabetes. Non-limiting examples include aldose reductase inhibitors (e.g., tolrestat, epalrestat, zopolrestat, fidarestat, CT-112, ranirestat, lidorestat), neurotrophic factors and their enhancers (e.g., NGF, NT-3, BDNF, neurotrophic production / secretion promoters described in WO01 / 14372 (e.g., 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole), compounds described in WO2004 / 039365), and PKC inhibitors (e.g., ruboxistaurin). mesylate), AGE inhibitors (e.g., ALT946, N-benzoylthiazolium bromide (ALT766), EXO-226, pyridorin, pyridoxamine), serotonin and norepinephrine reuptake inhibitors (e.g., duloxetine), sodium channel inhibitors (e.g., lacosamide), reactive oxygen species scavengers (e.g., lipoic acid), cerebral vasodilators (e.g., tiapuride, mexiletine), somatostatin receptor agonists (e.g., BIM23190), and apoptosis signal-regulated kinase-1 (ASK-1) inhibitors.
[0314] In some embodiments, one or more additional therapeutic agents include, for example, those used to treat hyperlipidemia. Non-limiting examples include HMG-COA reductase inhibitors (e.g., pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, rosuvastatin, pitavastatin, or salts thereof (e.g., sodium, calcium salts)), squalene synthase inhibitors (e.g., compounds described in WO97 / 10224, such as N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazazepone-3-yl]ethyl] Acyl[piperidine-4-acetic acid], fibrate compounds (e.g., bezafibrate, clofibrate, simfibrate, clinofibrate), anion exchange resins (e.g., colestyramine), nicotinic acid drugs (e.g., nicomol, niceritrol, niaspan), phytosterols (e.g., daidzein, gamma oryzanol, γ-oryzanol), cholesterol absorption inhibitors (e.g., zechia), CETP inhibitors (e.g., dalcetrapib, anacetrapib) and ω-3 fatty acid preparations (e.g., ω-3-fatty acid ethyl ester 90).
[0315] In some embodiments, one or more additional therapeutic agents include, for example, those that can be used as antihypertensive agents. Non-limiting examples include angiotensin-converting enzyme inhibitors (e.g., captopril, enalapril, delapril), angiotensin II antagonists (e.g., candesartan cilexetil, candesartan, losartan, losartan potassium, eprosartan, valsartan, telmisartan, irbesartan, tasosartan, olmesartan, olmesartan medoxomil, azilsartan, azilsartan medoxomil). medoxomil), calcium channel blockers (e.g., manidipine, nifedipine, amlodipine, efonidipine, nicardipine, cilnidipine) and beta-blockers (e.g., metoprolol, atenolol, propranolol, carvedilol, pindolol).
[0316] In some embodiments, one or more additional therapeutic agents include, for example, those that can be used as diuretics. Non-limiting examples include xanthine derivatives (e.g., sodium theobromine salicylate, calcium theobromine salicylate), thiazide preparations (e.g., ethiothiazide, cyclopenthiazine, trichlorothiazide, hydrochlorothiazide, hydrofluorothiazide, benzyl hydrochlorothiazide, penfluthiazide, polythiazide, methyclothiazide)), antialdosterone preparations (e.g., spironolactone, triamterene)), carbonic anhydrase inhibitors (e.g., acetazolamide) and chlorobenzenesulfonamide preparations (e.g., chlortalidone, mefruside, indapamide)).
[0317] In some embodiments, one or more additional therapeutic agents include, for example, those that can be used as immunotherapeutic agents. Non-limiting examples include microbial or bacterial compounds (e.g., muramyl dipeptide derivatives, picibanil), polysaccharides with immunomodulatory activity (e.g., lentinan, sizofiran, krestin), cytokines obtained through genetic engineering (e.g., interferons, interleukins (ILs), such as IL-1, IL-2, IL-12), and colony-stimulating factors (e.g., granulocyte colony-stimulating factor, erythropoietin).
[0318] In some embodiments, one or more additional therapeutic agents include, for example, those that can be used as antithrombotic agents. Non-limiting examples include heparin (e.g., heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium), warfarin (e.g., warfarin potassium); antithrombin agents (e.g., aragatroban, dabigatran), FXa inhibitors (e.g., rivaroxaban, apixaban, edoxaban, betrixaban, YM150, described in WO02 / 06234, WO200) Compounds in 4 / 048363, WO2005 / 030740, WO2005 / 058823 and WO2005 / 113504), thrombolytic agents (e.g., urokinase, tisokinase, alteplase, allteplase, montelpeplase, pamiplase), and platelet aggregation inhibitors (e.g., ticlopidine hydrochloride, clopidogrel, prasugrel, E5555, SHC530348, cilostazol, ethyl eicosapentaenoate, beraprost sodium, and sarpogrelate hydrochloride).
[0319] In some embodiments, one or more additional therapeutic agents include, for example, those used to treat osteoporosis. Non-limiting examples include alfacalcidol, calcitriol, elcatonin, calcitonin salmon, estriol, ipriflavone, pamidronate disodium, alendronate sodium hydrate, incadronate disodium, and riseronated sodium. Suitable examples of vitamins include vitamin B1 and vitamin B12. Suitable examples of erectile dysfunction medications include apomorphine and sildenafil citrate. Suitable examples of medications for treating urinary frequency or incontinence include flavorxate hydrochloride, oxybutynin hydrochloride, and propiverine hydrochloride. Suitable examples of medications for treating dysuria include acetylcholinesterase inhibitors (e.g., distigmine). Suitable examples of anti-inflammatory agents include nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, acetaminophen, and indomethacin.
[0320] Other exemplary therapeutic agents include agents that regulate hepatic glucose balance (e.g., fructose-1,6-bisphosphatase inhibitors, glycogen phosphorylase inhibitors, glycogen synthase kinase inhibitors, glucosamine activators); agents designed to treat complications of long-term hyperglycemia, such as aldose reductase inhibitors (e.g., epalrestat and ranisitar); agents for treating complications associated with microvascular complications; anti-dyslipidemia agents, such as HMG-CoA reductase inhibitors (statins, e.g., rosuvastatin), cholesterol-lowering agents, bile acid sequestrants (e.g., cholestyramine), cholesterol absorption inhibitors (e.g., phytosterols, such as plant sterols), cholesterol ester transfer protein (CETP) inhibitors, and ileal bile. Acid transport system inhibitors (IBAT inhibitors), bile acid conjugating resins, nicotinic acid (nicotinic acid) and its analogues, antioxidants (e.g., probucol), ω-3 fatty acids; antihypertensive agents, including adrenergic receptor antagonists such as beta blockers (e.g., atenolol), alpha blockers (e.g., doxazosin), and mixed alpha / beta blockers (e.g., lalobel); adrenergic receptor agonists, including alpha-2 agonists (e.g., clonidine), angiotensin-converting enzyme (ACE) inhibitors (e.g., lisinopril); calcium channel blockers such as dihydropyridine (e.g., nifedipine), phenylalkylamine (e.g., verapamil), and benzothiazazepine (e.g., diltiazem); angiotensin II receptor agonists... Anticoagulant antagonists (e.g., candesartan); aldosterone receptor antagonists (e.g., eplerenone); centrally acting adrenergic drugs, such as central alpha agonists (e.g., clonidine); diuretics (e.g., furosemide); hemostatic modifiers, including anticoagulants (e.g., fibrinolytic activators), thrombin antagonists, factor VIIa inhibitors, anticoagulants (e.g., vitamin K antagonists, such as warfarin), heparin and its low molecular weight analogs, factor Xa inhibitors and direct thrombin inhibitors (e.g., argatroban), antiplatelet agents (e.g., cyclooxygenase inhibitors (e.g., aspirin)); adenosine diphosphate (ADP) receptor inhibitors (e.g., clopidogrel); phosphodiesterase inhibitors (e.g., cephalosporins). Lotazobazole); glycoprotein IIB / IIA inhibitors (e.g., tirofiban); adenosine reuptake inhibitors (e.g., dipyridamole); norepinephrine agents (e.g., phentermine); serotonergic agents (e.g., sibutramine); diacylglycerol acyltransferase (DGAT) inhibitors; feeding behavior modifiers; pyruvate dehydrogenase kinase (PDK) modulators; serotonin receptor modulators; monoamine transmission modulators, such as selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine), norepinephrine reuptake inhibitors (NARIs), norepinephrine-serotonin reuptake inhibitors (SNRIs), and monoamine oxidase inhibitors (MAOIs) (e.g., toloxacin and amivamide);Compounds described in WO007 / 013694, WO2007 / 018314, WO2008 / 093639 and WO2008 / 099794; GPR40 agonists (e.g., fasiglitazone or its hydrate, compounds described in WO2004 / 041266, WO2004 / 106276, WO2005 / 063729, WO2005 / 063725, WO2005 / 087710, WO2005 / 095338, WO2007 / 013689 and WO2008 / 001931); SGLT1 inhibitors; adiponectin or its agonists; IKK inhibitors (e.g., AS-2868); somatostatin receptors. Body agonists; ACC2 inhibitors; cachexia modifiers, such as cyclooxygenase inhibitors (e.g., indomethacin), progesterone derivatives (e.g., megestrol acetate), glucocorticoids (e.g., dexamethasone), metoclopramide agents, tetrahydrocannabinol agents; agents for improving lipid metabolism (e.g., eicosapentaenoic acid), growth hormone, IGF-1, antibodies against cachexia-inducing factor TNF-α, LIF, IL-6, and tumor suppressor M; metabolic regulatory proteins or peptides, such as glucoskinase (GK), glucoskinase regulatory protein (GKRP), uncoupling proteins 2 and 3 (UCP2 and UCP3), peroxisome proliferator-activated receptor α (PPARα), MC4r agonists, insulin receptor agonists, PDEs. 5. Inhibitors, including glycation inhibitors (e.g., ALT-711); neurotrophic agents (e.g., Y-128, VX853, neurotrophic peptides); antidepressants (e.g., desipramine, amitriptyline, imipramine); antiepileptics (e.g., lamotrigine, oxcarbazepine, levetiracetam, zonisamide, pregabalin, lacosamide, carbamazepine); antiarrhythmics (e.g., mexiletine); acetylcholine receptor ligands (e.g., ABT-594); endothelial angiotensin receptor antagonists (e.g., ABT-627); anesthetic analgesics (e.g., morphine); α2 receptor agonists (e.g., clonidine); local analgesics (e.g., capsaicin); anxiolytics (e.g., benzothiazazepine); phosphorus Esterase inhibitors (e.g., sildenafil); dopamine receptor agonists (e.g., apomorphine); cytotoxic antibodies (e.g., T-cell receptor and IL-2 receptor-specific antibodies); B-cell depletion therapies (e.g., anti-CD20 antibodies (e.g., rituxan), i-BLyS antibodies); drugs affecting T-cell migration (e.g., anti-integrin α4 / β1 antibodies (e.g., tysabri)); drugs acting on immunoaffinity proteins (e.g., cyclosporine, tacrolimus, sirolimus, rapamycin); interferons (e.g., IFN-β); immunomodulators (e.g., glatiramer); TNF-binding proteins (e.g., circulating receptors); immunosuppressants (e.g., mycophenolate mofetil).And metaglitazone (metaglidasen), AMG-131, bagliflozin, MBX-2044, letagliflozin, agliflozin, sitagliptin, lobegliflozin, PLX-204, PN-2034, GFT-505, THR-0921, exenatide, exenatide-4, memantine hydrochloride, midazolam, ketoconazole, ethyl eicosapentaenoate, clonidine, azosemi, isosorbide, ethacrylic acid, pyrrolitanide, bumetanide, etoposide, piroxicam, NO donors (e.g., organic nitrates) and NO promoters (e.g., phosphodiesterase inhibitors).
[0321] In some implementations, one or more additional therapeutic agents include, for example, those that can be used as antiemetics. As used herein, an "antiemetic" means any agent that relieves (e.g., reduces or eliminates) nausea or vomiting. It should be understood that when referring to a therapeutically effective amount of an antiemetic, the amount administered is the amount required to relieve (e.g., reduce or eliminate) nausea or vomiting. While not wishing to be bound by theory, it is believed that administration of one or more antiemetics in combination with compounds of formula (I) described herein may allow for the administration of higher doses of compounds of formula (I), for example, because the patient may be able to maintain normal food intake, thereby resulting in a faster response to treatment.
[0322] Non-limiting examples of antiemetics include 5HT3 receptor antagonists (serotonin receptor antagonists), sedatives / antipsychotics, antihistamines, anticholinergics, steroids (e.g., corticosteroids), NK1 receptor antagonists (neurokine 1 substance P receptor antagonists), antidopaminergics / dopamine receptor antagonists, benzodiazepines, and cannabinoids.
[0323] For example, antiemetics can be selected from sedatives, antihistamines, anticholinergics, sterols, 5HT-3 receptor antagonists, NK1 receptor antagonists, antidopaminergics / dopamine receptor antagonists, benzodiazepines, and non-psychoactive cannabinoids.
[0324] In some implementations, the antiemetic is a 5HT3 receptor antagonist (serotonin receptor antagonist). Non-limiting examples of 5HT3 receptor antagonists (serotonin receptor antagonists) include: granisetron (Kytril), dolasetron, ondansetron (Zofran), tropisetron, ramosetron, palonosetron, alosetron, azasetron, bemistron, zatosetron, bartaprazole, MDL-73147EF; metoclopramide, N-3389 (ne-3,9-dimethyl-3,9-diazabicyclo[3,3,1]non-7-yl-1H-indazole-3-carboxamide dihydrochloride), Y-25130 hydrochloride, MDL 72222, scopolamine-3,5-dimethylbenzoate, 3-(4-allylpiperazin-1-yl)-2-quinoxaline carboxylate maleate, zacopride hydrochloride, and mirtazapine. Other non-limiting examples of 5HT3 receptor antagonists (serotonin receptor antagonists) include: celanisetron, clozapine, cyproheptadine, dazopride, hydroxyzine, lerisetron, metoclopramide, miansheline, olanzapine, palonosetron (+netostitan), quetiapine, carmustron (qamosetron), ramosetron, licastron, riperidone, ziprasidone, and zartosetron.
[0325] In some implementations, the 5HT-3 receptor antagonist is granisetron, dolasetron, ondansetron hydrochloride, tropisetron, ramosetron, palonosetron, alosetron, bemyrosetron, zartosetron, bartaprazole, MDL-73147EF, metoclopramide, N-3389, Y-25130 hydrochloride, MDL 72222, scopolamine-3,5-dimethylbenzoate, 3-(4-allyl-piperazin-1-yl)-2-quinoxaloline carboxylate maleate, zalcopride hydrochloride, and mirtazapine.
[0326] In some implementations, the 5HT-3 receptor antagonist is granisetron, dolasetron, ondansetron hydrochloride, tropisetron, ramosetron, palonosetron, alosetron, bemyrosetron, and zartosetron.
[0327] In some implementations, the 5HT-3 receptor antagonist is granisetron, dolasetron, or ondansetron.
[0328] In some implementations, the 5HT-3 receptor antagonist is granisetron.
[0329] In some implementations, the 5HT-3 receptor antagonist is ondansetron.
[0330] In some implementations, the antiemetic is an antihistamine. Non-limiting examples of antihistamines include: piperazine derivatives (e.g., cyproheptadine, meclopramide, and cinnarizine); promirtine; dimethoprim (Gravol); diphenhydramine; hydroxyzine; bucropramide; and meclopramide hydrochloride (Bonine, Antivert), doxylamine, and mirtazapine.
[0331] In some implementations, the antiemetic is an anticholinergic drug (an inhibitor of acetylcholine receptors). Non-limiting examples of anticholinergic drugs include: atropine, scopolamine, glycopyrron, hyoscine, trihexyphenidyl (trihexy-5, trihexyphenidyl hydrochloride), benzalkonium mesylate, bisperidone hydrochloride, disipal (norflex), diphenhydramine, hydroxyzine, scopolamine, and kemadrin (propiconazole hydrochloride).
[0332] In some implementations, the antiemetic is a steroid (e.g., a corticosteroid). Non-limiting examples of steroids include betamethasone, dexamethasone, methylprednisolone, Prednisone®, and trimethoprim (Tigan).
[0333] In some embodiments, the antiemetic is an NK1 receptor antagonist (e.g., a neurokinin 1 substance P receptor antagonist). Non-limiting examples of NK1 receptor antagonists include aprepitant, cassopitant, elopitant, fosaprepitant, maropitant, netupitant, lorapitant, and vertepitant.
[0334] Other non-limiting examples of NK1 receptor antagonists include: MPC-4505, GW597599, MPC-4505, GR205171, L-759274, SR 140333, CP-96,345, BIIF 1149, NKP 608C, NKP 608A, CGP 60829, SR 140333 (nomipitan ammonium besylate / nomipitan ammonium chloride), LY 303870 (lanepitan), MDL-105172A, MDL-103896, MEN-11149, MEN-11467, DNK 333A, YM-49244, YM-44778, ZM-274773, MEN-10930, S-19752, Neuronorm, YM-35375, DA-5018, MK-869, L-754030, CJ-11974, L-758298, DNK-33A, 6b-l, CJ-11974 j. Benserazide and carbidopa k. TAK-637 [(aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diaza-aranoctano[2,1-g] [1,7]naphthidine-6,13-dione], PD 154075, ([(2-benzofuran)-CH2OCO]-(R)-α-MeTrp-(S)-NHCH(CH3) Ph), FK888 and (D-Pro4, D-Trp7,9,10, Phe11)SP4-11.
[0335] In some embodiments, the antiemetic is an antidopaminer / dopamine receptor antagonist (e.g., a dopamine receptor antagonist, such as a D2 or D3 antagonist). Non-limiting examples include phenothiazines (e.g., propranolol, chlorpromazine, prochlorperazine, perphenazine, hydroxyzine, thiotetracycline, metoprolol); benzamides (e.g., metoclopramide, domperidone); butyric acid ketones (e.g., haloperidol, droperidol); aripiprazole, bromiprazole, clopazole, domperidone, itoprazole, metoclopramide, trimebenzamide, and amisulpride.
[0336] In some implementations, the antiemetic is a non-psychoactive cannabinoid (e.g., cannabidiol (CBD), dimethylheptylcannabidiol (CBD-DMH), tetrahydrocannabinol (THC), cannabinoid agonists such as WIN 55-212 (CB1 and CB2 receptor agonists), dronabinol (Marinol®), and cesamet).
[0337] Other exemplary antiemetics include: c-9280 (Merck); benzodiazepines (diazepam, midazolam, lorazepam); sedatives / antipsychotics (e.g., diazepam, haloperidol, and prochlorazine (Compazine®)); cerium oxalate; propofol; sodium citrate; dextrose; fructose (Nauzene); orthophosphate; fructose; glucose (Emetrol); bismuth subsalicylate (Pepto Bismol); ephedrine; vitamin B6; peppermint, lavender, and lemon essential oils; and ginger.
[0338] Other exemplary antiemetics include those disclosed in the following documents: US 20120101089A1; US 10,071,088 B2; US 6,673,792 B1; US 6,197,329 B1; US 10,828,297 B2; US 10,322,106 B2; US 10,525,033 B2; WO 2009080351 A1; WO 2019203753 A2; WO 2002020001 A2; US 8,119,697 B2; US 5,039,528; US 20090305964 A1; and WO 2006 / 111169, each of which is incorporated herein by reference in its entirety.
[0339] In some embodiments, an additional therapeutic agent or regimen is administered to the patient before contact with or application of the compound and pharmaceutical composition (e.g., about one hour, about six hours, about 12 hours, about 24 hours, about 48 hours, about one week, or about one month prior).
[0340] In some embodiments, an additional therapeutic agent or regimen is administered to the patient at substantially the same time as the contact with or application of the compound and pharmaceutical composition. For example, the additional therapeutic agent or regimen, along with the compound and pharmaceutical composition, is administered to the patient simultaneously in the same dosage form. As another example, the additional therapeutic agent or regimen, along with the compound and pharmaceutical composition, is administered to the patient in parallel in separate dosage forms. Patient selection
[0341] In some embodiments, the method described herein further includes the step of identifying a patient (e.g., a subject) who requires such treatment (e.g., by means of blood tests, body mass index, or other conventional methods known in the art).
[0342] In some embodiments, the method described herein further includes the step of identifying a patient with type 2 diabetes (e.g., a patient). In some embodiments, determining whether a patient has type 2 diabetes includes performing measurements to determine levels of hemoglobin A1c (HbA1c), fasting plasma glucose, non-fasting plasma glucose, or any combination thereof. In some embodiments, the HbA1c level is from about 6.5% to about 24.0%. In some embodiments, the HbA1c level is greater than or about 6.5%. In some embodiments, the HbA1c level is greater than or about 8.0%. In some embodiments, the HbA1c level is greater than or about 10.0%. In some embodiments, the HbA1c level is greater than or about 12.0%. In some embodiments, the HbA1c level is greater than or about 14.0%. In some embodiments, the HbA1c level is greater than or about 16.0%. In some embodiments, the HbA1c level is greater than or about 18.0%. In some embodiments, the HbA1c level is greater than or about 20.0%. In some implementations, the HbA1c level is greater than or about 22.0%. In some implementations, the HbA1c level is greater than or about 24.0%.
[0343] In some embodiments, the fasting plasma glucose level is greater than or about 120 mg / dL to greater than or about 750 mg / dL. In some embodiments, the fasting plasma glucose level is greater than or about 200 mg / dL to greater than or about 500 mg / dL. In some embodiments, the fasting plasma glucose level is greater than or about 300 mg / dL to greater than or about 700 mg / dL.
[0344] In some embodiments, the non-fasting plasma glucose level is greater than or about 190 mg / dL to greater than or about 750 mg / dL. In some embodiments, the non-fasting plasma glucose level is greater than or about 250 mg / dL to greater than or about 450 mg / dL. In some embodiments, the non-fasting plasma glucose level is greater than or about 400 mg / dL to greater than or about 700 mg / dL.
[0345] In some implementations, determining whether a patient has type 2 diabetes further includes determining the patient's BMI. In some implementations, the patient's BMI is greater than or about 22 kg / m². 2 Up to or about 100 kg / m 2 In some implementations, the patient's BMI is greater than or approximately 30 kg / m². 2 Up to or approximately 90 kg / m 2 In some implementations, the patient's BMI is greater than or approximately 40 kg / m². 2Up to or approximately 80 kg / m 2 In some implementations, the patient's BMI is greater than or approximately 50 kg / m². 2 Up to or about 70 kg / m 2 .
[0346] In some embodiments, additional factors (e.g., risk factors) used to determine whether a patient has type 2 diabetes further include the patient's age and race. In some embodiments, the patient is older than or about 10 years. In some embodiments, the patient is older than or about 15 years. In some embodiments, the patient is older than or about 20 years. In some embodiments, the patient is older than or about 25 years. In some embodiments, the patient is older than or about 30 years. In some embodiments, the patient is older than or about 35 years. In some embodiments, the patient is older than or about 40 years. In some embodiments, the patient is older than or about 42 years. In some embodiments, the patient is older than or about 44 years. In some embodiments, the patient is older than or about 46 years. In some embodiments, the patient is older than or about 48 years. In some embodiments, the patient is older than or about 50 years. In some embodiments, the patient is older than or about 52 years. In some embodiments, the patient is older than or about 54 years. In some embodiments, the patient is older than or about 56 years. In some embodiments, the patient's age is greater than or about 58 years. In some embodiments, the patient's age is greater than or about 60 years. In some embodiments, the patient's age is greater than or about 62 years. In some embodiments, the patient's age is greater than or about 64 years. In some embodiments, the patient's age is greater than or about 66 years. In some embodiments, the patient's age is greater than or about 68 years. In some embodiments, the patient's age is greater than or about 70 years. In some embodiments, the patient's age is greater than or about 72 years. In some embodiments, the patient's age is greater than or about 74 years. In some embodiments, the patient's age is greater than or about 76 years. In some embodiments, the patient's age is greater than or about 78 years. In some embodiments, the patient's age is greater than or about 80 years. In some embodiments, the patient's age is greater than or about 85 years. In some embodiments, the patient's age is greater than or about 90 years. In some embodiments, the patient's age is greater than or about 95 years. In some implementation schemes, the patient's race can be African American, American Indian or Alaskan Native, Asian American, Hispanic or Latino, or Native Hawaiian or Pacific Islander. Compound Synthesis
[0347] The compounds disclosed herein can be prepared from readily available starting materials using, for example, the following general methods and procedures. It should be understood that other process conditions may also be used, given certain process conditions (i.e., reaction temperature, time, molar ratio of reactants, solvent, pressure, etc.), unless otherwise stated. Optimal reaction conditions may vary depending on the reactants or solvents used, but such conditions can be determined by those skilled in the art through conventional optimization procedures.
[0348] Furthermore, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesirable reactions. Suitable protecting groups for a variety of functional groups, as well as suitable conditions for the protection and deprotection of certain functional groups, are well known in the art. For example, many protecting groups are described in TW Greene and GM Wuts (1999), Protecting Groups in Organic Synthesis, 3rd Edition, Wiley, New York, and the references cited therein.
[0349] Furthermore, the compounds of this disclosure may contain one or more chiral centers. Therefore, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as mixtures of enriched stereoisomers, if desired. All such stereoisomers (and enriched mixtures) are included within the scope of this disclosure unless otherwise indicated. Pure stereoisomers (or enriched mixtures) can be prepared using, for example, optically active starting materials or stereoselective reagents well known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, etc.
[0350] The starting materials used in the following reactions are well-known compounds, or can be prepared by known procedures or their obvious modifications. For example, many starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance, California, USA), EMKA-Chemie GmbH & Co. KG (Escherich, Germany), or Millipore Sigma (Burlington, Massachusetts, USA). Other starting materials can be prepared by procedures or obvious modifications thereof described in the following standard reference texts: Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1–15 (John Wiley, and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1–5 and Supplements (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1–40 (John Wiley, and Sons, 1991); March's Advanced Organic Chemistry (John Wiley, and Sons, 5th edition, 2001); and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
[0351] Scheme I describes a general method that can be used to synthesize the compounds described herein, wherein A, X 1 X 2 X 3 X 4 L 1 L 2 Y 1 Y 2 Y 3 R 4 and R 5 Each is independently defined as in this paper, and R 50 It is an alkyl or substituted alkyl group. Option I
[0352] As shown in Scheme I, coupling compound I-1 with compound I-2 provides compound I-3. Compound I-3 can then undergo a Hantzsch-type pyridine reaction with compounds I-4 and I-5 to provide compound I-6. In some embodiments, the reaction is carried out under heating conditions in a suitable solvent. Oxidation of I-6 (e.g., via CAN or DDQ) provides compound I.
[0353] For any of the compounds shown in Scheme I, it should be understood that multiple derivatives can be provided at any step through functional group tautomerism. In some embodiments, various substituents (e.g., A, X) of compounds I-1, I-2, I-3, I-4, I-5, or I-6 1 X 2 X 3 X 4 L 1 L 2 Y 1 Y 2 Y 3 R 4 and R 5 As defined herein. However, derivatization of compounds I-1, I-2, I-3, I-4, I-5, or I-6 prior to the reaction and / or further derivatization of the resulting reaction product at any step provides compounds of various formulas I. Suitable starting materials and reagents are commercially available or can be prepared by methods known to those skilled in the art.
[0354] After the reaction is complete, compound I can be recovered using conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration, etc. In some embodiments, appropriate control of reaction conditions and selection of substituents for reagents can at least partially determine or preserve the formation of various stereoisomers when stereochemistry is desired.
[0355] Furthermore, compounds of formula IB can be synthesized according to the route shown in Scheme II, wherein A, X 1 X 2 X 3 X 4 Ring B, L 1 L 2 Y 1 Y 2 Y 3 R 4 and R 5 Each independently, as defined in this article, R 50 It is an alkyl or substituted alkyl group, and PG is a suitable protecting group (such as tert-butyloxycarbonyl). Option II
[0356] As shown in Scheme II, compound I-7 can undergo a Hantzsch-type pyridine reaction with compounds I-5 and I-8, followed by oxidation under suitable conditions (e.g., in the presence of CAN or DDQ) to provide compound I-9. Alternatively, compound I-10 can be reacted with compounds I-5 and I-8 under similar conditions to provide compound I-11. Subsequently, compound I-11 can be reacted with hydroxylamine to provide an N-hydroxycarboxylimide amide intermediate, followed by reaction with CDI to provide compound I-9.
[0357] Compound I-9 can then undergo deprotection and subsequent cyclization under suitable conditions (such as in the presence of TFA) to provide a compound of formula IB. In some embodiments, appropriate control of reaction conditions and selection of substituents for reagents can at least partially determine or preserve the formation of various stereoisomers when stereochemistry is desired.
[0358] After each reaction is completed, each of the intermediates or final compounds can be recovered and optionally purified using conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration, etc. Other modifications for obtaining the compounds described in this disclosure are within the scope of the art. Universal synthesis
[0359] Typical embodiments of the compounds described herein can be synthesized using the general reaction scheme described below. As will be clear from the description herein, the general scheme can be modified by substituting the starting materials with other materials having similar structures to obtain correspondingly different products. The synthesis is described below to provide numerous examples of how the starting materials can be modified to provide the respective products. Given the desired product that defines the substituents, the necessary starting materials can generally be determined by examination. Starting materials are typically obtained from commercial sources or synthesized using published methods. For the synthesis of compounds as embodiments described in this disclosure, examination of the structure of the compound to be synthesized will provide the identity of each substituent. Given the embodiments herein, the identity of the final product will generally clarify the identity of the necessary starting materials through a simple examination process. Generally, the compounds described herein are typically stable and separable at room temperature and chamber pressure. Example
[0360] The following embodiments are included to illustrate specific implementations of this disclosure. Those skilled in the art will understand that the techniques disclosed in the following embodiments represent techniques that work well in the practice of this disclosure and can therefore be considered as constituting a specific pattern of its practice. However, based on this disclosure, those skilled in the art will understand that many changes can be made to the disclosed specific embodiments without departing from the spirit and scope of this disclosure and still obtaining the same or similar results.
[0361] General Information: All evaporation or concentration was performed in a vacuum using a rotary evaporator. Analytical samples were dried in a vacuum (1–5 mmHg) at room temperature. Thin-layer chromatography (TLC) was performed on silica gel plates, with spots visualized by UV light (214 nm and 254 nm). Purification was performed using silica gel (100–200 mesh) by column chromatography and rapid chromatography. Solvent systems were reported as mixtures by volume. NMR spectra were recorded on a Bruker 400 or Varian (400 MHz) spectrometer. Values were reported as δ in ppm. 1 H chemical shift, with deuterated solvent as internal standard. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad peak, m = multiply), coupling constant (Hz), and integral. LCMS spectra were obtained on a SHIMADZULC20-MS2020 or an Agilent 1260 series 6125B mass spectrometer or an Agilent 1200 series 6110 or 6120 mass spectrometer using electrospray ionization, unless otherwise specified.
[0362] Unless otherwise indicated in the examples described herein, certain compounds contain a stereocenter at the carbon atom shown below (e.g., compounds having stereochemistry at the C3 or C9a fusion), and the compositions obtained and tested in the following determinations are non-racemic compositions relative to that stereocenter. Consideration is given to some amount of racemization occurring during the synthesis of Hantzsch-type pyridines (e.g., less than 50% or less than 20%). However, the compositions tested are advantageous for the stereoisomers shown in the examples and Table 1.
[0363] For certain compounds prepared without chiral influence, stereochemistry can be assigned based on the expected potency as shown in the examples and Table 1 (e.g., compounds of Examples 33, 34, 35 and 42).
[0364] The separation of stereoisomers can be performed using standard techniques (e.g., SFC). For example: Example 1: Compound 101 Step A: 2-((S)-1-(tert-Butoxycarbonyl)pyrrolidine-2-yl)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophene-2-yl)-6-(4-fluorophenylethyl)-1,4-dihydropyridine-3-carboxylic acid ethyl ester
[0365] A mixture of 5-(4-fluorophenyl)-3-oxopentanilonitrile (350 mg, 1.830 mmol), N-(3,4-difluorobenzyl)-5-carboxythiophene-2-carboxamide (514.87 mg, 1.830 mmol) and (S)-2-(3-ethoxy-1-imino-3-oxopropyl)pyrrolidine-1-carboxylic acid tert-butyl ester (520.51 mg, 1.830 mmol) in EtOH (1 mL) was stirred at 110ºC for 12 hours. The reaction mixture was concentrated under reduced pressure to provide ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophene-2-yl)-6-(4-fluorophenylethyl)-1,4-dihydropyridine-3-carboxylate (1.2 g, crude). LC-MS: m / z 721.0 (M+H) + . Step B (S)-2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophene-2-yl)-6-(4-fluorophenylethyl)nicotinic acid ethyl ester
[0366] A mixture of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-5-cyano-4-(5-(((3,4-difluorobenzyl)carbamoyl)thiophene-2-yl)-6-(4-fluorophenylethyl)-1,4-dihydropyridine-3-carboxylate (1.2 g, 1.665 mmol) and ammonium cerium(IV) nitrate (1.37 g, 2.497 mmol) in EtOH (10 mL) was stirred at 50ºC for 2 h. After the reaction was complete, the mixture was washed with H2O (100 mL) and extracted with EA (60 mL x 3). The organic layer was dried over sodium sulfate, filtered, and concentrated under vacuum. The reaction was purified by column chromatography (PE / EA=1 / 1) to provide (S)-2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophene-2-yl)-6-(4-fluorophenylethyl)nicotinic acid ethyl ester (200 mg, 0.278 mmol, 16.71%). LC-MS: m / z 618.7 (M-100) + . Step C(S)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorophenylethyl)-2-(pyrrolidine-2-yl)nicotinic acid ethyl ester
[0367] TFA (2 mL) was added to a mixture of (S)-2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-5-cyano-4-(5-(((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorophenylethyl)nicotinic acid ethyl ester (200 mg, 0.278 mmol) in DCM (2 mL) and stirred at room temperature for 1 hour. After the reaction was complete, the reaction was concentrated under vacuum to provide (S)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorophenylethyl)-2-(pyrrolidine-2-yl)nicotinic acid ethyl ester TFA (170 mg crude). LC-MS: m / z 618.8 (M+H) + . Step D(S)-5-(3-cyano-2-(4-fluorophenylethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-N-(3,4-difluorobenzyl)thiophene-2-carboxamide
[0368] TEA (0.3 mL, 2.158 mmol) was added to a mixture of (S)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorophenylethyl)-2-(pyrrolidine-2-yl)nicotinic acid ethyl ester TFA (170 mg, 0.275 mmol) in DCM (1.5 mL) and stirred at room temperature for 1 hour. The reaction was concentrated under vacuum and purified by reversed-phase chromatography (0.1% FA) to provide (S)-5-(3-cyano-2-(4-fluorophenylethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-N-(3,4-difluorobenzyl)thiophene-2-carboxamide (80 mg, 0.140 mmol, 50.84%). LC-MS: m / z 573.2 (M+H) + . Step E (S,Z)-N-(3,4-difluorobenzyl)-5-(2-(4-fluorophenylethyl)-3-(N'-hydroxyaminoiminoyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thiophene-2-carboxamide
[0369] A mixture of (S)-5-(3-cyano-2-(4-fluorophenylethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-N-(3,4-difluorobenzyl)thiophene-2-carboxamide (60 mg, 0.105 mmol), aqueous solution of NH2OH (0.5 mL, 0.017 mmol), and TEA (0.044 mL, 0.314 mmol) in EtOH (1.0 mL) was stirred at 120ºC for 2 h. The reaction mixture was diluted with H2O (40 mL) and extracted with EA (30 mL x 3). The organic layer was dried over sodium sulfate, filtered, and concentrated under vacuum. The reaction was purified by column chromatography (DCM / MeOH = 15 / 1) to provide (S,Z)-N-(3,4-difluorobenzyl)-5-(2-(4-fluorophenylethyl)-3-(N'-hydroxyaminomethyliminoyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thiophene-2-carboxamide (15 mg, 0.025 mmol, 23.64%). LC-MS: m / z 605.7 (M+H) + . Step F Compound 101
[0370] A mixture of (S,Z)-N-(3,4-difluorobenzyl)-5-(2-(4-fluorophenylethyl)-3-(N'-hydroxyaminomethyliminoyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thiophene-2-carboxamide (15 mg, 0.025 mmol), CDI (4.02 mg, 0.025 mmol), and TEA (0.010 mL, 0.074 mmol) in THF (2 mL) was stirred at 70ºC for 6 h. The reaction mixture was washed with H2O (40 mL) and extracted with EA (40 mL x 3). The organic layer was dried over sodium sulfate, filtered, and concentrated under vacuum. The reaction mixture was purified by preparative HPLC to provide compound 101 (1.02 mg, 0.002 mmol, 6.52%).
[0371] 1 H NMR (400 MHz, CDCl3-d+CD3OD): δ 7.45-7.50 (m, 1 H), 7.10-7.22 (m,6 H), 6.97 (t, J-8.0 Hz, 2 H), 4.72-4.82 (m, 1 H), 4.52 (s, 2 H), 3.69-3.76 (m, 1 H), 3.37-3.47 (m, 1 H), 3.01-3.20 (m, 4 H), 2.20-2.34 (m, 3 H), 1.39-1.46 (m, 1 H). 19 F NMR (377 MHz, CDCl3-d+CD3OD-d4): -116.83, -137.52, -139.81. LC-MS: m / z 632.2 (M+H) + . Compound 110
[0372] Compound 110 was synthesized using a similar procedure as described in Example 1 above, by using suitable materials.
[0373] 1H NMR (400 MHz, DMSO-d6): δ 7.43-7.54 (m, 3 H), 7.28-7.35 (m, 2 H), 7.20-7.24 (m, 2 H), 7.05-7.15 (m, 4 H), 4.87 (d, J=3.2 Hz, 1 H), 4.74 (dd, J=6.0 Hz, J=10.0 Hz, 1 H), 4.39 (t, J=7.6 Hz, 2 H), 3.49-3.52 (m, 1 H), 3.23-3.25 (m, 1 H), 3.09 (t, J=8.0 Hz, 2 H), 2.97-3.04 (m, 4 H), 2.33-2.39 (m, 1H), 2.20-2.25 (m, 2 H), 1.31-1.36 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): δ -117.45, -139.15, -142.17. LC-MS: m / z 636.3 (M+H) + . Compound 111
[0374] Compound 111 was synthesized using a similar procedure as described in Example 1 above, by using suitable materials.
[0375] 1 H NMR (400 MHz, DMSO-d6): δ 12.72 (br s, 1 H), 8.27 (d, J=8.8 Hz, 1H), 8.10-8.17 (m, 1 H), 7.87 (d, J=5.6 Hz, 1 H), 7.63 (br s, 1 H), 7.31-7.44(m, 3 H), 7.19-7.28 (m, 3 H), 7.10 (t, J=8.8 Hz, 2 H), 6.90 (d, J=5.6 Hz, 1H), 4.87 (dd, J=5.6 Hz, J=10.0 Hz, 1 H), 4.73 (d, J=5.6 Hz, 2 H), 3.48-3.59(m, 1 H), 3.24-3.27 (m, 1 H), 2.98-3.17 (m, 4 H), 2.22-2.41 (m, 3 H), 1.32-2.46 (m, 1 H). 19F NMR (377 MHz, DMSO-d6): -117.10, -139.25, -142.13. LC-MS: m / z649.1 (M+H) + . Compound 113
[0376] Compound 113 was synthesized using a similar procedure as described in Example 1 above, by using suitable materials.
[0377] 1 H NMR (400 MHz, DMSO-d6): δ 12.65 (br s, 1 H), 7.38-7.46 (m, 3 H), 7.20-7.25 (m, 4 H), 7.05-7.12 (m, 3 H), 5.06 (t, J=5.6 Hz, 1 H), 4.83 (dd, J=6.4 Hz, J=10.4 Hz, 1 H), 4.55-4.65 (m, 2 H), 3.49-3.56 (m, 1 H), 3.21-3.25(m, 1 H), 2.95-3.13 (m, 5 H), 2.75-2.84 (m, 1 H), 2.21-2.43 (m, 4H), 1.98-2.10 (m, 1 H), 1.31-1.43 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): -117.10, -138.93, -140.74. LC-MS: m / z 639.2 (M+H) + . Compound 114
[0378] Compound 114 was synthesized using suitable materials through a similar procedure as described in Example 1 above.
[0379] 1H NMR (400 MHz, DMSO-d6): δ 12.52 (br s, 1 H), 7.39-7.51 (m, 1 H), 7.31-7.38 (m, 1 H), 7.18-7.25 (m, 2 H), 7.06-7.16 (m, 3 H), 6.97 (dd, J=8.4Hz, J=2.4 Hz, 1 H), 6.89-6.93 (m, 1 H), 6.60-6.71 (m, 1 H), 4.78 (dd, J=10.0Hz, J=6.0 Hz, 1 H), 3.48-3.53 (m, 2 H), 3.20-3.31 (m, 3 H), 3.01-3.12 (m, 3H), 2.78-2.86 (m, 2 H), 2.57-2.66 (m, 2 H), 2.18-2.40 (m, 4 H), 1.74-1.86 (m, 2 H), 1.18-1.37 (m, 2 H). 19 F NMR (377 MHz, DMSO-d6): -74.40, -117.10, -139.21, -142.51. LC-MS: m / z 652.3 (M+H) + Example 2 5-((S)-2-(4-fluorophenylethyl)-4-(7-((((R)-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 102) Step A 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one
[0380] 5-Methyl-3H-1,3,4-oxadiazol-2-one (1.02 g, 10.19 mmol) was added to a solution of LDA (2.0 M, 10.70 mL) in THF (25 mL) at -10ºC under N2. The mixture was stirred at -10ºC for 30 min. Ethyl 3-(4-fluorophenyl)propionate (1.0 g, 5.10 mmol) in THF (5.0 mL) was added to the reaction solution. The mixture was stirred at -10ºC for 1 h. HCl (1 M) was added to the solution until pH = 6–7. The mixture was extracted with EtOAc (100 mL). The organic layer was washed with brine (80 mL), dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The residue was purified by rapid silica gel chromatography (ISCO®; 20 g SepaFlash® silica gel column, 0–60% ethyl acetate / petroleum ether gradient eluent, 25 mL / min) to give 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (166 mg, 663.40 μmol, 13.02% yield, 80% purity determined by TLC). LC-MS: m / z 250.0 (M+H) + . Step B 5-((9aS)-2-(4-fluorophenylethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thiopheno[2,3-c]pyridin-2-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one
[0381] The mixture of (8S)-5,6,7,8-tetrahydropyrrolizin-1,3-dione (21.45 mg, 154.13 μmol), (R)-7-((4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thieno[2,3-c]pyridine-2-carboxaldehyde (50 mg, 154.13 μmol), NH4OAc (17.82 mg, 231.20 μmol), and 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (38.57 mg, 154.13 μmol) in AcOH (0.5 mL) was degassed and purged three times with N2. The mixture was then stirred at 120ºC for 2 h under N2 atmosphere. The mixture was cooled to room temperature and poured into water (5 mL), then extracted with EtOAc (25 mL). The organic layer was washed with an aqueous solution of NaHCO3 (25 mL), followed by washing with brine (25 mL), dried over anhydrous Na2SO4, and concentrated under vacuum. The crude product 5-((9aS)-2-(4-fluorophenylethyl)-4-(7-((((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (56 mg, crude) was obtained. LC-MS: m / z 677.7 (M+H) + . Step C 5-((S)-2-(4-fluorophenylethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thiopheno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one
[0382] Add CAN (90.73 mg, 165.49 μmol) to a solution of 5-((9aS)-2-(4-fluorophenylethyl)-4-(7-((((R)-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (56.00 mg, crude) in ACN (5 mL) and water (2.5 mL). Stir the mixture at 20ºC for 16 h. Pour the mixture into water (25 mL) and extract with EtOAc (25 mL). The organic layer was washed with brine (25 mL), dried over Na2SO4, filtered, and concentrated under vacuum. The residue was purified by rapid silica gel chromatography (ISCO®; 12 g SepaFlash® silica gel column, 0-10% MeOH / DCM gradient eluent, 12 mL / min), and then further purified by preparative HPLC (FA conditions). Column: Kromasil C18 150*30mm*5 µm; Conditions: Water (0.2% formic acid)-ACN; Start B: 25; End B: 55; Gradient time (min): 10; 100% B hold time (time): 5; Flow rate (mL / min): 25; Detection wavelength: 220 nm and 254 nm), to obtain 5-((S)-2-(4-fluorophenylethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thiopheno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (1.77 mg, 2.49 g / mL). μmol, 3.01% yield, 95% purity).
[0383] 1H NMR (400 MHz, CDCl3) δ ppm 8.06 (d, J=5.6 Hz, 1 H), 7.39 (s, 1 H), 7.17 - 7.22 (m, 1 H), 7.09 - 7.16 (m, 2 H), 7.06 (d, J=5.60 Hz, 1 H), 6.93 -7.02 (m, 3 H), 6.76 (d, J=8.0 Hz, 1 H), 5.83 (s, 1 H) 4.74 - 4.78 (m, 1 H), 3.85 (s, 3 H), 3.71 - 3.80 (m, 1 H), 3.39 - 3.43 (m, 1 H), 2.95 - 3.22 (m, 5H), 2.79 - 2.88 (m, 1 H), 2.72 - 2.78 (m, 1 H), 2.48 - 2.55 (m, 1 H), 2.32 -2.41 (m, 2 H), 1.91 - 1.99 (m, 2 H), 1.47 (m, 1 H). LC-MS: m / z 675.2 (M+H) + . (S)-N-(3,4-difluorobenzyl)-5-(2-(4-fluorophenylethyl)-5-oxo-3-(3-oxo-2,3-dihydroisoxazol-5-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thiophene-2-carboxamide (Compound 103)
[0384] Compound 103 was synthesized using a similar procedure as described in Example 2 above, by using suitable materials.
[0385] 1H NMR (400 MHz, DMSO-d6) δ ppm 11.42 (s, 1 H), 9.11 - 9.39 (m, 1 H), 7.70 (d, J=4.0Hz, 1 H), 7.35 - 7.44 (m, 2 H), 7.03 - 7.20 (m, 6 H), 6.04 (s,1 H), 4.81 - 4.85 (m, 1 H), 4.38 - 4.49 (m, 2 H), 3.51 - 3.60 (m, 1 H), 2.88- 3.08 (m, 4 H), 2.11 - 2.44 (m, 4 H), 1.33 - 1.45 (m, 1 H). LC-MS: m / z 633.2(M+H) + . Example 3: Compound 104 Step A: {2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolane-2-yl}acetonitrile
[0386] Ethylene glycol (4.375 mL, 78.448 mmol) and TMSCl (8.52 g, 78.448 mmol) were added to a solution of 5-(4-fluorophenyl)-3-oxopentanilonitrile (5 g, 26.149 mmol) in DCM (130 mL), and the reaction was stirred at 40ºC for 48 h. The reaction mixture was diluted with EA (200 mL) and water (100 mL). The organic layer was separated and washed with additional water (100 mL x 2) and saturated NaCl (100 mL). The organic layer was separated, dried over Na2SO4, and then filtered. The organic layer was collected and concentrated under vacuum. The residue was purified by silica gel column chromatography (eluting with PE:EA = 3:1). The organic layer was collected, concentrated under vacuum, and dried to provide the title compound {2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolane-2-yl}acetonitrile (5.8 g, 24.654 mmol, 94.28%). LC-MS: m / z 257.9 (M+Na) + . Step B: [(1Z)-1-amino-2-{2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolane-2-yl}ethylidene]hydroxylamine
[0387] Hydroxylamine hydrochloride (5.14 g, 73.962 mmol) and DIEA (19.12 g, 147.921 mmol) were added to a solution of {2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolane-2-yl}acetonitrile (5.8 g, 24.654 mmol) in EtOH (110 mL), and the reaction was stirred at 50ºC for 18 h. The reaction mixture was diluted with EA (100 mL) and water (50 mL). The organic layer was separated and washed with additional water (100 mL x 2) and saturated NaCl (50 mL). The organic layer was dried over Na2SO4 and then filtered. The organic layer was collected and concentrated under vacuum. The residue was purified by silica gel column chromatography (eluting with PE:EA = 1:1). The organic layer was collected, concentrated under vacuum, and dried to provide the title compound [(1Z)-1-amino-2-{2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolane-2-yl}ethylene]hydroxylamine (4.7 g, 17.518 mmol, 71.06%). LC-MS: m / z 269.1 (M+H) + . Step C 3-({2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolane-2-yl}methyl)-4H,5H-1,2,4-oxadiazol-5-one
[0388] CDI (1.21 g, 7.455 mmol) was added to a solution of [(1Z)-1-amino-2-{2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolane-2-yl}ethylene]hydroxylamine (2 g, 7.455 mmol) in dioxane (100 mL), and the reaction was stirred at 70ºC for 18 h. The reaction mixture was diluted with EA (100 mL) and water (50 mL). The organic layer was separated and washed with additional water (100 mL x 2) and saturated NaCl (50 mL). The organic layer was dried over Na2SO4 and then filtered. The organic layer was collected and concentrated under vacuum. The residue was purified by silica gel column chromatography (eluting with DCM: MeOH = 96:4). The organic layer was collected, concentrated under vacuum, and dried to provide the title compound 3-({2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolane-2-yl}methyl)-4H,5H-1,2,4-oxadiazol-5-one (1.7 g, 5.777 mmol, 77.49%). LC-MS: m / z 317.2 (M+Na) + . Step D 3-[4-(4-fluorophenyl)-2-oxobutyl]-4H,5H-1,2,4-oxadiazol-5-one
[0389] Concentrated H₂SO₄ (0.127 mL, 2.379 mmol) was added to a solution of 3-({2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolane-2-yl}methyl)-4H,5H-1,2,4-oxadiazol-5-one (700 mg, 2.379 mmol) in FA (7 mL), and the reaction was stirred at 45ºC for 1 h. The reaction mixture was diluted with EA (50 mL) and water (20 mL). The organic layer was separated and washed with additional water (20 mL x 2) and saturated NaCl (20 mL). The organic layer was dried over Na₂SO₄ and then filtered. The organic layer was collected and concentrated under vacuum. The residue was purified by silica gel column chromatography (eluting with DCM:MeOH = 96:4). The organic layer was collected, concentrated under vacuum, and dried to provide the title compound 3-[4-(4-fluorophenyl)-2-oxobutyl]-4H,5H-1,2,4-oxadiazol-5-one (490 mg, 1.958 mmol, 82.32%). LC-MS: m / z 273.0 (M+Na) + . Step E 2-((S)-1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-4-(7-chlorothiopheno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylic acid ethyl ester
[0390] A mixture of 3-(4-(4-fluorophenyl)-2-oxobutyl)-1,2,4-oxadiazol-5(4H)-one (1000 mg, 3.996 mmol), 7-chlorothieno[2,3-c]pyridine-2-carboxaldehyde (789.83 mg, 3.996 mmol), (S)-2-(3-ethoxy-3-oxopropionyl)pyrrolidine-1-carboxylic acid tert-butyl ester (1140.31 mg, 3.996 mmol), NH4OAC (616.07 mg, 7.993 mmol), and Yb((OTf)3 (247.77 mg, 0.400 mmol) in EtOH (20 mL) was stirred overnight at room temperature. After the reaction was complete, the mixture was diluted with EA (50 mL) and water (150 mL). The organic layer was washed with mL. The organic layer was dried over Na₂SO₄, filtered, and concentrated to give ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylate (2800 mg, crude). LC-MS: m / z 695.4 (M+H) - . Step F(S)-2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-4-(7-chlorothiopheno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) ethyl nicotinate
[0391] DDQ (1278.16 mg, 5.631 mmol) was added to a solution of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylate (2800 mg, crude) in THF (30 mL), and the reaction was stirred at 50ºC for 12 h. After the reaction was complete, the mixture was diluted with EA (50 mL) and washed with water (200 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to dryness under vacuum. The residue was purified by column chromatography on silica gel (DCM / MeOH = 20 / 1) to give (S)-2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinic acid ethyl ester (2 g, impure). LC-MS: m / z 693.4 (M+H) + . Step G (S)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidine-2-yl)nicotinic acid ethyl ester TFA salt.
[0392] TFA (7 mL, 91.414 mmol) was added to a solution of (S)-2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinic acid ethyl ester (2.0 g, impure) in DCM (30 mL), and the reaction was stirred at room temperature for 1 h. After the reaction was complete, the mixture was concentrated to give (S)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidine-2-yl)nicotinic acid ethyl ester TFA salt (2.5 g, crude). LC-MS: m / z 593.4 (M+H) + . Step H(S)-3-(4-(7-chlorothiophene[2,3-c]pyridin-2-yl)-2-(4-fluorophenylethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one
[0393] TEA (12 mL, 86.333 mmol) was added to a solution of (S)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidine-2-yl)nicotinic acid ethyl ester TFA salt (2.5 g, crude) in DCM (30 mL), and the reaction was stirred at room temperature for 1 h. After the reaction was complete, the mixture was diluted with EA (100 mL) and washed with water (300 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to dryness under vacuum. The residue was purified by column chromatography on silica gel (DCM / MeOH=20 / 1) to give (S)-3-(4-(7-chlorothieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenylethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (640 mg, 1.168 mmol, 29.22%). LC-MS: m / z 547.4 (M+H) + . Step I – Compound 104
[0394] A solution of (S)-3-(4-(7-chlorothieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenylethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (100 mg, 0.183 mmol), (R)-4-methoxy-2,3-dihydro-1H-indene-1-amine (61.85 mg, 0.311 mmol), RuPhos Pd G3 (15.29 mg, 0.018 mmol), RuPhos (16.80 mg, 0.036 mmol), and Cs2CO3 (119.20 mg, 0.366 mmol) in toluene (3 mL) was prepared in a 10 mL sealed tube under N2. The mixture was stirred overnight at 110ºC. After the reaction was complete, the mixture was filtered and concentrated to dryness under vacuum. The residue was purified by column chromatography on silica gel (DCM / MeOH = 20 / 1) to give compound 104 (20 mg, crude). The residue was further purified by column chromatography on C18-25 g (FA 0.1% / ACN = 36%) to give compound 104 (2.98 mg, 2.43%).
[0395] 1 H NMR (400 MHz, DMSO-d6): δ 12.79 (br s, 1 H), 7.98 (d, J=5.2 Hz, 1H), 7.41 (s, 1 H), 7.19-7.33 (m, 3 H), 7.04-7.17 (m, 4 H), 6.79-6.88 (m, 2H), 5.90 (q, J=8.0 Hz, 1 H), 4.87 (dd, J=6.0 Hz, J=10.0 Hz, 1 H), 3.79 (s, 3H), 3.50-3.59 (m, 1 H), 3.26-3.28 (m, 1 H), 2.89-3.18 (m, 6 H), 2.65-2.75 (m, 1 H), 2.22-2.40 (m, 3 H), 1.95-2.07 (m, 1 H), 1.33-1.46 (m, 1 H). 19 F NMR (377MHz, DMSO-d6): -117.07. LC-MS: m / z 675.3 (M+H) + . 4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorobenzyl)-2-isobutyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)nicotinamide (compound 123)
[0396] Compound 123 was synthesized using a similar procedure to that described in Example 3 above, by using suitable materials.
[0397] 1 H NMR (400 MHz, MeOD-d4) δ 7.78 (d, J=6.85 Hz, 1H), 7.65 (s, 1H), 7.57 (br d, J=7.95 Hz, 2H), 7.37-7.45 (m, 1H), 7.41 (dd, J=7.64, 10.33 Hz,3H), 7.28 (t, J=7.89 Hz, 1H), 6.98 (d, J=7.46 Hz, 1H), 6.92 (d, J=8.19 Hz,1H), 5.52 (br t, J=6.85 Hz, 1H), 3.86 (s, 3H), 3.61-3.73 (m, 1H), 3.40-3.52(m, 1H), 3.26-3.30 (m, 4H), 3.17-3.26 (m, 1H), 3.05-3.17 (m, 1H), 2.83-2.96(m, 1H), 2.69-2.70 (m, 1H), 2.68-2.81 (m, 1H), 2.37-2.53 (m, 3H), 2.10-2.22 (m, 1H), 1.37-1.50 (m, 1H). LC-MS: m / z 725.4 (M+H) + . 3-((S)-4-(7-((((R)-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-2-(3-(trifluoromethyl)phenethyl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 124)
[0398] Compound 124 was synthesized using a similar procedure to that described in Example 3 above, by using suitable materials.
[0399] 1H NMR (400 MHz, MeOD) δ ppm 8.24 (s, 1 H), 7.79 (d, J=6.36 Hz, 1 H), 7.44 – 7.55 (m, 5 H), 7.16 – 7.30 (m, 2 H), 6.94 (d, J=7.34 Hz, 1 H), 6.87(d, J=8.07 Hz, 1 H), 5.61 (t, J=6.91 Hz, 1 H), 4.65 (m, 1 H), 3.85 (s, 3 H), 3.55 – 3.73 (m, 1 H), 3.35 – 3.51 (m, 1 H), 3.04 – 3.25 (m, 5 H), 2.83 (dt, J=16.11, 7.90 Hz, 1 H), 2.65 – 2.75 (m, 1 H), 2.42 (d, J=13.69 Hz, 3 H), 2.04– 2.15 (m, 1 H). 1.34 – 1.46 (m, 1 H). LC-MS: m / z 725.4 (M+H) + . 3-((S)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-2-(2-(trifluoromethyl)phenethyl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 125)
[0400] Compound 125 was synthesized using a similar procedure to that described in Example 3 above, by using suitable materials.
[0401] 1H NMR (400 MHz, MeOD-d4) δ 7.66 - 7.71 (m, 1 H), 7.53 - 7.59 (m, 2H), 7.42 - 7.50 (m, 1 H), 7.25 - 7.37 (m, 3 H), 7.14 - 7.21 (m, 1 H), 6.80 -6.92 (m, 2 H), 5.37 - 5.47 (m, 1 H), 3.73 - 3.81 (m, 3 H), 3.49 - 3.63 (m, 1H), 3.30 - 3.40 (m, 1 H), 3.17 (d, J = 1.71 Hz, 4 H), 2.97 - 3.05 (m, 1 H),2.75 - 2.82 (m, 1 H), 2.58 - 2.71 (m, 1 H), 2.27 - 2.47 (m, 3 H), 2.00 - 2.13 (m, 1 H), 1.31 - 1.45 (m, 1 H), 1.21 - 1.24 (m, 1 H). LC-MS: m / z 725.4 (M+H) + . 3-((S)-2-(4-isopropylphenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 126)
[0402] Compound 126 was synthesized using a similar procedure to that described in Example 3 above, by using suitable materials.
[0403] 1H NMR (400 MHz, DMSO-d6) δ 9.24 (s, 1H), 7.89 (d, J=6.60 Hz, 1H), 7.63 (s, 1H), 7.40 (d, J=6.60 Hz, 1H), 7.23 (t, J=7.82 Hz, 1H), 7.11-7.16 (m,5H), 6.94 (dd, J=7.83, 15.16 Hz, 2H), 5.64 (q, J=7.09 Hz, 1H), 4.91 (dd, J=6.30, 10.21 Hz, 1H), 3.81 (s, 3H), 3.12-3.17 (m, 2H), 3.05 (d, J=5.50 Hz,1H), 2.94-3.00 (m, 2H), 2.71-2.86 (m, 4H), 2.62 (td, J=4.55, 12.65 Hz, 1H), 2.32-2.38 (m, 1H), 2.23-2.31 (m, 2H), 2.10 (dd, J=7.89, 12.78 Hz, 1H), 1.35-1.47 (m, 1H), 1.16 (d, J=6.85 Hz, 6H). LC-MS: m / z 699.4 (M+H) + . 3-((S)-2-(4-cyclopropylphenethyl)-4-(7-((((R)-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 127)
[0404] Compound 127 was synthesized using a similar procedure to that described in Example 3 above, by using suitable materials.
[0405] 1H NMR (400 MHz, MeOD-d4) δ ppm 8.32 (s, 1 H), 7.84 (d, J=6.24 Hz, 1H), 7.51 (s, 1 H), 7.19 - 7.28 (m, 2 H), 7.07 (d, J=7.95 Hz, 2 H), 6.93 -7.01 (m, 3 H), 6.87 (d, J=7.44 Hz, 1 H), 5.67 (t, J=6.79 Hz, 1 H), 4.63 (s, 1H), 3.86 (m, 3 H), 3.62 - 3.73 (m, 1 H), 3.38 - 3.48 (m, 1 H), 3.13 - 3.20(m, 2 H), 2.98 - 3.12 (m, 3 H), 2.84 (dt, J=16.11, 8.15 Hz, 1 H), 2.67 - 2.76(m, 1 H), 2.37 - 2.54 (m, 3 H), 2.09 (br dd, J=12.41, 8.13 Hz, 1 H), 1.83 -1.90 (m, 1 H), 1.38 - 1.50 (m, 1 H), 0.89 - 0.95 (m, 2 H), 0.64 (d, J=4.89Hz, 2 H). LC-MS: m / z 697.5 (M+H) + . 4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorobenzyl)-2-isobutyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)nicotinamide (compound 128)
[0406] Compound 128 was synthesized using a similar procedure to that described in Example 3 above, by using suitable materials.
[0407] 1H NMR (400 MHz, MeOD-d4) δ 7.78 (d, J=6.85 Hz, 1H), 7.67 (d, J=2.57Hz, 1H), 7.43 (d, J=6.85 Hz, 1H), 7.28 (t, J=7.83 Hz, 1H), 6.90-7.10 (m, 3H),6.78-6.88 (m, 1H), 5.52 (t, J=6.66 Hz, 1H), 3.86 (s, 3H), 3.63-3.81 (m, 2H),3.46 (dd, J=5.93, 11.19 Hz, 1H), 3.36-3.43 (m, 1H), 3.36-3.42 (m, 1H), 3.07-3.16 (m, 1H), 2.65-3.06 (m, 6H), 2.39-2.56 (m, 3H), 2.10-2.27 (m, 2H), 1.80-1.98 (m, 1H), 1.50 (d, J=3.91 Hz, 1H). LC-MS: m / z 701.4 (M+H) + . Compound 130
[0408] Compound 130 was synthesized using a similar procedure to that described in Example 3 above, by using suitable materials.
[0409] 1 H NMR (400 MHz, DMSO-d6): δ 12.84 (br s, 1 H), 7.85-7.95 (m, 1 H), 7.17-7.66 (m, 8 H), 7.10 (t, J=8.8 Hz, 2 H), 4.86-4.97 (m, 1 H), 4.64-4.79(m, 2 H), 3.54-3.58 (m, 1 H), 3.16-3.21 (m, 2 H), 3.03-3.15 (m, 3 H), 2.36-2.40 (m, 1 H), 2.26-2.34 (m, 2 H), 1.36-1.48 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): -117.01, -71.08, -69.19. LC-MS: m / z 655.2 (M+H) + . (S)-3-(4-(7-((3,4-difluorobenzyl)oxy)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenylethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 133)
[0410] Compound 133 was synthesized using a similar procedure to that described in Example 3 above, by using suitable materials.
[0411] 1 H NMR (400 MHz, MeOD-d4) δ 7.92 - 7.99 (m, 1 H), 7.40 - 7.49 (m, 1H), 7.29 - 7.38 (m, 2 H), 7.14 - 7.24 (m, 2 H), 7.06 - 7.12 (m, 2 H), 6.84 -6.93 (m, 2 H), 5.45 (s, 2 H), 3.51 - 3.62 (m, 1 H), 3.28 - 3.39 (m, 1 H), 3.07 - 3.14 (m, 2 H), 2.91 - 3.04 (m, 2 H), 2.23 - 2.45 (m, 3 H), 1.29 - 1.45(m, 1 H), 1.19 (m, 1 H). LC-MS: m / z 656.1 (M+H) + . (S)-3-(4-(7-(4-fluoroisoindoline-2-yl)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenylethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 137)
[0412] Compound 137 was synthesized using a similar procedure to that described in Example 3 above, by using suitable materials.
[0413] 1H NMR (400 MHz, MeOD-d4) δ 7.79 - 7.89 (m, 1 H), 7.72 (s, 1 H), 7.44- 7.56 (m, 2 H), 7.35 (d, J = 7.70 Hz, 1 H), 7.16 - 7.27 (m, 3 H), 6.94 -7.07 (m, 2 H), 5.39 - 5.54 (m, 4 H), 3.64 - 3.77 (m, 1 H), 3.43 - 3.53 (m, 1H), 3.23 - 3.31 (m, 3 H), 3.22 (m, 2 H), 2.40 - 2.59 (m, 3 H), 1.43 - 1.57(m, 1 H). LC-MS: m / z 649.3 (M+H) + . (S)-3-(4-(7-(6-fluoro-3,4-dihydroisoquinoline-2(1H)-yl)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenylethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 138)
[0414] Compound 138 was synthesized using a similar procedure to that described in Example 3 above, by using suitable materials.
[0415] 1 H NMR (400 MHz, MeOD-d4) δ 7.83 - 7.90 (m, 1 H), 7.70 - 7.76 (m, 1H), 7.50 (d, J=6.72 Hz, 1 H), 7.32 - 7.40 (m, 1 H), 7.18 - 7.25 (m, 2 H),7.06 - 7.15 (m, 2 H), 7.01 (t, J = 8.74 Hz, 2 H), 5.06 (s, 2 H), 4.14 (s, 2H), 3.63 - 3.76 (m, 1 H), 3.39 - 3.53 (m, 1 H), 3.19 - 3.28 (m, 5 H), 3.10 -3.19 (m, 2 H), 2.41 - 2.60 (m, 3 H), 1.41 - 1.56 (m, 1 H). LC-MS: m / z 663.3 (M+H) + . Compound 139
[0416] Compound 139 was synthesized using a similar procedure to that described in Example 3 above, by using suitable materials.
[0417] 1 H NMR (400 MHz, DMSO-d6): δ 12.79 (br s, 1 H), 7.97 (d, J=5.6 Hz, 1H), 7.41 (s, 1 H), 7.20-7.37 (m, 4 H), 7.05-7.17 (m, 6 H), 5.57-5.67 (m, 1H), 4.89 (dd, J=10.0 Hz, J=6.0 Hz, 1 H), 3.49-3.60 (m, 1 H), 3.24-3.28 (m, 1H), 2.99-3.18 (m, 4 H), 2.72-2.84 (m, 2 H), 2.23-2.38 (m, 3 H), 1.71-2.04 (m,4 H), 1.34-1.47 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): δ -117.06. LC-MS: m / z659.3 (M+H) + . Example 4 (Compound 148) Step A (S)-2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-4-(7-(((2,3-dihydro-1H-inden-5-yl)methyl)amino)thiopheno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) ethyl nicotinate
[0418] A mixture of (S)-2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinic acid ethyl ester (100 mg, 0.144 mmol), (2,3-dihydro-1H-indene-5-yl)methylamine (106.04 mg, 0.720 mmol), Cs2CO3 (234.68 mg, 0.720 mmol), RuPhos (13.44 mg, 0.029 mmol), and RuPhos-Pd-G3 (12.06 mg, 0.014 mmol) in NMP (2 mL) was stirred overnight at 130ºC under N2. After the reaction was complete, the mixture was filtered, diluted with EA (20 mL), and washed with water (40 mL). The organic layer was dried over Na₂SO₄, filtered, and concentrated to dryness under vacuum. The residue was purified by preparative TLC (DCM / MeOH = 15 / 1) to give (S)-2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-4-(7-(((2,3-dihydro-1H-inden-5-yl)methyl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinic acid ethyl ester (40 mg, 0.050 mmol, 34.49%). LC-MS: m / z 804.4 (M+H) + . Step B (S)-4-(7-(((2,3-dihydro-1H-inden-5-yl)methyl)amino)thiopheno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidine-2-yl)nicotinic acid ethyl ester TFA salt
[0419] TFA (1 mL) was added to a solution of (S)-2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-4-(7-(((2,3-dihydro-1H-indene-5-yl)methyl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinic acid ethyl ester (40 mg, 0.050 mmol) in DCM (3 mL), and the reaction was stirred at room temperature for 1 h. After the reaction was complete, the mixture was concentrated to give (S)-4-(7-(((2,3-dihydro-1H-inden-5-yl)methyl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidine-2-yl)nicotinic acid ethyl ester TFA salt (50 mg, crude). LC-MS: m / z 704.5 (M+H) - . Step C Compound 148
[0420] TEA (1 mL) was added to a solution of (S)-4-(7-(((2,3-dihydro-1H-inden-5-yl)methyl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidine-2-yl)nicotinic acid ethyl ester TFA salt (50 mg, crude) in DCM (2 mL), and the reaction was stirred at room temperature for 1 h. After the reaction was complete, the mixture was filtered, diluted with EA (20 mL), and washed with water (40 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to dryness under vacuum. The residue was purified by preparative HPLC to give compound 148 (9.99 mg, 0.015 mmol, 30.54%).
[0421] 1H NMR (400 MHz, DMSO-d6): δ 12.79 (bs, 1 H), 7.97 (d, J=5.2 Hz, 1H), 7.52 (s, 1 H), 7.44 (s, 1 H), 7.17-7.30 (m, 3 H), 7.01-7.16 (m, 5 H),4.85-4.94 (m, 1 H), 4.65 (d, J=5.6 Hz, 2 H), 3.49-3.65 (m, 1 H), 2.95-3.22(m, 5 H), 2.72-2.86 (m, 4 H), 2.20-2.42 (m, 3 H), 1.88-2.07 (m, 2 H), 1.31-1.48 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): -117.05. LC-MS: m / z 659.3 (M+H) + . (S)-3-(4-(7-((3,4-difluorobenzyl)(methyl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenylethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 107)
[0422] Compound 107 was synthesized using a similar procedure to that described in Example 4 above, by using suitable materials.
[0423] 1 H NMR (400 MHz, DMSO-d6): δ 12.81 (br s, 1 H), 8.04 (d, J=5.2 Hz, 1H), 7.53 (s, 1 H), 7.30-7.42 (m, 2 H), 7.19-7.27 (m, 3 H), 7.04-7.16 (m, 3H), 4.80-4.95 (m, 3 H), 3.51-3.60 (m, 1 H), 3.25 (s, 3 H), 2.95-3.18 (m, 5H), 2.23-2.39 (m, 3 H), 1.31-1.46 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): -141.23, -138.54, -117.07. LC-MS: m / z 669.3 (M+H)+ . Compound 117
[0424] Compound 117 was synthesized using a similar procedure to that described in Example 4 above, by using suitable materials.
[0425] 1 H NMR (400 MHz, DMSO-d6): δ 12.77 (br s, 1 H), 7.79-7.85 (m, 1 H), 7.41 (s, 1 H), 7.19-7.33 (m, 4 H), 7.00-7.17 (m, 4 H), 5.44-5.53 (m, 1 H),4.79-4.89 (m, 1 H), 4.13-4.26 (m, 1 H), 3.91-4.01 (m, 1 H), 3.51-3.57 (m, 1H), 2.93-3.16 (m, 4 H), 2.32-2.38 (m, 2 H), 2.22-2.31 (m, 2 H), 1.77-2.06 (m,4 H), 1.33-1.43 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): -142.17, -138.87, -117.17. LC-MS: m / z 695.2 (M+H) + . Compound 140
[0426] Compound 140 was synthesized using a similar procedure to that described in Example 4 above, by using suitable materials.
[0427] 1H NMR (400 MHz, DMSO-d6): δ 12.77 (br s, 1 H), 7.86 (d, J=5.2 Hz, 1H), 7.44-7.55 (m, 2 H), 7.18-7.43 (m, 5 H), 7.04-7.17 (m, 3 H), 5.35-5.47 (m,1 H), 4.87-4.95 (m, 1 H), 3.51-3.59 (m, 1 H), 2.98-3.22 (m, 5 H), 2.36-2.42(m, 1 H), 2.25-2.33 (m, 2 H), 1.47-1.59 (m, 3 H), 1.36-1.46 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): -142.39, -139.21, -117.02. LC-MS: m / z 669.3 (M+H) + . Compound 141
[0428] Compound 141 was synthesized using a similar procedure to that described in Example 4 above, by using suitable materials.
[0429] 1 H NMR (400 MHz, DMSO-d6): δ 12.81 (br s, 1 H), 7.86 (d, J=6.0 Hz, 1H), 7.45-7.53 (m, 2 H), 7.18-7.44 (m, 5 H), 7.05-7.17 (m, 3 H), 5.36-5.47 (m,1 H), 4.91 (dd, J=10.0 Hz, J=6.0 Hz, 1 H), 3.51-3.60 (m, 1 H), 3.29-3.31 (m,1 H), 3.00-3.21 (m, 4 H), 2.24-2.40 (m, 3 H), 1.54 (d, J=6.8 Hz, 3 H), 1.34–1.48 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): -142.03, -139.00, -117.02. LC-MS: m / z669.3 (M+H) + . Compound 146
[0430] Compound 146 was synthesized using a similar procedure to that described in Example 4 above, by using suitable materials.
[0431] 1 H NMR (400 MHz, DMSO-d6): δ 12.81 (br s, 1 H), 7.92 (d, J=5.6 Hz, 1H), 7.51-7.68 (m, 2 H), 7.47 (s, 1 H), 7.29-7.38 (m, 2 H), 7.21-7.27 (m, 2H), 7.04-7.16 (m, 3 H), 4.90 (dd, J=10.4 Hz, J=6.8 Hz, 1 H), 4.66 (d, J=5.6Hz, 2 H), 3.52-3.61 (m, 1 H), 3.00-3.19 (m, 5 H), 2.24-2.40 (m, 3 H), 1.36-1.46 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): δ -117.03, -119.79. LC-MS: m / z 671.1(M+H) + . Compound 147
[0432] Compound 147 was synthesized using a similar procedure to that described in Example 4 above, by using suitable materials.
[0433] 1 H NMR (400 MHz, DMSO-d6): δ 12.80 (br s, 1 H), 7.91 (d, J=5.6 Hz, 1H), 7.58-7.65 (m, 1 H), 7.50 (t, J=8.0 Hz, 1 H), 7.45 (s, 1 H), 7.35 (d, , 2.95-3.23 (m, 5 H), 2.20-2.44 (m, 3 H), 1.34-1.49 (m, 1 H). 19F NMR (377 MHz, DMSO-d6): δ -116.94,-117.05. LC-MS: m / z 671.2 (M+H) + . Compound 149
[0434] Compound 149 was synthesized using a similar procedure to that described in Example 4 above, by using suitable materials.
[0435] 1 H NMR (400 MHz, DMSO-d6): δ 12.79 (br s, 1 H), 7.91 (d, J=5.2 Hz, 1H), 7.51 (t, J=6.0 Hz, 1 H), 7.43 (s, 1 H), 7.22-7.26 (m, 2 H), 7.16 (dd, J=8.4 Hz, 5.6 Hz, 1 H), 7.04-7.11 (m, 4 H), 6.85-6.89 (m, 1 H), 4.87 (dd, J=10.4 Hz, J=6.4 Hz, 1 H), 4.64(d, J=5.6 Hz, 2 H), 4.05(q, J=7.2 Hz, 2 H),3.51-3.59 (m, 1 H), 3.22-3.30 (m, 1 H), 2.97-3.17 (m, 4 H), 2.22-2.40 (m, 3H), 1.34-1.47 (m, 1 H), 1.32 (t, J=6.8 Hz, 3 H). 19 F NMR (377 MHz, DMSO-d6): δ-117.10, -138.13. LC-MS: m / z 681.2 (M+H) + . Example 5: Compound 109 Step A: 2-((S)-1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-6-(4-fluorophenylethyl)-4-(5-(methoxycarbonyl)thiophen-2-yl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylic acid ethyl ester
[0436] To a solution of 3-(4-(4-fluorophenyl)-2-oxobutyl)-1,2,4-oxadiazol-5(4H)-one (1 g, 4.00 mmol) in EtOH (10 mL), methyl 5-formylthiophene-2-carboxylate (680 mg, 4.00 mmol), (S)-2-(3-ethoxy-3-oxopropionyl)pyrrolidine-1-carboxylate tert-butyl ester (1140 mg, 4.00 mmol), Yb(OTf)3 (248 mg, 0.40 mmol), and NH4OAc (616 mg, 8.00 mmol) were added. The reaction was stirred at room temperature for 12 hours. The mixture was diluted with EA (200 mL x 2) and washed with water (50 mL). The organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. The reaction was concentrated under vacuum to provide crude ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-6-(4-fluorophenylethyl)-4-(5-(methoxycarbonyl)thiophen-2-yl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylate (2.5 g, crude). LC-MS: m / z 669.3 (M+H) + . Step B (S)-2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-6-(4-fluorophenylethyl)-4-(5-(methoxycarbonyl)thiophen-2-yl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) ethyl nicotinate
[0437] A mixture of 4-(5-((benzyloxy)carbonyl)thiophen-2-yl)-2-((S)-1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-5-(5-methyl-1,3,4-oxadiazol-2-yl)-6-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1,4-dihydropyridine-3-carboxylate (2.5 g, crude) and DDQ (1816 mg, 8.0 mmol) in THF (50 mL) was stirred at 50ºC for 2 hours. The mixture was diluted with EA (500 mL) and washed with water (100 mL). The organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with MeOH / DCM (1 / 20) to give (S)-2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-6-(4-fluorophenylethyl)-4-(5-(methoxycarbonyl)thiophen-2-yl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinic acid ethyl ester (1.1 g, yield: 41.4%). LC-MS: m / z 667.3 (M+H)+ . Step C(S)-5-(2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-3-(ethoxycarbonyl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-4-yl)thiophene-2-carboxylic acid
[0438] To a solution of (S)-2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-6-(4-fluorophenylethyl)-4-(5-(methoxycarbonyl)thiophen-2-yl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinic acid ethyl ester (1.1 g, 1.65 mmol) in THF (50 mL), NaOH (5 mL, 2 M in water) was added and stirred for 3 hours at room temperature. The mixture was diluted with EA (100 mL) and adjusted with 1 M HCl (15 mL) until pH < 7. The mixture was then washed with H2O (50 mL) and extracted with EA (100 mL x 3). The organic layer was concentrated under reduced pressure to give (S)-5-(2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-3-(ethoxycarbonyl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-4-yl)thiophene-2-carboxylic acid (900 mg, yield: 83.6%). LC-MS: m / z 653.1 (M+H) + . Step D(S)-5-(3-(ethoxycarbonyl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidone-2-yl)pyridin-4-yl)thiophene-2-carboxylic acid TFA salt
[0439] TFA (9 mL) was added to a solution of (S)-5-(2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-3-(ethoxycarbonyl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-4-yl)thiophene-2-carboxylic acid (900 mg, 1.38 mmol) in DCM (9 mL), and the mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure to give (S)-5-(3-(ethoxycarbonyl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidine-2-yl)pyridin-4-yl)thiophene-2-carboxylic acid TFA salt (1 g, crude). LC-MS: m / z 553.2 (M+H) + . Step E (S)-5-(2-(4-fluorophenylethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thiophene-2-carboxylic acid
[0440] TEA (10 mL) was added to a solution of (S)-5-(3-(ethoxycarbonyl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidine-2-yl)pyridin-4-yl)thiophene-2-carboxylic acid TFA salt (1 g, crude) in DCM (5 mL), and the mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure and purified by preparative HPLC to give (S)-5-(2-(4-fluorophenylethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thiophene-2-carboxylic acid (500 mg, yield: 71.6%). LC-MS: m / z 507.1 (M+H) + . Step F Compound 109
[0441] To a solution of (S)-5-(2-(4-fluorophenylethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thiophene-2-carboxylic acid (40 mg, 0.079 mmol) in DMA (1 mL), HATU (36 mg, 0.0949 mmol), (3-methoxyphenyl)methylamine (14 mg, 0.103 mmol), and DIEA (39 mg, 0.103 mmol) were added. The reaction was stirred at room temperature for 2 hours. The residue was purified by preparative HPLC to provide compound 109 (26.52 mg, yield: 54.1%).
[0442] 1 H NMR (400 MHz, DMSO-d6): δ 12.78 (br s, 1 H), 9.18 (t, J=6.0 Hz, 1H), 7.79 (d, J=4.0 Hz, 1 H), 7.19-7.30 (m, 4 H), 7.05-7.13 (m, 2 H), 6.89-6.91 (m, 2 H), 6.80-6.85 (m, 1 H), 4.86 (dd, J=6.0 Hz, J=10.0 Hz, 1 H), 4.44(d, J=6.0 Hz, 2 H), 3.74 (s, 3 H), 3.53-3.61 (m, 1 H), 3.31-3.32 (m, 1 H),2.94-3.15 (m, 4 H), 2.24-2.38 (m, 3 H), 1.34-1.45 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): -117.05. LC-MS: m / z 626.2 (M+H) + . 5-((S)-2-(4-fluorophenylethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-N-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)thiophene-2-carboxamide (Compound 108)
[0443] Compound 108 was synthesized using a similar procedure to that described in Example 5 above, by using suitable materials.
[0444] 1 H NMR (400 MHz, DMSO-d6): δ 12.80 (br s, 1 H), 8.94 (d, J=8.4 Hz, 1H), 7.78 (d, J=3.6 Hz, 1 H), 7.17-7.28 (m, 4 H), 7.04-7.13 (m, 2 H), 6.86 (d,J=7.6 Hz, 2 H), 5.46-5.56 (m, 1 H), 4.79-4.89 (m, 1 H), 3.80 (s, 3 H), 3.49-3.62 (m, 2 H), 2.91-3.05 (m, 3 H), 2.66-2.75 (m, 2 H), 2.22-2.39 (m, 4 H), 1.87-2.05 (m, 2 H), 1.33-1.45 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): -117.09. LC-MS: m / z 652.3 (M+H) + . Compound 115
[0445] Compound 115 was synthesized using a similar procedure to that described in Example 5 above, by using suitable materials.
[0446] 1 H NMR (400 MHz, DMSO-d6): δ 12.80 (br s, 1 H), 7.34-7.70 (m, 3 H), 7.19-7.28 (m, 3 H), 7.05-7.18 (m, 3 H), 4.85 (dd, J=10.4 Hz, J=6.0 Hz, 1 H),4.69 (s, 2 H), 3.52-3.62 (m, 1 H), 3.26-3.29 (m, 1 H), 2.95-3.20 (m, 7 H), 2.20-2.40 (m, 3 H), 1.34-1.43 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): -117.05, -138.50, -140.71. LC-MS: m / z 646.2 (M+H) + . Compound 116
[0447] Compound 116 was synthesized using a similar procedure to that described in Example 5 above, by using suitable materials.
[0448] 1 H NMR (400 MHz, DMSO-d6): δ 12.80 (br s, 1 H), 7.73 (s, 1 H), 7.31-7.41 (m, 2 H), 7.19-7.29 (m, 3 H), 7.03-7.15 (m, 3 H), 5.13-5.21 (m, 1 H),4.80-4.90 (m, 1 H), 4.11-4.22 (m, 1 H), 3.85-3.97 (m, 1 H), 3.49-3.63 (m, 1H), 2.95-3.18 (m, 4 H), 2.65-2.70 (m, 1 H), 2.21-2.36 (m, 4 H) 1.93-2.02 (m,2 H), 1.67-1.79 (m, 1 H), 1.30-1.43 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): -117.06, -139.00, -141.97. LC-MS: m / z 672.2 (M+H) + . Compound 118
[0449] Compound 118 was synthesized using a similar procedure to that described in Example 5 above, by using suitable materials.
[0450] 1H NMR (400 MHz, DMSO-d6): δ 12.79 (br s, 1 H), 9.25 (t, J=6.0 Hz, 1H), 7.77 (d, J=4.0 Hz, 1 H), 7.58-7.61 (m, 2 H), 7.32 (dd, J=1.6 Hz, J=8.0Hz, 1 H), 7.21-7.37 (m, 3 H), 7.08 (t, J=8.8 Hz, 2 H), 4.85 (dd, J=5.6 Hz, J=9.6 Hz, 1 H), 4.46 (d, J=5.6 Hz, 2 H), 3.54-3.59 (m, 1 H), 3.27-3.33 (m, 1H), 2.97-3.15 (m, 4 H), 2.27-2.36 (m, 3 H), 1.36-1.40 (m, 1 H). 19 F NMR (377MHz, DMSO-d6): -117.04. LC-MS: m / z 664.3 (M+H) + . Compound 119
[0451] Compound 119 was synthesized using a similar procedure to that described in Example 5 above, by using suitable materials.
[0452] 1 H NMR (400 MHz, DMSO-d6): δ 12.80 (br s, 1 H), 9.02 (t, J=6.0 Hz, 1H), 7.82 (d, J=4.0 Hz, 1 H), 7.41-7.49 (m, 2 H), 7.20-7.28 (m, 4 H), 7.06-7.12 (m, 2 H), 4.82-4.92 (m, 1 H), 4.50 (d, J=5.6 Hz, 2 H), 3.50-3.64 (m, 1H), 3.25-3.30 (m, 1 H), 2.98-3.18 (m, 4 H), 2.24-2.40 (m, 3 H), 1.32-1.47 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): -113.52, -117.05. LC-MS: m / z 648.1 (M+H) + . Compound 120
[0453] Compound 120 was synthesized using a similar procedure to that described in Example 5 above, by using suitable materials.
[0454] 1 H NMR (400 MHz, DMSO-d6): δ 12.81 (br s, 1 H), 8.99 (d, J=8.0 Hz, 1H), 7.80 (d, J=4.0 Hz, 1 H), 7.20-7.40 (m, 5 H), 7.05-7.13 (m, 2 H), 5.45 (q,J=8.0 Hz, 1 H), 4.86 (dd, J=6.0 Hz, J=10.0 Hz, 1 H), 3.53-3.60 (m, 1 H), 3.28-3.34 (m, 2 H), 2.94-3.17 (m, 5 H), 2.78-2.88 (m, 1 H), 2.26-2.38 (m, 3H), 1.97-2.06 (m, 1 H), 1.34-1.44 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): -117.05, -139.94, -141.15. LC-MS: m / z 658.4 (M+H) + . Compound 121
[0455] Compound 121 was synthesized using a similar procedure to that described in Example 5 above, by using suitable materials.
[0456] 1H NMR (400 MHz, DMSO-d6): δ 12.80 (br s, 1 H), 9.05 (d, J=8.8 Hz, 1H), 7.81 (dd, J=1.2 Hz, J=4.0 Hz, 1 H), 7.37-7.42 (m, 1 H), 7.19-7.34 (m, 6H), 7.06-7.12 (m, 2 H), 5.39 (q, J=8.4 Hz, 1 H), 4.78-4.89 (m, 2 H), 3.52-3.62 (m, 1 H), 3.44 (s, 3 H), 3.28-3.29 (m, 1 H), 2.91-3.13 (m, 5 H), 2.24-2.38 (m, 3 H), 1.81-1.92 (m, 1 H), 1.33-1.44 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): -117.13. LC-MS: m / z 652.3 (M+H) + . Compound 122
[0457] Compound 122 was synthesized using a similar procedure to that described in Example 5 above, by using suitable materials.
[0458] 1 H NMR (400 MHz, DMSO-d6): δ 12.76 (br s, 1 H), 9.15 (t, J=6.0 Hz, 1H), 7.75 (d, J=4.0 Hz, 1 H), 7.21-7.26 (m, 3 H), 7.08 (t, J=17.6 Hz, 2 H),6.66-6.77 (m, 3 H), 4.82 (dd, J=6.0 Hz, J=10.0 Hz, 1 H), 4.43 (d, J=5.60 Hz,2 H), 3.76 (s, 3 H), 3.52-3.57 (m, 1 H), 2.90-3.15 (m, 5 H), 2.20-2.40 (m, 3H), 1.30-1.43 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): -111.86, -117.19. LC-MS: m / z644.3 (M+H) + . Example 6 3-((S)-2-(4-fluorophenylethyl)-4-(7-((®-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-4-methyl-1,2,4-oxadiazol-5(4H)-one (Compound 112) Step A: 3-((2-(4-fluorophenylethyl)-1,3-dioxolane-2-yl)methyl)-4-methyl-1,2,4-oxadiazol-5(4H)-one
[0459] A mixture of 3-[[2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolane-2-yl]methyl]-4H-1,2,4-oxadiazol-5-one (500 mg, 1.70 mmol), CH3I (1.37 g, 9.64 mmol, 0.6 mL), and K2CO3 (705 mg, 5.10 mmol) in DMF (5 mL) was degassed and purged three times with N2. The mixture was then stirred at 22ºC for 16 h under N2 atmosphere. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (100 mL). The organic layer was washed with brine (50 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by column chromatography on silica gel (eluting with 0–30% EA in PE). 3-[[2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolane-2-yl]methyl]-4-methyl-1,2,4-oxadiazol-5-one (352 mg, 1.14 mmol, 67.2% yield) was obtained.
[0460] 1 H NMR (400 MHz, CDCl3) δ ppm 7.07 (dd, J=8.44, 5.50 Hz, 2 H), 6.86 -6.96 (m, 2 H), 3.82 - 3.97 (m, 4 H), 3.20 (s, 3 H), 2.82 - 2.89 (m, 1 H), 2.86 (s, 2 H), 2.61 - 2.71 (m, 2 H), 1.88 - 2.02 (m, 2 H). Step B 3-(4-(4-fluorophenyl)-2-oxobutyl)-4-methyl-1,2,4-oxadiazol-5(4H)-one
[0461] A mixture of 3-[[2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolane-2-yl]methyl]-4-methyl-1,2,4-oxadiazol-5-one (350 mg, 1.14 mmol) in formic acid (5 mL) and H₂SO₄ (1 mL) was degassed and purged three times with N₂. The mixture was then stirred at 45ºC for 2 h under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was diluted with water (80 mL) and extracted with EtOAc (100 mL x 2). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to give the residue. The crude compound 3-[4-(4-fluorophenyl)-2-oxo-butyl]-4-methyl-1,2,4-oxadiazol-5-one (291 mg) was obtained.
[0462] 1 H NMR (400 MHz, CDCl3) δ ppm 7.07 (dd, J=8.44, 5.50 Hz, 2 H), 6.91 (t, J=8.62 Hz, 2 H), 3.61 (s, 2 H), 2.99 (s, 3 H), 2.79 - 2.91 (m, 4 H). LC-MS: m / z 263.4 (M+H) + . Step C: 2-((R)-1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-6-(4-fluorophenylethyl)-4-(7-((((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(4-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylic acid ethyl ester
[0463] The mixture of 3-[4-(4-fluorophenyl)-2-oxo-butyl]-4-methyl-1,2,4-oxadiazol-5-one (50 mg, 189.21 μmol), 7-[[(1R)-4-methoxydihydroindene-1-yl]amino]thieno[2,3-c]pyridine-2-carboxaldehyde (62 mg, 191.12 μmol), tris(trifluoromethylsulfonyloxy)ytterbium (59 mg, 95.12 μmol), NH4OAc (30 mg, 389.19 μmol) and (2S)-2-(3-ethoxy-3-oxo-propionyl)pyrrolidine-1-carboxylic acid tert-butyl ester (54 mg, 189.25 μmol) in EtOH (5 mL) was degassed and purged three times with N2. The mixture was then stirred at 50ºC for 16 h under N2 atmosphere. The reaction mixture was concentrated under reduced pressure to give crude 2-[(2R)-1-tert-butoxycarbonylpyrrolidine-2-yl]-6-[2-(4-fluorophenyl)ethyl]-4-[7-[[(1R)-4-methoxydihydroindene-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-5-(4-methyl-5-oxo-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylic acid ethyl ester (170 mg, crude). LC-MS: m / z 837.9 (M+H) + . Step D: 2-((R)-1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-6-(4-fluorophenylethyl)-4-(7-((((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(4-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl) ethyl nicotinate
[0464] A mixture of 2-[(2R)-1-tert-butoxycarbonylpyrrolidine-2-yl]-6-[2-(4-fluorophenyl)ethyl]-4-[7-[[(1R)-4-methoxydihydroindene-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-5-(4-methyl-5-oxo-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylate (170 mg, 203.11 μmol) and dipotassium sulfonyloxysulfate (55 mg, 203.46 μmol) in MeCN (6 mL) and H2O (2 mL) was degassed and purged three times with N2. The mixture was then stirred at 85ºC for 2 h under N2 atmosphere. The reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (100 mL x 2). The combined organic layers were washed with brine (50 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by preparative TLC (SiO2, PE / EA = 1:1). Crude 2-[(2R)-1-tert-butoxycarbonylpyrrolidine-2-yl]-6-[2-(4-fluorophenyl)ethyl]-4-[7-[[(1R)-4-methoxydihydroindene-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-5-(4-methyl-5-oxo-1,2,4-oxadiazol-3-yl)pyridine-3-carboxylic acid ethyl ester (38 mg) was obtained. LC-MS: m / z 835.9 (M+H) + . Step E: 6-(4-fluorophenylethyl)-4-(7-((((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thiopheno[2,3-c]pyridin-2-yl)-5-(4-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-((R)-pyrrolidine-2-yl) ethyl nicotinate
[0465] The mixture of 6-[2-(4-fluorophenyl)ethyl]-5-(4-methyl-5-oxo-1,2,4-oxadiazol-3-yl)-2-[racemic-(2R)-1-tert-butoxycarbonylpyrrolidine-2-yl]-4-[7-[[racemic-(1R)-4-methoxydihydroindene-1-yl]amino]thiopheno[2,3-c]pyridin-2-yl]pyridine-3-carboxylic acid ethyl ester (20 mg, crude) in DCM (2 mL) and HCl / dioxane (4 M, 2 mL) was degassed and purged three times with N2. The mixture was then stirred at 22ºC for 1 h under N2 atmosphere. The reaction mixture was concentrated under reduced pressure to give the crude compound 6-[2-(4-fluorophenyl)ethyl]-5-(4-methyl-5-oxo-1,2,4-oxadiazol-3-yl)-4-[7-[[racemic-(1R)-4-methoxydihydroindene-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-2-[racemic-(2R)-pyrrolidine-2-yl]pyridine-3-carboxylic acid ethyl ester (18 mg, crude). LC-MS: m / z 735 (M+H) + . Step I 3-((S)-2-(4-fluorophenylethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thiopheno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-4-methyl-1,2,4-oxadiazol-5(4H)-one
[0466] A mixture of 6-[2-(4-fluorophenyl)ethyl]-5-(4-methyl-5-oxo-1,2,4-oxadiazol-3-yl)-4-[7-[[racemic-(1R)-4-methoxydihydroindene-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-2-[racemic-(2R)-pyrrolidine-2-yl]pyridine-3-carboxylate (18 mg, crude) and TEA (363.50 mg, 3.59 mmol, 0.5 mL) in DCM (5 mL) was degassed and purged three times with N2. The mixture was then stirred at 22ºC for 16 h under N2 atmosphere. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by reversed-phase HPLC (column: Kromasil 100-5-C18; eluent: 30% to 60% water (0.1% NH3·H2O)-ACN). 4-Methyl-3-[racemic-(9aS)-2-[2-(4-fluorophenyl)ethyl]-5-oxo-4-[7-[[racemic-(1R)-4-methoxydihydroindene-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-7,8,9,9a-tetrahydropyrido[2,3-a]pyrrolizin-3-yl]-1,2,4-oxadiazol-5-one (1.2 mg, 1.70 μmol, 6.25% yield, 97.7% purity).
[0467] 1 H NMR (400 MHz, MeOD) δ ppm 7.94 (d, J=5.62 Hz, 1 H), 7.52 (s, 1 H), 7.07 - 7.22 (m, 4 H), 6.97 (t, J=8.19 Hz, 2 H), 6.89 (d, J=9.05 Hz, 1 H), 6.81 (d, J=8.07 Hz, 1 H), 5.80 (d, J=7.82 Hz, 1 H), 3.83 (s, 3 H), 3.69 (s, 1H), 3.46 (s, 1 H), 3.29 - 3.30 (m, 3 H), 3.10 - 3.23 (m, 4 H), 3.02 (d, J=12.47 Hz, 1 H), 2.59 - 2.84 (m, 3 H), 2.43 (s, 2 H), 2.16 - 2.22 (m, 1 H), 2.03 (m, 1 H), 1.60 (m, 1 H). LC-MS: m / z 689.2 (M+H) + . Example 7 (S)-3-(4-(2-(3,4-difluorobenzyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-yl)-2-(4-fluorophenylethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 129) Step A: 2-(3,4-difluorobenzyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one To a solution of 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one (200 mg, 1.47 mmol) in DMF (5 mL), NaH (235 mg, 5.88 mmol, 60% purity) and 4-(chloromethyl)-1,2-difluorobenzene (239 mg, 1.47 mmol) were added. The mixture was stirred at 0–20°C for 16 h. The reaction mixture was quenched at 0°C with ice-water (5 mL), diluted with EtOAc (15 mL), and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by rapid silica gel chromatography (ISCO®; 12 g SepaFlash® silica gel column, 0–30% ethyl acetate / petroleum ether gradient eluent, 40 mL / min). 2-(3,4-difluorobenzyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one was obtained (328 mg, 1.25 mmol, 85.1% yield).
[0468] 1 H NMR (400 MHz, CDCl3) δ ppm 7.03 - 7.20 (m, 3 H), 6.96 - 7.02 (m, 1H), 6.73 (s, 1 H), 6.21 - 6.28 (m, 1 H), 4.70 (s, 2 H), 4.05 - 4.16 (m, 2 H),3.50 - 3.62 (m, 2 H). Step B: 2-(3,4-difluorobenzyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxaldehyde
[0469] DMF (139 mg, 1.91 mmol) and POCl3 (292 mg, 1.91 mmol) were added to a solution of 2-[(3,4-difluorophenyl)methyl]-3,4-dihydropyrrolo[1,2-a]pyrazin-1-one (250 mg, 953 μmol) in DCE (5 mL). The mixture was stirred at 0–85°C for 16 h. The reaction mixture was quenched at 0°C with ice-water (5 mL), diluted with EtOAc (15 mL), and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by rapid silica gel chromatography (ISCO®; 4 g SepaFlash® silica gel column, 0–40% ethyl acetate / petroleum ether gradient eluent, 20 mL / min). 2-(3,4-difluorobenzyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-carboxaldehyde (254 mg, 875 μmol, 91.8% yield) was obtained.
[0470] 1 H NMR (400 MHz, CDCl3) δ ppm 9.68 (s, 1 H), 7.13 - 7.19 (m, 2 H), 7.07 (m, 1 H) 7.00 - 7.03 (m, 1 H), 6.97 (d, J=4.16 Hz, 1 H), 4.71 (s, 2 H), 4.62 (t, J=6.05 Hz, 2 H), 3.61 (t, J=6.05 Hz, 2 H). Step C: 2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-4-(2-(3,4-difluorobenzyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,6-dihydropyridine-3-carboxylic acid ethyl ester
[0471] Tris(trifluoromethylsulfonyloxy)ytterbium (21.4 mg, 34.5 μmol), 3-(4-(4-fluorophenyl)-2-oxobutyl)-1,2,4-oxadiazol-5(4H)-one (86.2 mg, 345 μmol), (S)-2-(3-ethoxy-3-oxopropionyl)pyrrolidine-1-carboxylic acid tert-butyl ester (98.3 mg, 345 μmol), and NH4OAc (53.1 mg, 689 μmol) were added to a solution of 2-[(3,4-difluorophenyl)methyl]-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-6-carboxaldehyde (100 mg, 345 μmol) in EtOH (3 mL). The mixture was stirred at 50ºC for 16 h. The reaction mixture was concentrated under reduced pressure. The crude product 2-(1-(tert-butoxycarbonyl)pyrrolidine-2-yl)-4-(2-(3,4-difluorobenzyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-yl)-6-(4-fluorophenylethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,6-dihydropyridine-3-carboxylic acid ethyl ester (272 mg) was obtained. Step D: 2-(1-tert-butoxycarbonylpyrrolidine-2-yl)-4-[2-[(3,4-difluorophenyl)methyl]-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-6-yl]-6-[2-(4-fluorophenyl)ethyl]-5-(5-oxo-4H-1,2,4-oxadiazol-3-yl)pyridine-3-carboxylic acid ethyl ester
[0472] Add dipotassium sulfonyloxypyrrolidine-2-yl)-4-[2-[(3,4-difluorophenyl)methyl]-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-6-yl]-2-[2-(4-fluorophenyl)ethyl]-3-(5-oxo-4H-1,2,4-oxadiazol-3-yl)-1,2-dihydropyridine-5-carboxylate (272 mg, 344 μmol) to a solution of ethyl sulfonyloxypyrrolidine in MeCN (3 mL) / H2O (1 mL). Stir the mixture at 85ºC for 2 h. Dilute the reaction mixture with H2O (10 mL) and extract with EtOAc (15 mL x 3). The combined organic layers were washed with brine (20 mL x 3), dried over Na₂SO₄, filtered, and concentrated under reduced pressure to obtain the residue. The residue was purified by preparative TLC (SiO₂, ethyl acetate). Ethyl 2-(1-tert-butoxycarbonylpyrrolidine-2-yl)-4-[2-[(3,4-difluorophenyl)methyl]-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-6-yl]-6-[2-(4-fluorophenyl)ethyl]-5-(5-oxo-4H-1,2,4-oxadiazol-3-yl)pyridine-3-carboxylic acid (80 mg, 101.68 μmol, 29.52% yield). LC-MS: m / z 787.8 (M+H) + . Step E: 4-[2-[(3,4-difluorophenyl)methyl]-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-6-yl]-6-[2-(4-fluorophenyl)ethyl]-5-(5-oxo-4H-1,2,4-oxadiazol-3-yl)-2-pyrrolidine-2-yl-pyridine-3-carboxylic acid ethyl ester
[0473] TFA (1.54 g, 13.5 mmol, 1 mL) was added to a solution of 2-(1-tert-butoxycarbonylpyrrolidine-2-yl)-4-[2-[(3,4-difluorophenyl)methyl]-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-6-yl]-6-[2-(4-fluorophenyl)ethyl]-5-(5-oxo-4H-1,2,4-oxadiazol-3-yl)pyridine-3-carboxylic acid ethyl ester (80 mg, 102 μmol) in DCM (5 mL). The mixture was stirred at 20ºC for 16 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. Crude 4-[2-[(3,4-difluorophenyl)methyl]-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-6-yl]-6-[2-(4-fluorophenyl)ethyl]-5-(5-oxo-4H-1,2,4-oxadiazol-3-yl)-2-pyrrolidine-2-yl-pyridine-3-carboxylic acid ethyl ester (69.8 mg). Step F(S)-3-(4-(2-(3,4-difluorobenzyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-yl)-2-(4-fluorophenylethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one
[0474] TEA (2.18 g, 21.5 mmol, 3 mL) was added to a solution of ethyl 4-[2-[(3,4-difluorophenyl)methyl]-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-6-yl]-6-[2-(4-fluorophenyl)ethyl]-5-(5-oxo-4H-1,2,4-oxadiazol-3-yl)-2-pyrrolidine-2-yl-pyridine-3-carboxylate (69.8 mg, 102 μmol) in DCM (5 mL). The mixture was stirred at 20ºC for 16 h. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by preparative TLC (SiO2, ethyl acetate) and further purified by preparative HPLC (column: Kromasil 100-5-C18; eluent: 45% to 70% water (0.1% FA)-ACN). (S)-3-(4-(2-(3,4-difluorobenzyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-yl)-2-(4-fluorophenylethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (4.7 mg, 6.96 μmol, 7.43% yield, 94.8% purity).
[0475] 1 H NMR (400 MHz, CDCl3) δ ppm 7.00 - 7.16 (m, 7 H), 6.92 (t, J=8.50Hz, 3 H), 6.08 - 6.22 (m, 1 H), 4.75 - 4.85 (m, 1 H), 4.52 - 4.68 (m, 2 H), 3.92 - 4.09 (m, 1 H), 3.64 - 3.87 (m, 3 H), 3.42 (s, 2 H), 3.05 - 3.26 (m, 3H), 2.28 - 2.57 (m, 3 H), 1.40 - 1.50 (m, 1 H). LC-MS: m / z 641.4 (M+H) - . Example 8 5-((S)-2-(4-fluorophenylethyl)-4-(7-((((R)-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one (Compound 150) Step A: 5-((9aS)-2-(4-fluorophenylethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one
[0476] A mixture of (8S)-5,6,7,8-tetrahydropyrrolizin-1,3-dione (17.16 mg, 123.31 μmol), (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carboxaldehyde (40 mg, 123.31 μmol), NH4OAc (14.26 mg, 184.96 μmol), and 5-(4-(4-fluorophenyl)-2-oxobutyl)isoxazol-3(2H)-one (30.73 mg, 123.31 μmol) in AcOH (1.5 mL) was degassed and purged three times with N2. The mixture was then stirred at 120ºC for 2 h under N2 atmosphere. The solution was cooled to room temperature and poured into water (25 mL), and extracted with EtOAc (25 mL). The organic layer was washed with 25 mL of NaHCO3 aqueous solution, followed by 25 mL of brine, dried over anhydrous Na2SO4, filtered, and concentrated under vacuum. The residue was purified by rapid silica gel chromatography (ISCO®; 4 g SepaFlash® silica gel column, 0–10% MeOH / DCM gradient eluent, 12 mL / min) to give 5-((9aS)-2-(4-fluorophenylethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one (47 mg, 69.55 μmol, 56.40% yield). LC-MS: m / z 676.7 (M+H) + . Step B: 5-((S)-2-(4-fluorophenylethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thiopheno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazo-3(2H)-one
[0477] Add CAN (76.26 mg, 139.10 μmol) to a solution of 5-((9aS)-2-(4-fluorophenylethyl)-4-(7-((((R)-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one (47 mg, 69.55 μmol) in ACN (10 mL) and water (5 mL). Stir the mixture at 20ºC for 2 h. Add water (25 mL) and extract the mixture with EtOAc (25 mL). Wash the organic layer with brine (25 mL), dry to Na2SO4, filter, and concentrate under vacuum. The residue was purified by rapid silica gel chromatography (ISCO®; 12 g SepaFlash® silica gel rapid column, 0-10% MeOH / DCM gradient eluent, 12 mL / min), and then further purified by preparative HPLC (FA conditions). Column: Kromasil C18 150*30mm*5um; Conditions: Water (0.2% formic acid)-ACN; Start B: 30; End B: 85; Gradient time (min): 20; 100% B hold time (time): 5; Flow rate (ml / min): 20; Detection wavelength: 220 nm and 254 nm) to obtain 5-((S)-2-(4-fluorophenylethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one (2.58 mg, 3.83 μmol, 5.51% yield).
[0478] 1H NMR (400 MHz, DMSO-d6) δ ppm 11.47 (s, 1 H), 7.88 (d, J=6.0 Hz, 1H), 7.51 (s, 1 H), 7.31 (s, 1 H), 7.02 - 7.25 (m, 6 H), 6.88 - 6.99 (m, 2 H),6.06 (s, 1 H), 5.57 - 5.73 (m, 1 H), 4.87 - 4.91 (m, 1 H), 3.81 (s, 3 H),2.90 - 3.06 (m, 6 H), 2.72 - 2.79 (m, 1 H), 2.55 - 2.65 (m, 2 H), 2.37 - 2.39(m, 1 H), 2.26 - 2.29 (m, 2 H), 2.06 - 2.09 (m, 1 H), 1.33 - 1.50 (m, 1 H). LC-MS: m / z 674.4 (M+H) - . 3-((9aS)-4-(7-((((R)-4-methoxy-2,3-dihydro-1H-indene-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-2-(3-(tetrahydrofuran-3-yl)phenethyl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 151)
[0479] Compound 151 was synthesized using a similar procedure to that described in Example 3 above, by using suitable materials.
[0480] 1H NMR (400 MHz, MeOD-d4) δ ppm 7.78 (d, J=6.72 Hz, 1 H), 7.66 (s, 1H), 7.41 (d, J=6.72 Hz, 1 H), 7.22 - 7.31 (m, 1 H), 7.14 - 7.20 (m, 2 H),7.08 - 7.13 (m, 2 H), 6.97 (d, J=7.21 Hz, 1 H), 6.93 - 6.94 (m, 1 H), 6.88 -6.93 (m, 1 H), 5.53 (t, J=6.48 Hz, 1 H), 4.30 - 4.72 (m, 1 H), 3.99 - 4.10(m, 2 H), 3.86 - 3.91 (m, 1 H) 3.86 (s, 3 H), 3.59 - 3.68 (m, 2 H), 3.35 -3.47 (m, 2 H), 3.21 (d, J=7.58 Hz, 2 H), 3.02 - 3.16 (m, 3 H), 2.83 - 2.95(m, 1 H), 2.75 (d, J=6.60 Hz, 1 H), 2.37 - 2.54 (m, 3 H), 2.33 (d, J=5.99 Hz, 1 H), 2.15 (dd, J=12.65, 6.54 Hz, 1 H), 1.91 - 2.04 (m, 1 H), 1.45 (q, J=10.21 Hz, 1H). LC-MS: m / z 727.4 (M+H) + . Compound 152
[0481] Compound 152 was synthesized using suitable materials through a similar procedure as described in Example 1 above.
[0482] 1H NMR (400 MHz, DMSO-d6): δ 8.38 (d, J=3.6 Hz, 1 H), 8.24 (s, 1 H), 7.64 (s, 1 H), 7.37-7.42 (m, 2 H), 7.30 (t, J=7.2 Hz, 1 H), 7.05-7.23 (m, 7H), 6.22 (dd, J=6.0 Hz, J=8.0 Hz, 1 H), 4.75 (dd, J=6.0 Hz, J=8.8 Hz, 1 H), 3.46-3.53 (m, 1 H), 3.19-3.25 (m, 2 H), 2.95-3.06 (m, 5 H), 2.71-2.76 (m, 1H), 2.57-2.62 (m, 1 H), 2.31-2.36 (m, 1 H), 2.19-2.27 (m, 2 H), 1.32-1.36 (m, 1 H). 19 F NMR (377 MHz, DMSO-d6): δ -117.43. LC-MS: m / z 613.3 (M+H) - Compound 153
[0483] Compound 153 was synthesized using a similar procedure as described in Example 1 above, by using suitable materials.
[0484] 1 H NMR (400 MHz, DMSO-d6): δ 12.51 (s, 1 H), 7.61 (d, J=3.2 Hz, 1 H), 7.52-7.56 (m, 2 H), 7.34-7.49 (m, 2 H), 7.19-7.27 (m, 2 H), 7.06-7.15 (m, 3H), 7.02 (dd, J=8.4 Hz, J=1.2 Hz, 1 H), 6.54 (d, J=3.2 Hz, 1 H), 5.44 (s, 2H), 4.83 (dd, J=10.0 Hz, J=6.0 Hz, 1 H), 3.46-3.58 (m, 1 H), 3.21-3.31 (m, 1H), 2.95-3.16 (m, 4 H), 2.18-2.42 (m, 3 H), 1.30-1.43 (m, 1 H). 19F NMR (377MHz, DMSO-d6): δ -117.09, -138.27, -140.28. LC-MS: m / z 622.3 (M+H) + 5-(7-(7-(((R)-6,7-dihydro-5H-cyclopentadieno[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-isopropyl-1,1-dioxo-5-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-2,3-dihydrothieno[3,2-b]pyridin-6-yl)isoxazol-3(2H)-one (Compound 154)
[0485] Compound 154 was synthesized using a similar procedure as described in Example 2 above, by using appropriate materials.
[0486] 1 H NMR (400 MHz, MeOD-d4) δ 8.32 - 8.40 (m, 1 H), 7.93 - 8.01 (m, 1H), 7.71 - 7.79 (m, 1 H), 7.57 - 7.63 (m, 1 H), 7.19 - 7.27 (m, 1 H), 7.11 -7.18 (m, 1 H), 5.94 - 6.00 (m, 1 H), 5.85 - 5.93 (m, 1 H), 3.88 - 3.95 (m, 2H), 3.77 - 3.82 (m, 1 H), 3.37 - 3.43 (m, 2 H), 3.11 - 3.17 (m, 1 H), 2.99 -3.09 (m, 1 H), 2.86 - 2.96 (m, 2 H), 2.70 - 2.84 (m, 2 H), 2.04 - 2.25 (m, 2H), 1.68 - 1.78 (m, 2 H), 1.56 - 1.67 (m, 3 H), 1.35 (d, J = 1.34 Hz, 2 H), 1.22 - 1.29 (m, 2 H), 1.12 - 1.20 (m, 3 H), 0.91 (d, J = 6.36 Hz, 3 H). LC-MS:m / z 672.2 (M+H) + . Compound 155
[0487] Compound 155 was synthesized using a similar procedure as described in Example 2 above, by using appropriate materials.
[0488] 1 H NMR (400 MHz, DMSO-d6): δ 7.98 (d, J=5.6 Hz, 1 H), 7.51 (s, 1 H), 7.20-7.30 (m, 3 H), 7.04-7.15 (m, 4 H), 6.83 (t, J=8.8 Hz, 2 H), 5.90 (q, J=8.0 Hz, 1 H), 3.97 (t, J=6.8 Hz, 2 H), 3.85 (t, J=6.8 Hz, 2 H), 3.79 (s, 3H), 3.07-3.10 (m, 2 H), 2.89-3.05 (m, 3 H), 2.58-2.74 (m, 4 H), 1.97-2.06 (m,1 H). 19 F NMR (377 MHz, DMSO-d6): -117.08. LC-MS: m / z 676.0 (M+H) + . 5-(5-(4-fluorophenylethyl)-3-isopropyl-7-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,1-dioxo-2,3-dihydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 156)
[0489] Compound 156 was synthesized using a similar procedure as described in Example 2 above, by using appropriate materials.
[0490] 1H NMR (400 MHz, MeOD-d4) δ ppm 7.92 - 7.97 (m, 1 H), 7.65 - 7.71 (m,1 H), 7.12 - 7.17 (m, 4 H), 6.93 - 6.99 (m, 2 H), 6.86 - 6.91 (m, 1 H), 6.79(d, J=7.87 Hz, 1 H), 5.77 - 5.83 (m, 1 H), 3.82 - 3.84 (m, 3 H), 3.72 - 3.81(m, 2 H), 3.52 - 3.59 (m, 1 H), 3.21 - 3.29 (m, 1 H), 2.99 - 3.15 (m, 3 H),2.71 - 2.82 (m, 2 H), 2.60 - 2.69 (m, 1 H), 1.96 - 2.04 (m, 1 H), 1.12 - 1.16 (m, 3 H), 0.84 (dd, J=6.56, 3.22 Hz, 3 H). LC-MS: m / z 712.2 (M+H) + . 2-Fluoro-4-((5-(3-isopropyl-1,1-dioxo-6-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-2,3-dihydrothieno[3,2-b]pyridin-7-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)benzonitrile (Compound 157)
[0491] Compound 157 was synthesized using a similar procedure as described in Example 2 above, by using appropriate materials.
[0492] 1H NMR (400 MHz, CDCl3) δ ppm 8.93 - 9.08 (m, 1 H), 8.31 (d, J=1.79Hz, 1 H), 8.12 - 8.23 (m, 1 H), 7.54 - 7.66 (m, 1 H), 7.26 (d, J=3.70 Hz, 1H), 7.03 - 7.14 (m, 2 H), 6.56 - 6.73 (m, 1 H), 5.48 - 5.66 (m, 2 H), 3.93 -4.02 (m, 2 H), 3.70 - 3.80 (m, 1 H), 3.55 - 3.66 (m, 1 H), 3.30 - 3.46 (m, 3H), 2.80 - 3.01 (m, 3 H), 1.72 - 1.80 (m, 2 H), 1.65 (dd, J=8.17, 1.97 Hz, 3H), 1.30 - 1.39 (m, 2 H), 1.16 (d, J=6.91 Hz, 3 H), 0.86 - 0.94 (m, 3 H). LC-MS: m / z 657.2 (M+H) + . 2-Fluoro-4-((5-(2-(4-fluorophenylethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-8,9-dihydro-5H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridin-4-yl)-1H-indol-1-yl)methyl)benzonitrile (Compound 158)
[0493] Compound 158 was synthesized using a similar procedure as described in Example 2 above, by using appropriate materials.
[0494] 1H NMR (400 MHz, MeOD-d4) δ ppm 7.64 - 7.69 (m, 2 H), 7.36 - 7.40 (m,1 H), 7.30 - 7.34 (m, 1 H), 7.14 - 7.19 (m, 2 H), 7.07 - 7.13 (m, 2 H), 7.02- 7.06 (m, 1 H), 6.93 - 7.00 (m, 2 H), 6.59 - 6.63 (m, 1 H), 5.52 - 5.56 (m,2 H), 4.08 - 4.13 (m, 2 H), 3.96 - 4.02 (m, 2 H), 3.10 - 3.14 (m, 2 H), 3.03- 3.09 (m, 2 H), 2.72 - 2.80 (m, 2 H). LC-MS: m / z 630.1 (M+H) + . 2-Fluoro-4-[1-[5-[11-[2-(4-fluorophenyl)ethyl]-7-oxo-10-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-2,6,12-triazatricyclo[6.4.0.02,6]dodecyl-1(8),9,11-trien-9-yl]indol-1-yl]ethyl]benzonitrile (Compound 159)
[0495] Compound 159 was synthesized using a similar procedure as described in Example 2 above, by using appropriate materials.
[0496] 1 H NMR (400 MHz, MeOD-d4) δ ppm 7.61 - 7.70 (m, 2 H), 7.55 - 7.60 (m,1 H), 7.26 - 7.31 (m, 1 H), 7.13 - 7.21 (m, 3 H), 7.06 - 7.13 (m, 2 H), 6.94- 6.99 (m, 2 H), 6.59 - 6.68 (m, 1 H), 5.85 - 5.95 (m, 1 H), 4.04 - 4.14 (m, 2 H), 3.93 - 4.02 (m, 2 H), 3.02 - 3.16 (m, 4 H), 2.70 - 2.81 (m, 2 H), 1.94- 2.00 (m, 3 H). LC-MS: m / z 644.3 (M+H) + . Compound 161
[0497] Compound 161 was synthesized using a similar procedure as described in Example 2 above, by using suitable materials.
[0498] 1 H NMR (400 MHz, DMSO-d6): 12.45 (br s, 1 H), 8.13 (d, J=2.0 Hz, 1H), 7.99 (d, J=2.0 Hz, 1 H), 7.87 (t, J=7.6 Hz, 1 H), 7.75 (d, J=3.6 Hz, 1H), 7.41 (d, J= 10.0 Hz, 1 H), 7.21-7.27 (m, 2 H), 7.19 (d, J=7.6 Hz, 1 H), 7.04-7.12 (m, 2 H), 6.62 (d, J=3.2 Hz, 1 H), 5.62 (s, 2 H), 3.97 (t, J=6.8Hz, 2 H), 3.82 (t, J=6.8 Hz, 2 H), 3.05-3.13 (m, 2 H), 2.98-3.05 (m, 2 H), 2.60 (t, J=7.2 Hz, 2 H). 19 F NMR (377 MHz, DMSO-d6): δ -108.14, -117.12. LC-MS:m / z 631.1 (M+H) + . 6-[[6-[(9aS)-2-[2-(4-fluorophenyl)ethyl]-5-oxo-3-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-7,8,9,9a-tetrahydropyrido[2,3-a]pyrrolizin-4-yl]-2-oxo-1,3-benzoxazol-3-yl]methyl]pyridin-3-carboxylonitrile (Compound 176)
[0499] Compound 176 was synthesized using a similar procedure as described in Example 2 above, by using appropriate materials.
[0500] 1H NMR (400 MHz, DMSO-d6) δ ppm 8.94 (d, J = 1.6 Hz, 1H), 8.35 (dd, J= 2.0, 8.4 Hz, 1H), 7.73 (d, J = 8.0 Hz, 1H), 7.40 (s, 1H), 7.18 - 7.24 (m,3H), 7.04 - 7.10 (m, 2H), 6.98 -7.03 (m, 1H), 5.33 (s, 2H), 4.83 (dd, J =6.4, 10.2 Hz, 1H), 3.43 - 3.57 (m, 2H), 3.11 - 3.17 (m, 2H), 2.96 - 3.09 (m,2H), 2.22 - 2.36 (m, 3H), 1.32 - 1.45 (m, 1H). 19 F NMR (400 MHz, DMSO-d6) δ ppm-117.067. LC-MS: m / z 630.1 (M+H) + . 2-Fluoro-4-((6-(2-(4-fluorophenylethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-8,9-dihydro-5H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)methyl)benzonitrile (Compound 162)
[0501] Compound 162 was synthesized using a similar procedure as described in Example 2 above, by using appropriate materials.
[0502] 1 H NMR (400 MHz, DMSO-d6) δ 12.52 (s, 1 H), 7.94 (t, J=7.2 Hz, 1 H), 7.63 (d, J=10.0 Hz, 1 H), 7.40-7.46 (m, 2 H), 7.29 (d, J=8.0 Hz, 1 H), 7.19-7.26 (m, 2 H), 7.04-7.11 (m, 3 H), 5.19 (s, 2 H), 3.96 (t, J=6.8 Hz, 2 H), 3.82 (t, J=6.8 Hz, 2 H), 2.97-3.11 (m, 4 H), 2.55-2.64 (m, 2 H). 19F NMR (377MHz, DMSO-d6) δ -107.78, -117.09. LC-MS: m / z 648.2 (M+H) + . 6-((6-(5-(4-fluorophenylethyl)-3-isopropyl-1,1-dioxo-6-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2,3-dihydrothieno[3,2-b]pyridin-7-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)methyl)nicotinonitrile (Compound 163)
[0503] Compound 163 was synthesized using a similar procedure as described in Example 2 above, by using appropriate materials.
[0504] 1 H NMR (400 MHz, DMSO-d6) δ 12.67 (s, 1 H), 8.94 (dd, J=2.0 Hz, J=0.8Hz, 1 H), 8.36 (dd, J=8.4 Hz, J=2.4 Hz, 1 H), 7.74 (d, J=8.0 Hz, 1 H), 7.41(s, 1 H), 7.30 (d, J=8.4 Hz, 1 H), 7.15-7.24 (m, 2 H), 7.02-7.09 (m, 3 H), 5.34 (s, 2 H), 3.71-3.87 (m, 2 H), 3.59 (dd, J=13.6 Hz, J=4.8 Hz, 1 H), 3.17-3.28 (m, 2 H), 3.00-3.10 (m, 2 H) 2.54-2.64 (m, 1 H), 1.05 (d, J=6.8 Hz, 3H), 0.76 (d, J=6.8 Hz, 3 H). 19 F NMR (377 MHz, DMSO-d6) δ -117.09. LC-MS: m / z667.2 (M+H) + . 6-[1-[6-[(9aS)-2-[2-(4-fluorophenyl)ethyl]-5-oxo-3-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-7,8,9,9a-tetrahydropyrido[2,3-a]pyrrolizin-4-yl]-2-oxo-1,3-benzoxazol-3-yl]ethyl]pyridine-3-carboxylonitrile (Compound 160)
[0505] Compound 160 was synthesized using a similar procedure as described in Example 2 above, by using appropriate materials.
[0506] 1 H NMR (400 MHz, DMSO-d6) δ ppm 8.97 (s, 1H), 8.29 - 8.51 (m, 1H), 7.77 (d, J = 8.4 Hz, 1H), 7.33 - 7.51 (m, 1H), 7.13 - 7.30 (m, 3H), 7.01 -7.12 (m, 2H), 6.97 (d, J = 8.0 Hz, 1H), 5.80 (q, J = 7.2 Hz, 1H), 4.70 - 4.90(m, 1H), 3.49 - 3.61 (m, 2H), 3.09 - 3.19 (m, 2H), 2.92 - 3.07 (m, 2H), 2.20- 2.40 (m, 3H), 1.93 (d, J = 7.2 Hz, 3H), 1.30 - 1.47 (m, 1H). 19 F NMR (400MHz, DMSO-d6) δ ppm -117.059. LC-MS: m / z 644.1 (M+H) + . (S)-6-(2-(4-fluorophenylethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-3-((5-fluoropyridin-2-yl)methyl)benzo[d]oxazol-2(3H)-one (Compound 164)
[0507] Compound 164 was synthesized using a similar procedure as described in Example 2 above, by using appropriate materials.
[0508] 1H NMR (400 MHz, CDCl3) δ ppm 8.47 - 8.58 (m, 1 H), 8.43 (s, 1 H), 7.39 - 7.45 (m, 2 H), 7.22 (s, 1 H), 7.13 (dd, J=8.46, 5.60 Hz, 2 H), 7.08 (s, 2 H), 6.94 - 7.00 (m, 2 H), 5.08 - 5.19 (m, 2 H), 4.71 - 4.82 (m, 1 H), 3.65 - 3.80 (m, 1 H), 3.34 - 3.49 (m, 1 H), 3.02 - 3.19 (m, 4 H), 2.46 - 2.55(m, 1H), 2.32 - 2.41 (m, 2 H), 1.39 - 1.48 (m, 1 H). LC-MS: m / z 623.2 (M+H) + . Example 9: (R)-6-fluoro-1-((2-((S)-2-(4-fluorophenylethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thieno[2,3-c]pyridin-7-yl)amino)-2,3-dihydro-1H-indene-5-carboxynitrile (Compound 165) Step A: 6-Fluoro-1-oxo-2,3-dihydro-1H-inden-5-carboxynitrile
[0509] To a solution of 5,6-difluorodihydroindene-1-one (3.4 g, 20.22 mmol) in DMSO (40 mL), NaCN (991 mg, 20.22 mmol) was added. The mixture was stirred at 40ºC for 16 h. The solution was diluted with water (40 mL) and filtered through diatomaceous earth. The filtrate was extracted with ethyl acetate (50 mL x 2). The combined organic phases were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to give a residue. The residue was purified by column chromatography (SiO2, 16% ethyl acetate in petroleum ether) to give 6-fluoro-1-oxo-2,3-dihydro-1H-indene-5-carboxynitrile (560 mg, 15.81% yield) as a black oil.
[0510] 1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 5.2 Hz, 1H), 7.54 (d, J = 7.2Hz, 1H), 3.13-3.29 (m, 2H), 2.72-2.99 (m, 2H). 19 F NMR (377 MHz, chloroform-d) δ -107.985. LC-MS: m / z 176.1 (M+H) + . Step B (R,Z)-N-(5-cyano-6-fluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide
[0511] Ti(OEt)4 (663 μL, 3.20 mmol) was added to a solution of 6-fluoro-1-oxo-2,3-dihydro-1H-indene-5-carboxynitrile (280 mg, 1.60 mmol) and (R)-2-methylpropane-2-sulfinamide (200 mg, 1.65 mmol) in 2-methyltetrahydrofuran (5 mL). The mixture was stirred at 80ºC for 16 h. The mixture was combined with another batch (280 mg of the compound ketone) from ES28217-38, poured into water (50 mL) at 0ºC, and diluted with ethyl acetate (50 mL). Diatomaceous earth (10 g) was added to the mixture and stirred for 10 min. The mixture was then filtered to remove the precipitate. The filtrate was extracted with ethyl acetate (50 mL x 2). The combined organic phases were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to obtain the residue. The residue was purified by rapid column chromatography (SiO2, 27% ethyl acetate in petroleum ether) to give (R,Z)-N-(5-cyano-6-fluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide (275 mg, 30.90% average yield) as a brown oil.
[0512] 1 H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 5.2 Hz, 1H), 7.54 (d, J = 8.0Hz, 1H), 3.52-3.65 (m, 1H), 3.27 (s, 1H), 3.14-3.19 (m, 2H), 1.34 (s, 9H). LC-MS: m / z 279.1 (M+H) + . Step C(R)-N-((R)-5-cyano-6-fluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide
[0513] NaBH4 (150 mg, 3.97 mmol) was added to a solution of (R,Z)-N-(5-cyano-6-fluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide (275 mg, 0.99 mmol) in THF (5 mL) at -70ºC under a nitrogen atmosphere. The reaction mixture was stirred at -70ºC for 30 min and then allowed to rise naturally to 0ºC. The mixture was stirred at 0ºC for 1 h under a nitrogen atmosphere. The reaction mixture was quenched with saturated NH4Cl solution (20 mL) and extracted with ethyl acetate (20 mL x 2). The combined organic phases were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to obtain the residue. The residue was purified by column chromatography (SiO2, 30-40% ethyl acetate in petroleum ether) to give (R)-N-((R)-5-cyano-6-fluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide (100 mg, 36.10% yield).
[0514] 1 H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 8.4 Hz, 1H), 7.44 (d, J = 5.6Hz, 1H), 4.91 (q, J = 7.2 Hz, 1H), 3.54 (d, J = 6.4 Hz, 1H), 2.94-3.06 (m,1H), 2.77-2.88 (m, 1H), 2.54-2.67 (m, 1H), 2.00-2.08 (m, 1H), 1.26 (s, 9H). LC-MS: m / z 281.1 (M+H) + . Step D(R)-1-amino-6-fluoro-2,3-dihydro-1H-inden-5-carboxynitrile
[0515] A mixture of (R,Z)-N-(5-cyano-6-fluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfinamide (100 mg, 0.36 mmol) in HCl / dioxane (2 M, 2 mL) was stirred at 20ºC for 1.5 h. The mixture was concentrated to give (R)-1-amino-6-fluoro-2,3-dihydro-1H-inden-5-carboxynitrile (130 mg, 99.49% yield, 68% purity, 2HCl).
[0516] 1 ¹H NMR (400 MHz, chloroform-d) δ 7.76 (d, J = 6.0 Hz, 1H), 7.49 (d, J = 9.2 Hz, 1H), 4.84–4.90 (m, 1H), 3.11–3.22 (m, 1H), 2.95–3.07 (m, 1H), 2.65–2.75 (m, 1H), 2.08–2.23 (m, 1H). Step E(R)-1-((2-(1,3-dioxolane-2-yl)thieno[2,3-c]pyridin-7-yl)amino)-6-fluoro-2,3-dihydro-1H-inden-5-carboxynitrile)
[0517] A mixture of (R)-N-((R)-5-cyano-6-fluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide (110 mg, 0.30 mmol, 2HCl), 7-chloro-2-(1,3-dioxolane-2-yl)thieno[2,3-c]pyridine (73 mg, 0.30 mmol), Cs₂CO₃ (300 mg, 0.92 mmol), Pd(OAc)₂ (7 mg, 0.03 mmol), and BINAP (40 mg, 0.06 mmol) in dioxane (5 mL) was degassed and purged three times with nitrogen. The mixture was then stirred at 100ºC for 16 h under a nitrogen atmosphere. The mixture was combined with ES28217-44 (20 mg of heterocyclic compound) and concentrated. The residue was purified by rapid column chromatography (SiO2, 34% ethyl acetate in petroleum ether) to give (R)-1-((2-(1,3-dioxolane-2-yl)thieno[2,3-c]pyridin-7-yl)amino)-6-fluoro-2,3-dihydro-1H-indene-5-carboxylonitrile (120 mg, 88.79% average yield).
[0518] 1H NMR (400 MHz, DMSO-d6) δ 7.96 (d, J = 5.6 Hz, 1H), 7.81 (d, J = 6.4Hz, 1H), 7.50 (s, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.21-7.26 (m, 1H), 7.09 (d,J = 5.6 Hz, 1H), 6.21 (s, 1H), 5.89 (q, J = 8.4 Hz, 1H), 3.92-4.14 (m, 4H), 2.95-3.07 (m, 1H), 2.79-2.93 (m, 1H), 2.54-2.60 (m, 1H), 2.03-2.17 (m, 1H). LC-MS: m / z 382.1 (M+H) + . Step F(R)-6-fluoro-1-((2-formylthiopheno[2,3-c]pyridin-7-yl)amino)-2,3-dihydro-1H-inden-5-carboxynitrile
[0519] A mixture of (R)-1-amino-6-fluoro-2,3-dihydro-1H-indene-5-carboxynitrile (120 mg, 0.31 mmol), aqueous HCl (4 M, 400 μL), and THF (2 mL) was stirred at 45ºC for 16 h. The reaction mixture was quenched by adding aqueous NaHCO3 (10 mL) at 0ºC, diluted with ethyl acetate (50 mL), and extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the residue. The residue was purified by rapid column chromatography (SiO2, 34% ethyl acetate in petroleum ether) to give (R)-1-((2-(1,3-dioxolane-2-yl)thieno[2,3-c]pyridin-7-yl)amino)-6-fluoro-2,3-dihydro-1H-indene-5-carboxylonitrile (70 mg, 8.2% yield).
[0520] 1H NMR (400 MHz, DMSO-d6) δ 10.18 (s, 1H), 8.34 (s, 1H), 8.05 (d, J =5.6 Hz, 1H), 7.82 (d, J = 5.6 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.24-7.31(m, 2H), 5.91 (q, J = 8.0 Hz, 1H), 2.96-3.07 (m, 1H), 2.81-2.94 (m, 1H), 2.55-2.64 (m, 1H), 2.02-2.22 (m, 1H). 19 F NMR (377 MHz, DMSO-d6) δ -112.17. LC-MS: m / z 338.1 (M+H) + . Step G (1R)-6-fluoro-1-((2-((9aS)-2-(4-fluorophenylethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4,5,7,8,9,9a-hexahydro-1H-pyrido[2,3-a]pyrrolizin-4-yl)thieno[2,3-c]pyridin-7-yl)amino)-2,3-dihydro-1H-inden-5-carboxynitrile
[0521] NH4OAc (40 mg, 0.52 mmol) was added to a solution of (R)-1-((2-(1,3-dioxolane-2-yl)thieno[2,3-c]pyridin-7-yl)amino)-6-fluoro-2,3-dihydro-1H-indene-5-carboxynitrile (65 mg, 0.19 mmol) and 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (52 mg, 0.21 mmol) and (S)-tetrahydro-1H-pyrrolizin-1,3(2H)-dione (39 mg, 0.28 mmol) in HOAc (3 mL). The mixture was stirred at 120ºC for 1 h. The mixture was combined with ES28217-49 (5 mg of nitrile compound) and concentrated under vacuum to give the residue. The residue was purified by column chromatography (SiO2, ethyl acetate) to give (1R)-6-fluoro-1-((2-((9aS)-2-(4-fluorophenylethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4,5,7,8,9,9a-hexahydro-1H-pyrido[2,3-a]pyrrolizin-4-yl)thieno[2,3-c]pyridin-7-yl)amino)-2,3-dihydro-1H-indene-5-carboxylonitrile (35 mg, 24.61% average yield).
[0522] 1 H NMR (400 MHz, DMSO-d6) δ 12.19 (d, J = 8.4 Hz, 1H), 9.69-10.06 (m,1H), 7.88 (d, J = 5.6 Hz, 1H), 7.78 (d, J = 6.0 Hz, 1H), 7.19-7.29 (m, 4H),7.06-7.13 (m, 3H), 6.99 (dd, J = 2.4, 5.6 Hz, 1H), 5.77-5.96 (m, 1H), 5.08-5.24 (m, 1H), 4.18-4.34 (m, 1H), 3.24-3.29 (m, 1H), 2.93-3.04 (m, 2H), 2.79-2.92 (m, 6H), 2.03-2.15 (m, 4H), 1.22-1.35 (m, 1H). LC-MS: m / z 690.2 (M+H) + . Step H(R)-6-fluoro-1-((2-((S)-2-(4-fluorophenylethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thieno[2,3-c]pyridin-7-yl)amino)-2,3-dihydro-1H-indene-5-carboxynitrile
[0523] A mixture of (1R)-6-fluoro-1-((2-((9aS)-2-(4-fluorophenylethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4,5,7,8,9,9a-hexahydro-1H-pyrido[2,3-a]pyrrolizin-4-yl)thieno[2,3-c]pyridin-7-yl)amino)-2,3-dihydro-1H-indene-5-carboxynitrile (35 mg, 0.05 mmol) and CAN (28 mg, 0.05 mmol) in acetonitrile (2 mL) was stirred at 50ºC for 1 h. The reaction mixture was then concentrated. The mixture was purified by reversed-phase HPLC (column: Welch Xtimate C18 150*25mm*5um; mobile phase: [water (NH3H2O+NH4HCO3)-ACN]; gradient: 26%-56% B for 8 min) and lyophilized to give (R)-6-fluoro-1-((2-((S)-2-(4-fluorophenylethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thieno[2,3-c]pyridin-7-yl)amino)-2,3-dihydro-1H-indene-5-carboxylonitrile (5.97 mg, 17.11% yield).
[0524] 1H NMR (400 MHz, DMSO-d6) δ 7.99 (d, J = 5.6 Hz, 1H), 7.81 (d, J = 5.6Hz, 1H), 7.41-7.47 (m, 2H), 7.28 (dd, J = 9.2, 2.4 Hz, 1H), 7.21 (dd, J =8.8, 5.6 Hz, 2H), 7.14 (d, J = 5.6 Hz, 1H), 7.01-7.10 (m, 2H), 5.81-6.02 (m,1H), 4.87 (dd, J = 6.4, 10.2 Hz, 1H), 3.51-3.57 (m, 1H), 3.16-3.23 (m, 2H),2.97-3.13 (m, 3H), 2.80-2.93 (m, 1H), 2.54-2.63 (m, 2H), 2.35-2.39 (m, 1H),2.23-2.30 (m, 2H), 2.08-2.16 (m, 1H), 1.37-1.49 (m, 1H). 19 F NMR (377 MHz, DMSO-d6) δ -112.11, -117.04. LC-MS: m / z 688.0 (M+H) + . Example 10 5-((S)-4-(7-(((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)thiopheno[2,3-c]pyridin-2-yl)-2-(4-fluorophenylethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 166) Step A (R)-N-(5,6-difluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide
[0525] Tetraethoxytitanium (4.93 mL, 23.79 mmol) was added to a mixture of 5,6-difluorodihydroindene-1-one (2 g, 11.89 mmol) and (R)-2-methylpropane-2-sulfinamide (1.51 g, 12.49 mmol) in 2-MeTHF (20 mL) under nitrogen, and the mixture was stirred at 80ºC for 14 h. The reaction mixture was diluted with water (500 mL) and ethyl acetate (500 mL) and filtered through diatomaceous earth. The mixture was extracted with ethyl acetate (300 mL x 3). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The crude product was purified by silica gel column chromatography (35% ethyl acetate in petroleum ether) to give (R)-N-(5,6-difluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfinamide (2.73 g, 42.29% yield).
[0526] 1 H NMR (400 MHz, DMSO-d6) δ 7.59-7.71 (m, 2H), 3.32-3.29 (m, 1H), 3.08-3.14 (m, 2H), 2.98-3.08 (m, 1H), 1.22 (s, 9H). 19 F NMR (377 MHz, DMSO-d6)δ -129.75, -138.67. LC-MS: m / z 272.1 (M+H) + . Step B (R)-N-((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide
[0527] DIBAL-H (1 M in toluene, 30.19 mL) was added dropwise to a mixture of (R)-N-(5,6-difluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide (2.73 g, 10.06 mmol) in DCM (150 mL) at -70°C under nitrogen and stirred for 3 h. The reaction was slowly quenched with MeOH (10 mL) and then heated to 0°C. 50 mL of saturated NH4Cl solution was added and the resulting mixture was stirred for 30 min. The organic layers were then separated. The aqueous layer was washed with DCM (300 mL). The combined organic layers were washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to give the residue. The crude product was purified by silica gel column chromatography (50% ethyl acetate in petroleum ether) to give (R)-N-((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide (1.19 g, 43.27% yield).
[0528] 1 H NMR (400 MHz, DMSO-d6) δ 7.56 (dd, J = 7.9, 10.7 Hz, 1H), 7.29 (dd,J = 7.5, 10.5 Hz, 1H), 5.86 (d, J = 8.8 Hz, 1H), 4.71 (q, J = 8.4 Hz, 1H),2.80-2.92 (m, 1H), 2.67-2.77 (m, 1H), 2.36-2.45 (m, 1H), 1.91-2.00 (m, 1H),1.15 (s, 9H). 19 F NMR (377 MHz, DMSO-d6) δ -140.55, -141.44. LC-MS: m / z 274.1 (M+H) + SFC t R = 1.712 min, 100%. Step C(R)-5,6-difluoro-2,3-dihydro-1H-inden-1-amine
[0529] A mixture of (R)-N-((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide (1.19 g, 4.35 mmol, 1 equivalent) in HCl / dioxane (20 mL) was stirred at 15–20 °C for 14 h. The reaction was concentrated under vacuum to give (R)-5,6-difluoro-2,3-dihydro-1H-inden-1-amine (960 mg, 99.73% yield, HCl).
[0530] 1 H NMR (400 MHz, DMSO-d6) δ 8.71 (s, 3H), 7.77 (dd, J = 7.8, 10.8 Hz,1H), 7.41 (dd, J = 7.7, 10.6 Hz, 1H), 4.58-4.84 (m, 1H), 3.00-3.11 (m, 1H), 2.78-2.90 (m, 1H), 2.51-2.56 (m, 1H), 2.43-2.49 (m, 1H), 1.99-2.11 (m, 1H). 19 FNMR (377 MHz, DMSO-d6) δ -137.90, -140.58. Step D(R)-N-(5,6-difluoro-2,3-dihydro-1H-inden-1-yl)-2-(1,3-dioxolane-2-yl)thiopheno[2,3-c]pyridine-7-amine
[0531] Dioxane (6 mL) was added to a mixture of (R)-5,6-difluoro-2,3-dihydro-1H-inden-1-amine (204 mg, 0.99 mmol, HCl), 7-chloro-2-(1,3-dioxolane-2-yl)thieno[2,3-c]pyridine (200 mg, 0.83 mmol), Pd(OAc)2 (20 mg, 0.09 mmol), BINAP (104 mg, 0.17 mmol), and Cs2CO3 (800 mg, 2.46 mmol) under nitrogen and stirred at 100ºC for 16 h under nitrogen. The reaction was filtered and concentrated under vacuum. The crude product was purified by silica gel column chromatography (50% ethyl acetate in petroleum ether) to give (R)-N-(5,6-difluoro-2,3-dihydro-1H-inden-1-yl)-2-(1,3-dioxolane-2-yl)thieno[2,3-c]pyridine-7-amine (353 mg, 91.15% yield).
[0532] 1H NMR (400 MHz, DMSO-d6) δ ppm 7.96 (d, J = 5.5 Hz, 1H), 7.48 (s,1H), 7.33 (dd, J = 7.6, 10.7 Hz, 1H), 7.14-7.21 (m, 2H), 7.07 (d, J =...
Claims
1. A compound of formula I: I Or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein: A is C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 Cycloalkylene, heterocyclic cycloidene, arylene or heteroarylene; wherein the C of A 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 3-10 Cycloalkylene, heterocycloalkylene, arylene or heteroaryl are independently and optionally separated by one to five Z A replace; X 1 It is O, S, NH, NR A CH or CR B ; X 2 and X 3 One of them is C(O); and X 2 and X 3 The other one is O, S, NH, NR A CH or CR B ; X 4 Is it N, CH or CR? B ; The condition is X 1 X 2 X 3 and X 4 At least one of them is a heteroatom; Each R A Independently selected from cyano, C 1-3 Alkyl and C 1-3 Halogenated alkyl groups; wherein R A Each C 1-3 Alkyl groups are independently and optionally prefixed with -NH2 or -NHC. 1-3 Alkyl, -N(C) 1-3 alkyl)2, hydroxyl or C 1-3 Alkyl substitution; Each R B Independently selected from halogenated groups, hydroxyl groups, -NH2 groups, cyano groups, and C groups. 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; wherein R B Each C 1-3 Alkyl groups are independently and optionally prefixed with -NH2 or -NHC. 1-3 Alkyl, -N(C) 1-3 alkyl)2, hydroxyl or C 1-3 Alkyl substitution; •Y 1 Is -C(O)-, -C(S)-, -S(O)2-, -S(O)(NR 6 - or - P(O)(R 7 )-; Y 2 It is -O-, -S-, -NR 2 -or-C(R) 2 )2-; where Y 1 With Y 2 The key between them is a single key; and Y 3 is -NR 8 -, -O-, -S-, -C(R 3 )2-, -NR 8 -C(R 3 )2-, -O-C(R 3 )2-, -S-C(R 3 )2-, -C(R 3a )2-C(R 3a )2-, -C(R 3a )2-C(R 3a )2-C(R 3a )2- or -CR 3 =CR 3 -; or •Y 1 Is -C(O)-, -C(S)-, -S(O)2-, -S(O)(NR 6 - or - P(O)(R 7 )-; Y 2 Is it -N- or -CR? 2 -,and Y 3 Is it -N- or -CR? 3 -;where Y 2 With Y 3 The key between them is a double bond; or •Y 1 Is it -N- or -CR? 1 -; Y 2 Is it -N- or -CR? 2 -;where Y 1 With Y 2 The bond between them is a double bond; and Y 3 Yes -NR 8 -、-O- or -S-; The condition is that it contains Y. 1 Y 2 and Y 3 The ring contains at least one heteroatom; L 1 It is C 1-3 Alkylene, C 2-3 imidene group, C 2-3 Ethyne group, C 1-3 Heteroalkylene, C 3-6 Cycloalkylene or 4-6-membered heterocyclic alkylene groups; wherein L 1 C 1-3 Alkylene, C 2-3 imidene group, C 2-3 Ethyne group, C 1-3 Heteroalkylene, C 3-6 The cycloalkylene group or the 4- to 6-membered heterocyclic group is independently and optionally substituted by one to five substituents independently selected from the following: halogen, oxo, hydroxyl, cyano, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; L 2 It is a key, -O-, -S-, -NR 2a -, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -C(O)NR 2a -、-NR 2a C(O)-、-OC(O)NR 2a -、-NR 2a C(O)O-、-NR 2a C(O)NR 2b -, -S(O)-, -S(O)2-, -S(O)NR 2a -、-S(O)2NR 2a -、-NR 2a S(O)-、-NR 2a S(O)2-、-NR 2a S(O)NR 2b -、-NR 2a S(O)2NR 2b -、C 1-6 Alkylene, C 2-6 imidene group, C 2-6 Ethyne group, C 1-6 Heteroalkylene, C 3-6 Cycloalkylene, 4-6-membered heterocyclic cycloidene or 5-membered heteroarylene; wherein L 2 C 1-3 Alkylene, C 2-3 imidene group, C 2-3 Ethyne group, C 1-3 Heteroalkylene, C 3-6 The cycloalkylene, 4-6-membered heterocyclic or 5-membered heteroarylene is independently and optionally substituted by one to five substituents independently selected from the following: halogen, oxo, hydroxy, cyano, -NH2, -NHC. 1-3 Alkyl, -N(C) 1-3 Alkyl)2, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; R 1 It is hydrogen, halogenated group, hydroxyl group, cyano group, C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy or C 1-3 Halogenated alkoxy groups; Each R 2 Independently, it is hydrogen and C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 3-6 Cycloalkyl, phenyl, 4- to 6-membered heterocyclic or 5- to 6-membered heteroaryl; wherein R 2 Each C 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 3-6 The cycloalkyl, phenyl, 4- to 6-membered heterocyclic or 5- to 6-membered heteroaryl groups are independently and optionally substituted by one to five substituents independently selected from the following: halogroup, hydroxyl group, cyano group, C4 group, C6 group, C5 group, C6 ... 1-3 Alkyl, C 2-3 alkenyl, C 2-3 alkynyl group, C 1-3 Haloalkyl, C 1-3 Alkoxy or C 1-3 Halogenated alkoxy groups; Or R 2 and R 1 R 3 R 3a R 6 R 7 and R 8 Any one or two of them together with the atoms to which they are attached form C 3-10 cycloalkyl, heterocyclic, or heteroaryl; wherein the C 3-10 Cycloalkyl, heterocyclic, or heteroaryl groups are optionally separated by one to five Z groups. 2 replace; Each R 2a and R 2b Independently, it is hydrogen and C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 2a and R 2b Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 2a replace; Or R 2a and R 2b Together with the atoms to which they are attached, they form independently, optionally, one to five Z. 2a Substituted heterocyclic groups; Each R 3 Independently, it is hydrogen, hydroxyl, -NR 3b R 3c C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 3 Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy groups, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 3 replace; Or two Rs 3 Together with one or more atoms to which they are attached, they form C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein the C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally separated by one to five Z groups. 3 replace; Or two Rs 3 Together with the carbon atoms attached to both, they form oxo groups; Each R 3a Independently, it is hydrogen and C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 3a Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Halogenated alkoxy groups, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 3a replace; Or two Rs 3a Together with one or more atoms to which they are attached, they form C 3-10 cycloalkyl, heterocyclic, or heteroaryl; wherein the C 3-10 Cycloalkyl, heterocyclic, or heteroaryl groups are optionally separated by one to five Z groups. 3a replace; Or two Rs 3a Together with the carbon atoms attached to both, they form oxo groups; R 3b and R 3c Each is independently hydrogen, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 3b and R 3c Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 The cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally and independently substituted by one to five substituents independently selected from the following: halogenated, hydroxyl, cyano, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; Or R 3b and R 3c Together with the nitrogen atoms to which they are attached, they form optional groups of one to five Zn atoms. 3b Substituted heterocyclic groups; R 4 It is C 1-6 Alkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 4 C 1-6 Alkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 4 replace; R 5 It is hydrogen, halogenated group, hydroxyl group, amino group, cyano group, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 5 C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 5 replace; R 6 It is hydrogen, C 1-3 Alkyl, C 1-3 Haloalkyl, C 3-6 cycloalkyl or 4- to 6-membered heterocyclic groups; wherein the C 1-3 Alkyl, C 1-3 Haloalkyl, C 3-6 The cycloalkyl or 4- to 6-membered heterocyclic group is optionally substituted by one to five independent substituents selected from the following: halogen, oxo, hydroxyl, cyano, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; R 7 It is hydroxyl, C 1-3 Alkoxy, C 1-3 Halogenated alkoxy groups, C 1-3 Alkyl or C 1-3 Halogenated alkyl groups; R 8 It is hydrogen, -S(O)2-C 1-3 Alkyl, -S(O)2-C 1-3 Haloalkyl, C 1-3 Alkyl, C 1-3 Halogenated alkyl C 3-6 cycloalkyl or 4- to 6-membered heterocyclic groups; wherein R 8 -S(O)2-C 1-3 Alkyl, -S(O)2-C 1-3 Haloalkyl, C 1-3 Alkyl, C 1-3 Halogenated alkyl C 3-6 The cycloalkyl or 4- to 6-membered heterocyclic group is optionally substituted by one to five independent substituents selected from the following: halogen, oxo, hydroxyl, cyano, C 1-3 Alkyl, C 1-3 Haloalkyl, C 1-3 Alkoxy and C 1-3 Halogenated alkoxy groups; Each Z A Z 2 Z 2a Z 3 Z 3a Z 3b Z 4 and Z 5 Independently, it is a halogenated group, a cyano group, a nitro group, an oxo group, or a C group. 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, heteroaryl, -LH, -LC 1-6 Alkyl, -LC 2-6 alkenyl, -LC 2-6 alkynyl, -LC 1-6 Halogenated alkyl, -LC 3-10 Cycloalkyl, -L-heterocyclic, -L-aryl, or -L-heteroaryl; wherein Z A Z 2 Z 2a Z 3 Z 3a Z 3b Z 4 and Z 5 Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are each independently and optionally divided by one to five Z groups. 1a replace; each L is independently -O-, -S-, -NR 20 -, -C(O)-, -C(O)O-, -OC(O)-, -OC(O)O-, -C(O)NR 20 -, -NR 20 C(O)-, -OC(O)NR 20 -, -NR 20 C(O)O-, -NR 20 C(O)NR 21 -, -S(O)-, -S(O)2-, -S(O)NR 20 -, -S(O)2NR 20 -, -NR 20 S(O)-, -NR 20 S(O)2-, -NR 20 S(O)NR 21 - or -NR 20 S(O)2NR 21 -; Each R 20 and R 21 Independently, it is hydrogen and C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein R 20 and R 21 Each C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are independently and optionally separated by one to five Z groups. 1a Replace; or R 20 and R 21 Together with the atoms to which they are attached, they form independently, optionally, one to five Z. 1a Substituted heterocyclic groups; and Each Z 1a Independently, it can be a halogenated group, hydroxyl group, cyano group, nitro group, oxo group, -SH, -NH2, or -NH-C group. 1-6 Alkyl, -N(C) 1-6 Alkyl)2, -SC 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein Z 1a Each -NH-C 1-6 Alkyl, -N(C) 1-6 Alkyl)2, -SC 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkyl, C 2-6 alkenyl, C 2-6 alkynyl group, C 1-6 Haloalkyl, C 3-10 The cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally and independently substituted by one to five substituents independently selected from the following: C 1-6 Alkyl, oxo, halogen, hydroxyl, and cyano groups.
2. The compound according to claim 1, wherein: Y 1 is -C(O)-, -S(O)2-, -S(O)(NR 6 - or - P(O)(R 7 )-; Y 2 It is -O-, -S-, -NR 2 -or-C(R) 2 )2-; and Y 1 With Y 2 The key between them is a single key; and Y 3 is -NR 8 -, -C(R 3 )2-, -C(R 3a )2-C(R 3a )2- or -C(R 3a )2-C(R 3a )2-C(R 3a )2-.
3. The compound according to claim 2, wherein Y 1 It is -C(O)- or -S(O)2-.
4. The compound according to any of the preceding claims, wherein Y 2 Yes -NR 2 -or-C(R) 2 )2-; and Y 1 With Y 2 The key between them is a single key.
5. The compound according to any of the preceding claims, wherein Y 3 Is it -N- or -C(R)? 3 )2-.
6. The compound according to claim 1, wherein the compound is represented by formula IA or IB: IA ONE Or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or solvate thereof.
7. The compound according to any of the preceding claims, wherein R 2 and R 3 Together with the atoms to which they are attached, they form a group optionally bounded by one to five Z. 2 Substituted heterocyclic groups.
8. The compound according to any of the preceding claims, wherein R 2 and R 3 Together with the atoms to which they are attached, they form unsubstituted heterocyclic groups.
9. The compound according to claim 1, wherein the compound is represented by the formula IC, ID, IE, or IF: IC ID IE IF Or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or solvate thereof.
10. The compound according to any of the preceding claims, wherein A is C 3-10 Cycloalkylene, 3- to 10-membered heterocyclic cycloidenes, C 6-10 arylene or 5- to 10-membered heteroarylene; wherein each group is independently and optionally surrounded by one to five Z. A replace.
11. The compound according to any of the preceding claims, wherein A is unsubstituted C. 3-10 Cycloalkylene, unsubstituted 3- to 10-membered heterocyclic groups, unsubstituted C 6-10 Aryl or unsubstituted 5 to 10 heteroarylene compounds.
12. The compound according to any of the preceding claims, wherein A is , , , , , , , , , , , , , , , , , or Each of them is arbitrarily selected by one to five Z; A Replacement; and where bond a and L 2 Bonding.
13. The compound according to any of the preceding claims, wherein X 2 It is C(O).
14. The compound according to any of the preceding claims, wherein X 3 It is C(O).
15. The compound according to any of the preceding claims, wherein X 1 Is it O, NH or NR? A .
16. The compound according to any of the preceding claims, wherein X 4 It is N or CH.
17. The compound according to any of the preceding claims, wherein a portion thereof... yes , or Each group is optionally R B replace.
18. The compound according to any of the preceding claims, wherein L 1 It is C 1-3 Alkylene.
19. The compound according to any of the preceding claims, wherein R 4 It is C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein the C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally separated by one to five Z groups. 4 replace.
20. The compound according to any of the preceding claims, wherein R 4 It is C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein the C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl groups are optionally replaced by halogenated groups, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 alkoxy, heteroaryl or C 3-10 Cycloalkyl substitution.
21. The compound according to any of the preceding claims, wherein R 4 It is phenyl, , , , , , ,or Each group is independently and optionally divided by one to three Z groups. 4 replace.
22. The compound according to any of the preceding claims, wherein L 2 It is a key, -NR 2a -、-C(O)-、-C(O)NR 2a -、C 1-6 Alkylene, C 1-6 Heteroalkylene or 4-6-membered heterocyclic alkylene; wherein R 2a It is hydrogen or methyl; and wherein the C is... 1-6 Alkylene or C 1-6 The heteroalkylene group is optionally substituted by one to three independent substituents selected from methyl and oxo groups.
23. The compound according to any of the preceding claims, wherein R 5 It is C 3-10 Cycloalkyl, heterocyclic, aryl, or heteroaryl; wherein the cycloalkyl, heterocyclic, aryl, or heteroaryl group is optionally independently composed of one to five Z groups. 5 replace.
24. The compound according to any of the preceding claims, wherein R 5 yes , , , , , , , , , , , , or Each group is independently and optionally divided by one to five Z groups. 5 replace.
25. A compound as shown in Table 1 or Table 2, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof.
26. A pharmaceutical composition comprising a compound according to any of the preceding claims, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, and a pharmaceutically acceptable excipient.
27. A method for treating a subject in need of calcitonin receptor and / or amylin receptor-related disease or disorder, the method comprising administering to the subject in need a therapeutically effective amount of the compound of any one of claims 1-25, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or solvate thereof, or the pharmaceutical composition of claim 24.
28. The method of claim 27, wherein the calcitonin receptor and / or amylin receptor-related disease or disorder is a bone disorder, metabolic disorder, pain, neurodegenerative disease or disorder, cardiovascular disease, or other disease or disorder.
29. The method of claim 27, wherein the calcitonin receptor and / or amylin receptor-related disease or disorder is osteoporosis, Paget's disease, hypercalcemia, Zudeck atrophy, multiple fibrous dysplasia of bone, costoclavicular ossification, osteogenesis imperfecta, osteopenia, periodontal disease or periodontal defects, osteolytic bone disease, metastatic bone disorder, malignancy, autoimmune arthritis, bone fracture or fracture, or bone loss due to immobility or disuse, osteopathic pain, phantom limb pain, general pain, hyperalgesia, pain associated with diabetic neuropathy, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), Alzheimer's disease, insulin-dependent diabetes mellitus, non-insulin-dependent diabetes mellitus, impaired glucose tolerance, obesity, Syndrome X, diabetic complications, primary or secondary hyperthyroidism, endocrine disorders, conditions associated with inhibition of gastric juice secretion, gastrointestinal disorders, renal osteodystrophy, or male infertility.
30. The method according to any one of claims 27-29, further comprising administering additional therapy or treatment agent to the patient.
31. The method of claim 30, wherein the additional therapy or treatment agent is selected from antidiabetic agents, antiobesity agents, weight loss agents, GLP-1 receptor agonists, antiemetics, agents for treating nonalcoholic steatohepatitis (NASH), gastric electrical stimulation, dietary monitoring, physical activity, or combinations thereof.
Citation Information
Patent Citations
Reduced moisture chemical reactions
IN256918B
Anti-nausea drug combinations
US10071088B2
Combinations of amisulpride and another anti-emetic for treating nausea and vomiting
US10322106B2
Use of amisulpride as an anti-emetic
US10525033B2
Compositions and methods for treating centrally mediated nausea and vomiting
US10828297B2
